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ABSTRACT
NF-KB/Rel transcription factors and IkB proteins play a central role in the rapid 
induction of genes transcribed in response to a variety of extracellular stimuli. Signal 
induction results in the phosphorylation and ubiquitination of IkB a prior to proteasomal 
degradation and release of NF-kB. The objective of this work was to identify residues 
within the N- and C-termini of IkBoc which were important for the function of the protein, 
specifically the residues contacting the p65 subunit of NF- kB and those involved in the 
turnover of IKBa. In addition, the structure of the C-terminal region of IkB a was also 
examined to gain a better understanding of the functional properties of this domain.
The identification of conserved stretches of acidic residues in the C-terminal region 
of IkB a prompted the suggestion that perhaps these amino acids were important for 
interacting with the positively charged nuclear localisation signal of the p65 subunit of NF- 
kB. Accordingly two regions, residues 284-286 and residues 300-302 (glutamic acid, 
aspartic acid, glutamic acid in both regions), were targeted for mutation (and referred to as 
the C-terminal mutants) to examine their role, if any, in IkB a -p65 association.
A second set of mutants were generated following a protease sensitivity study on 
IkBoc which revealed that residues 251 (tyrosine), 258 (tryptophan) and 275 (glutamic acid) 
were protected from digestion in the presence of p65. These amino acids were located in the 
low homology sixth ankyrin repeat of IkB a, thought to act as a flexible linker region 
between the highly conserved central five ankyrin repeats and the C-terminal region of the 
protein. Consequently, amino acids 258 and 275 were selected for mutation (referred to as 
the linker mutants).
The in vitro characterisation of the C-terminal and linker mutants demonstrated that 
neither amino acids 258 and 275 nor amino acids 284-286 and 300-302 affected the ability 
of IkBoc to interact with p65 homodimers, even under conditions of varying pH or ionic 
strength. However, residues 284-286 reduced the inhibitory capacity of IkBoc with respect to 
p65 homodimers. The results indicated that the region of IkB a required for the inhibition of 
p65 DNA binding activity, possibly located in or around residues 284-286, was separable 
from the area of the protein responsible for association with p65.
Attempts to phosphorylate the C-terminal and linker mutants in vitro using either 
casein kinase I or casein kinase II demonstrated that the C-terminal mutants were not 
efficiently phosphorylated by casein kinase II but were phosphorylated by casein kinase I. 
Both kinases were shown to phosphorylate wild-type IkB a and the linker mutants. 
Therefore, residues 284-286 and 300-302 were possibly important for the in vivo 
phosphorylation of IkBoc through casein kinase II.
The expression of the C-terminal and linker mutants from vectors transiently 
transfected into 293 cells revealed that residues 284-286 and residues 300-302 were
required for either inducible or constitutive degradation of IkB a, but more likely 
constitutive turnover. All mutants appeared to undergo signal-induced ubiquitination. 
Furthermore, the mutants were capable of interacting with p65 and in a different cell line 
(Cos7 cells) all appeared to allow NF-KB-dependent transcription from a luciferase 
reporter. The final result was thought to be a consequence of different degradation 
characteristics existing within Cos7 cells compared to 293 cells. In the light of recent data, it 
was concluded that the C-terminal residues of IkB a were important for constitutive, rather 
than inducible turnover of IkB a.
A mutational study carried out in collaboration with colleagues at the Pasteur 
Institute, France to identify potential lysine residues in the N-terminus of IkB a which may 
be targeted for ubiquitination revealed that lysine 21 and 22 were the primary targets for 
ubiquitination, with lysine 38 and 47 acting as secondary targets.
A Circular Dichroism study of proteins corresponding to the C-terminal region of 
iKBa illustrated that the domain was comprised largely of p-sheet with other secondary 
structure constituents such as p-turns and possibly areas of random coil contributing to the 
overall structure. The secondary structure of the C-terminal region may be important for its 
proposed interaction with the DNA binding domain of p65. The finding that at lower pH’s 
(e.g. pH5.6) the p-sheet content of the C-terminal region was raised suggested that this may 
mimic the structure adopted by the region when it interacts with the DNA binding domain 
of p65 (low pH conditions will lead to the protonation of carboxyl groups in the C-terminus, 
thereby making the groups available for hydrogen bond formation with p65).
In summary, the overall domain structure of IkB a can be seen to comprise an 
unstructured N-terminal signal response domain essential for inducible phosphorylation and 
degradation of IkB a, a central a-helical region of five ankyrin repeats responsible for 
protein-protein interactions, a flexible linker region (the low homology sixth ankyrin repeat) 
implicated in protein-protein interactions and possibly signal-induced degradation of IkB a 
and a C-terminal region of high P-sheet content required for constitutive phosphorylation 
and degradation of IkB a.
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INTRODUCTION
l.THE ROLE OF TRANSCRIPTION FACTORS IN THE CONTROL OF
EUKARYOTIC GENE EXPRESSION.
1.1. factors and the machinery.
The control of gene expression is fundamental to the survival of all living organisms 
as it provides a route for the selective expression of genes in response to a particular 
developmental or extracellular signal. Gene expression can be regulated in several ways, for 
example post-transcriptionally through RNA splicing or stability (Hodges and Bernstein., 
1994; Ross et al., 1996), at the level of protein translation (Kaufman et al., 1994) or via the 
stability of the mature protein product. The ubiquitin-conjugation system plays an important 
role in protein stability, essentially marking the protein for proteolytic degradation by the 
covalent attachment of a small, highly stable protein known as ubiquitin to lysine residues in 
the target protein (Jennissen, 1995; Jentsch and Schlenker, 1995). This mechanism will be 
discussed in more detail in section 3 of the introduction.
Although gene expression can be modulated via many routes, the major control point 
exists at the stage of transcription initiation and in eukaryotes initiation is modulated by 
sequence-specific DNA-binding proteins referred to as transcription (frans-acting) factors. 
These regulatory proteins can associate with recognition sites in the promoter region (the 
transcriptional start site) and in additional regulatory (cw-regulatory) elements known as 
enhancers, where they can operate singly or associated with other proteins to either repress or 
activate transcription initiation.
Typically transcription factors consist of a DNA binding domain which is functionally 
separable from a transcriptional activation or repression domain. Several different classes of 
activation domain have been identified including acidic, glutamine-rich and proline-rich. In 
parallel, specific classes of repression domains have also been discovered, for example 
alanine-rich and basic regions. The structure and organisation of these domains will be 
discussed in more detail in section 2 with reference to the ubiquitous mammalian transcription 
factor, NF-kB.
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Transcription factors can act as the rate-limiting step in the assembly of the so-called 
basal transcription machinery at the core promoter elements (the TATA boxes and initiator 
elements) by interacting directly or via intermediary proteins with specific components of the 
basal transcription unit. In the absence of these r^<an5-acting factors, in vitro studies have 
shown that only a minimal level of transcription can be supported by the basal transcription 
machinery (Buratowski, 1994). The basal transcription unit in eukaryotes is comprised of 
RNA polymerase II (pol II), the enzyme responsible for mRNA synthesis and a plethora of 
accessory proteins referred to as the basal transcription factors (TFIIA, TFIIB, TFIID (TBP), 
TFIIE, TFIIF, TFIIH and TFIIJ) (reviewed in Maldonado and Reinberg, 1995). In yeast there 
are also a number of additional proteins called SRBs (suppressors of RNA polymerase B) 
which have been shown in vivo to participate in transcription initiation (Koleske and Young, 
1995). Most of the basal transcription factors are composed of multiple subunits. For example, 
TFIID is comprised of the TATA box-binding protein (TBP) which can bind the TATA box 
alone and eight or more TBP-associated factors (TAFs) which can direct promoter selectivity 
via protein-DNA recognition (Goodrich and Tjian, 1994).
Transcription initiation can be divided into three main stages: preinitiation complex 
assembly, isomerisation and promoter clearance (Goodrich and Tjan, 1994). The initial step 
involves the reversible binding of RNA polymerase II and its accessory proteins to the 
promoter DNA. In the second, almost irreversible step a small region of DNA close to the site 
of transcription initiation becomes unwound and in the third and final step RNA polymerase 
leaves the promoter to elongate the primary transcript.
Two models have been proposed for the assembly of the preinitiation complex, the 
multistep model and the holoenzyme assembly model (Maldonado and Reinberg, 1995). The 
first model was derived from in vitro studies using purified components of the basal 
transcription machinery. In this multistep model TBP, either alone or in a TFIID multisubunit 
complex containing TAFs, binds to the TATA element, followed by TFIIB. This 
inter mediatory TFIID/TFIIB complex acts as a bridge for the delivery of RNA polymerase II 
by TFIIF and is followed by the successive association of the remaining factors, TFIIA, 
TFIIE, TFIIH and TFIIJ (figure 1).
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Figure 1: Multistep model for the assembly of the pre-initiation complex.
Multiple cooperative interactions between activators, cofactors and the general or 
basal transcription factors mediate transcriptional activation. This mechanism is derived 
mainly from studies performed in vitro utilising mammalian systems. TBP, TATA 
binding protein; TAFs, TBP-associated factors; PC, positive co-activators; RNAPIl, 
RNA polymerase II (adapted from Maldonado and Reinberg, 1995).
The second model for the assembly of the initiator complex was proposed after the 
discovery of the holoenzyme in yeast (reviewed in Emili and Ingles, 1995) and the 
identification of SRBs (Koleske and Young, 1994). In this holoenzyme assembly model it is 
proposed lhal a pre-formed holoenzyme consisting of RNA polymerase II, TFIIB, TFIIF, 
TFIIH, the SRBs and other unidentified polypeptides can be recruited to the promoter in one 
step via interactions with TFIIE and after the binding of TFIID to the TATA box (figure 2). A 
second form of the yeast RNA polymerase II holoenzyme has also been purified which 
appears to be a subcomplex of the form represented in figure 2. It is composed of RNA 
polymerase II, and the so-called “mediator” complex of TFIIF, the SRB proteins. Gall 1, Sugl 
and other unidentified polypeptides (but lacks TFIIB and TFIIH). Possibly both forms of the 
holoenzyme exist together in vivo. Recently two mammalian forms of the RNA polymerase II 
holoenzyme have also been identified: One form consists of RNA polymerase II, TFIID, 
TFIIB, TFIIH, TFIIF and TFIIE (Ossipow et al., 1995) and the other form is comprised of 
RNA polmerase II, TFIIE, TFIIH and a human homologue of the yeast SRB7 protein (Chao et 
al, 1996).
One of the major regulatory steps in both of the models for the assembly of the 
transcription initiation complex is the binding of TFIID to the TATA-box. Indeed, numerous 
studies have shown that transcriptional regulatory proteins such as the mammalian Sp l factor 
can establish specific protein-protein interactions with the polypeptides comprising TFIID, 
namely TBP (Maldonado and Reinberg, 1995) and the TAFs (Chiang and Roeder, 1995). It 
has been suggested that regulatory transcription factors may affect either TFIID recruitment to 
the TATA-box, or induce a conformational change in TFIID once it is bound to the promoter. 
Efficient activator-dependent transcription initiation cannot be supported by TBP alone but 
appears to require intact TFIID indicating the importance of the TAF subunits for TFIIDs 
interaction with trans-acting factors. Furthermore, in vitro studies using reconstituted TFIID 
have revealed that distinct transcriptional activators require specific combinations of TAF 
proteins. For example, the isoleucine-rich activator NTF-1 requires a complex composed of 
TBP, TAFn250 and TAFnl50 whereas the glutamine-rich activator Spl additionally requires 
TAFn 110 (Chen et al, 1994).
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Figure 2: Model for the assembly of the RNA polymerase II (Pol II) holoenzyme 
into an initiation complex.
Multiple interactions between components of the holoenzyme, activator proteins and 
transcription factor IID (TFIID) facilitate stable intiadon complex formation. TBP, TATA- 
binding protein; TAFs, TBP-associated factors. Double arrows indicate possible interactions
between the proteins of the initiation complex.
Other components of the basal transcription machinery have also been shown to 
interact with regulatory transcription factors including TFIIA, TFIIB and TFIIH (Maldonado 
and Reinberg, 1995). TFIIA is required for high level stimulation by transcriptional activators 
such as herpes simplex virus VP 16, Spl and NTF-1 in vitro (Ozer et al., 1994). Recent crystal 
structures of TFIIA in complex with TBP and the TATA element have revealed large areas of 
both TBP and TFIIA that would be accessible to interactions with such activators (in addition 
to other members of the basal transcription machinery) (Tan et al., 1996; Geiger et al., 1996).
TFIIB has been shown to interact with numerous transcription factors including VP 16 
(Roberts and Green, 1994) and the ubiquitous human POU domain protein, Oct-1 (Nakshatri 
et al., 1995). It has been suggested that VP 16 may stimulate transcription through TFIIB by 
inducing a conformational change in TFIIB, thereby exposing the binding sites for TBP, 
TFIIF and RNA polymerase II and thus driving forward the formation of an preinitiation 
complex. Experimental evidence also indicates that activators of TFIIB may function by 
increasing the amount of TFIIB recruited to the preinitiation complex (Roberts et al., 1995). 
The recent crystal structure of TFIIB in complex with TBP and the TATA binding site has 
provided a direct view of some of the transcription factor binding surfaces of TFIIB (Nikolov 
etal, 1995).
TFIIH represents a prime target for regulation by trans-acting factors as it has been 
implicated in other processes besides transcriptional initiation including DNA repair and cell 
cycle control. Recent studies have shown that the tumour repressor p53 interacts both 
physically and functionally with TFIIH (Leveillard et al., 1996) and earlier studies 
demonstrated a direct interaction with VP16 (Xiao etal, 1994).
Besides the components of the basal transcription machinery there exists a group of 
factors referred to as positive cofactors which are also targets for the regulation of 
transcription at the stage of initiation. These positive cofactors do not stimulate basal level 
transcription but rather they enhance the response to a transcriptional activator (Maldonado 
and Reinberg, 1995). A large amount of information has been collected on the positive 
coactivator, PC4 which has been shown to interact with free and DNA-bound VP 16 activation
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domains. Recently it was also demonstrated that PC4 could initiate transcriptional activation 
during TFIIA-TFUD-promoter complex formation (Kaiser etal, 1995).
In the yeast holoenzyme assembly model, the RNA polymerase II holoenzyme 
represents a target for regulation by transcription factors and this is believed to be 
accomplished by a TAF-independent mechanism. As previously described, two different 
complexes of the yeast holoenzyme have been isolated. Both forms of the holoenzyme are 
responsive to trans-acting factors. The SRB proteins and the Gal 11 and Sugl proteins of the 
“mediator” are essential for this responsiveness (Koleske and Young, 1995). It has been 
proposed that trans-acting factors may recruit the holoenzyme to the promoter in one step by 
interacting with these proteins. Recently, the SWI and SNF gene products, formerly identified 
as global gene regulators whose functions included remodelling of chromatin (see section 
1.314), have been found as integral components of the SRB complex of proteins in the yeast 
holoenzyme (Wilson et al., 1996). The SWI/SNF components possess the ability to disrupt 
nucleosomal DNA and facilitate the association of the transcription initiation complex with 
the promoter. However, the first mammalian form of the RNA polymerase II holoenzyme to 
be isolated from rat liver nuclear extracts (Ossipow et al., 1995) has not been found to be 
associated with, or stimulated by, the liver-enriched transcriptional activators, HNF1, HNF4 
or C/EBPa. Clearly other transcriptional activators will have to be tested before any firm 
conclusions can be reached on the requirement of regulatory transcription factors by the 
holoenzyme. In contrast, the second mammalian form of the holoenzyme to be identified was 
found to be responsive to transcriptional activators (Gal4-VP16) when assayed in the presence 
of coactivators (PC4) (Chao et al., 1996). Therefore such coactivators may be required to 
stimulate the activity of the rat liver purified holoenzyme.
1.2. THe control of transcription factor activity.
Since transcription factors represent the rate-limiting step in the assembly of the basal 
transcription machinery their activity will ultimately govern the level of gene expression. 
Consequently, several mechanisms have evolved to tightly control transcription factor 
activity. These can be grouped into two basic categories, either those that involve regulating
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their synthesis or those that act post-translationally to modify the activity of a pre-existing 
transcription factor. Control can be exerted by a combination of these mechanisms which 
serves to create an intricate and finely balanced regulatory program for transcription factor 
activity. These mechanisms will be discussed under the headings which follow.
1.21. The control of eukaryotic transcription factor synthesis as a mechanism to 
regulate their activity.
Regulating the synthesis of a transcription factor offers a metabolically inexpensive 
way of controlling its activity because the protein will only be synthesised when it is 
required. This mechanism of regulation depends upon generating changes in the actual 
amount of a transcription factor by modulating the processes which are involved in the 
proteins synthesis, for example the transcription of the gene which encodes the factor and the 
splicing and translation of the corresponding mRNA transcript. It can be appreciated that if, 
for example control is applied at the level of transcription it will be necessary to go through 
all of the remaining steps in the synthesis pathway before the amount of transcription factor 
which is produced is accordingly altered. Subsequently, this mechanism of control tends to be 
adopted in situations where a particular transcription factor activity is maintained for long 
periods, for example in the expression of cell-type specific or developmentally regulated 
genes. Alternatively, it can be used to supplement more rapid methods of control for example, 
the post-translational regulatory mechanisms.
The headings which follow describe some examples of transcription factors which are 
modulated at three main stages during their synthesis: transcription, RNA splicing or 
translation of their mRNA.
1.211. Transcriptional regulation.
The transcriptional regulation of a gene encoding a transcription factor usually occurs 
at the stage of initiation and involves the recruitment of other trans -acting factors to either 
repress or induce gene expression. These additional factors will also be regulated, perhaps 
transcriptionally by different trans-acting factors, leading to complex gene networks and
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hierarchies of transcription factors. As previously mentioned, this strategy is exploited by 
many transcription factors which are involved in cell type-specific and developmental gene 
expression. For example, the mammalian CCAAT box-binding factor, C/EBP a which directs 
the expression of several liver and adipose specific genes has been shown to be 
transcriptionally regulated. Mice deficient in C/EBP a fail to develop normal metabolic 
functions, such as hepatic glycogen synthesis, in the liver and white and brown adipose tissue 
(Darlington et al., 1995). Controlling the activity of this transcription factor is therefore 
essential for the proper functioning of the liver and adipose tissue. The promoter of the gene 
encoding murine C/EBP a has been shown to be autoregulated: C/EBP a can bind within 200 
base pairs of the transcriptional start site to elevate the activity of the C/EBP a gene by 
approximately three fold. However, the human C/EBPa gene promoter does not contain a 
binding site for C/EBP a but recent studies have shown that C/EBPa can stimulate 
transcription from this promoter. This activation has been attributed to a ubiquitously 
expressed upstream stimulatory factor (USF) which is stimulated by the C/EBPa protein to 
bind a specific USF element (CACGTG) in the C/EBPa gene promoter (Timchenko et al, 
1995).
The expression of two mammalian proto-oncogenes, c-Jun and c-Fos which encode 
the proteins, Jun and Fos respectively have both been shown to be transcriptionally controlled. 
Jun and Fos (in addition to other Jun and Fos related proteins) can heterodimerise to form the 
transcription factor AP-1 which renders genes which contain an AP-1 binding site inducible 
by treatment with phorbol esters (Angel et al, 1987). Jun can also form homodimers which 
tend to be less stable than Fos-Jun heterodimers but they are still capable of binding to AP-1 
sites (Angel et al, 1991). Both Jun and Fos play a critical role in the induction of phorbol 
ester- and growth-dependent genes. Transcription of the c-Fos proto-oncogene following 
treatment with growth factors or mitogens is dependent on the activity of a region located in 
the c-Fos promoter referred to as the serum response element (SRE). The SRE binds the 
transcription factor, SRF (serum response factor) and additional protein, TCF (ternary 
complex factor) to mediate the induction of c-Fos gen\ %sion (reviewed in Treisman, 
1995 and discussed in more detail in section 1.313). .tingly, the formation and
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modification (by phosphorylation-see section 1.313) of the ternary complex at the c-Fos SRE 
induces DNA bending in the promoter region (Sharrocks and Shore, 1995). This protein- 
induced DNA bending may allow the ternary complex at the SRE to interact with components 
of the basal transcription machinery so that transcription can be initiated. Indeed, previous 
studies have demonstrated that protein-induced DNA bending by the repressor, YY1 at the c­
fos promoter act to prevent interactions between the CREB activator protein and members of 
the basal transcription machinery. YYl may also affect the binding of the basal transcription 
factor, TFIID to the TATA box (reviewed in Grosschedl, 1995). The promoter of c-Jun 
contains binding sites for many transcription factors including Spl, CTF and AP-1. It has 
been demonstrated that Jun homodimers and Fos-Jun heterodimers (AP-1) may be partially 
responsible for activating transcription of the c-Jun gene via two AP-1 binding sites in 
response to phorbol ester treatment (Unlap et al, 1992). Studies on the serum induction of c- 
Jun expression in HeLa cells have suggested that serum may regulate expression via a 
member of the MEF2 family of transcription factors, MEF2D. This protein binds a MEF2 site 
in the c-Jun promoter and renders the gene responsive to serum. The MEF2 proteins appear to 
be related to the serum response factor through their DNA binding domains. Both types of 
transcription factor require this domain to retain their ability to trans-activate. It is possible 
that the serum induction of c-Fos and c-Jun gene expression may be regulated by common 
mechanisms (Han and Prywes, 1995).
1.212. Regulation of RNA splicing.
The synthesis of many transcription factors is controlled via the differential splicing 
of their RNA transcript. This post-transcriptional mechanism of control avoids the need for 
additional trans -acting factors to activate or repress the gene which encodes the transcription 
factor. However, RNA splicing does require specific splicing factors and their activity will 
also have to be controlled. To date, little is known about the nature and regulation of the 
splicing factors involved in the processing of transcription factor RNA transcripts.
The transcript of the mammalian transcription factor, CREB undergoes alternative 
splicing. CREB is activated in response to cyclic AMP (cAMP) and induces the expression of
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specific genes by binding to promoter regions known as cAMP response elements (CRE) 
(Montminy and Bilezikjian., 1987). Several alternatively spliced forms of CREB have been 
identified in mice (Ruppert et al., 1993) but the most abundant isoforms with DNA binding 
activity and transactivation potential appear to be CREB a and CREB A (a homologue of the 
human and rat CREBA).The role of many of the other CREB isoforms is unclear but several, 
including CREB y and CREB ay exist at elevated levels in the primary spermatocytes of the 
testis. It is possible that by generating these isoforms the level of mRNA species encoding 
active CREB A will be lowered, leading to a reduction in CREB-mediated gene expression.
Recently a set of novel p-exon containing CREB splice products have been identified. 
High levels of these new splice variants heve been correlated with poor responses to cAMP in 
certain tissues. They possess a transactivation domain but lack a target serine residue which is 
required for cAMP-dependent phosphorylation (see section 1.312 and activation of CREB). It 
has been suggested that these variants may assist in reducing CREB activity and hence cAMP 
responsiveness in some tissues (Ellis et al., 1995). The generation of mice with a mutation in 
the CREB gene has led to the isolation and characterisation of a further CREB isoform, 
termed CREBP (Blendy et al., 1996). In wild-type mice this isoform is expressed at relatively 
low levels but in the mutant mice it is present in high quantities due to an increase in 
alternative splicing. This isoform appears to participate in many CREB-related functions 
suggesting that in instances where CREB A and CREB a are absent, CREBp may partially 
compensate for this loss.
The primary RNA transcript derived from the gene encoding Oct-2, a member of the 
POU family of transcription factors that share two common domains (Herr et al., 1988), is 
alternatively spliced to yield a number of different mRNAs which encode different isoforms 
of the protein. In addition to activating immunoglobulin gene expression in B cells (Clerc et 
al., 1987 and Staudt et al., 1988), Oct-2 has also been shown to act as a repressor of 
transcription in neuronal cells (Dent et al., 1991). Two isoforms of Oct-2 predominate in 
neuronal cells, Oct-2c and mini Oct-2 (Lillycrop et al., 1992). Oct-2c lacks a C-terminal 
activation domain whereas mini Oct-2c consists only of the central DNA binding POU
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domain. It is thought that these isoforms may be involved in the inhibitory effect of Oct-2 on 
gene expression in neuronal cells. It has recently been discovered that these isoforms occur in 
other tissues with the proportion of mini Oct-2 mRNA being much higher in the spleen than 
the brain. Also, mini Oct-2 mRNA levels are increased in response to differentiation-inducing 
stimuli and decreased upon exposure to growth factors in neuronal cell lines (Liu et al, 1995). 
This means that the splicing of the Oct-2 transcript is regulated both in a tissue specific 
manner and in neuronal cells in response to certain stimuli. As yet the precise mechanism 
which mediates the regulation of alternative splicing remains to be elucidated.
Several functionally distinct isoforms of the T-cell specific transcription factor, TCF-1 
have been recently identified (Vandewetering et al, 1996). TCF-1 is essential for early T-cell 
differentiation and isofo^rms of the transcription factor are generated via alternative splicing of 
the mRNA transcript and also through the existence of two promoters and a second reading 
frame in the gene which encodes TCF-1. Transfection studies have been performed to 
determine the ability of the TCF-1 isoforms to transactivate the transcription of a reporter 
gene via a T-cell receptor a-chain (TCR-a) enhancer (which contains a recognition site for 
TCF-1) (Vandewetering et al, 1996). It was discovered that the transactivation potential of 
the TCF-1 isoforms was highly dependent upon their length: the longer isoforms failed to 
transactivate whereas the shorter isoforms could successfully upregulate gene expression. 
However, the longer isoforms of TCF-1 were still able to bind DNA. It was therefore 
proposed that the larger isoforms were sterically hindered in their ability to transactivate the 
reporter gene possibly through the exclusion of additional proteins which are also required for 
transactivation (for example the previously described CREB trans-acting factor).
1.213. Regulation oft ranslation.
Influencing the translation of transcription factor mRNA in order to regulate synthesis 
of the protein can be achieved by either altering the levels of the rate-limiting protein factors 
which participate in translation (generally at the stage of initiation) or by using a more 
specific mechanism which affects only a single mRNA or class of mRNAs. The 
synthesis of a yeast transcription factor, GCN4 has been shown to be controlled at the level of
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translation initiation. GCN4 is activated under conditions of amino acid starvation to facilitate 
the expression of genes which are required for amino acid production. This activation occurs 
when the a-subunit of translation initiation factor 2 (eIF2a, one of three non-identical 
subunits which comprise eIF2) is phosphorylated (via a protein kinase, GCN2) and 
inactivated which allows the translation of GCN4 mRNA and an increase in the level of 
GCN4 protein (reviewed in Hinnebusch , 1994). The increase in GCN4 mRNA translation in 
response to eIF2a phosphorylation depends on four short upstream open reading frames 
(uORFs) in the leader GCN4 mRNA. Under starvation conditions the phosphorylation of 
eIF2a prevents the formation of a ternary complex between eIF2, GTP and initiator transfer 
RNA charged with methionine (Met-tRNA^et). This is thought to reduce the rate of 
ribosome binding since under conditions of non-starvation the small ribosomal subunit must 
associate with the ternary complex before it can successfully bind to the capped 5’ end of the 
mRNA and proceed with translation at the nearest AUG-start codon. However, any ribosomes 
that do bind to the mRNA will recognise and translate the first uORF (uORFl). Following the 
translation of uORFl it is believed that ribosomes possessing a bound ternary complex bypass 
the remaining AUG codons of the uORFs 2,3 and 4 and re-initiate translation further 
downstream at GCN4. Under conditions of non-starvation where ternary complexes are in 
abundance and therefore available to bind ribosomes, translation of uORFs 1,2,3 and 4 is 
favoured. However, unlike ribosomes that translate uORFl, most that translate uORFs 2,3 and 
4 dissociate from the mRNA following peptide chain termination and therefore fail to reach 
the GCN4 start codon.
Several isoforms of the previously mentioned CCAAT enhancer binding transcription 
factor, C/EBPa and the related factor, C/EBPp have been detected in mouse liver. Four 
C/EBPa proteins with molecular masses ranging from 20-42 kDa were found to possess DNA 
binding activity. Differences existed between the pool levels of each isoform in the nucleus of 
liver cells. In addition, these levels were altered in response to lipopolysaccharide (LPS) 
treatment: The levels of the smallest isoform (20kDa) were found to increase whereas the 
levels of the largest isoforms (42kDa & 30kDa) were shown to decrease. Three C/EBPp 
proteins were identified with molecular masses of 35, 20 and 16 kDa and in parallel to the
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C/EBPa proteins their nuclear pool levels and response to LPS also varied. It has been 
proposed that EPS can mediate the differential initiation or inhibition of translation at specific 
AUG sites within each mRNA. It is believed that the pool levels of each isoform are either 
regulated by EPS or an upstream-stimulated factor (possibly a translational trans-activator) 
via the selection of AUG start sites for the activation and repression of translation (An et al., 
1996).
The GC-box binding transcription factor, BTEB which can activate HIV type 1 long 
terminal repeat and cellular gene promoters containing multiple GC-boxes, is partly regulated 
through its translation. In mammals, BTEB protein expression is confined to the brain, 
although BTEB mRNA is found in many other mammalian tissues and cell lines. This cell- 
specific protein expression has been attributed, in part, to an upstream AUG in the 5’ 
untranslated region (5’ UTR) of the BTEB mRNA (Imataka et al, 1994). Since the events of 
translation initiation take place on the 5’ UTR of the mRNA both the primary and secondary 
structures of this region have an important role to play in the efficiency of mRNA translation. 
Therefore, the presence of additional AUG codon(s) upstream of the initiator AUG reduces 
the chances of the pre-initiation complex for translation reaching the authentic initiating 
AUG. It is possible that the activity of the proteins involved in translation initiation (for 
example, eIF-2a) vary between different cells and tissues. Therefore, the ability of ribosomes 
to reinitiate translation at the BTEB open reading frame may be more efficient in brain cells 
compared to other cells.
1.31. Control of eukaryotic transcription factor activity using post-translational
mechanisms of regulation.
The modification of a pre-existing transcription factor as a mechanism to control its 
activity is used in situations where rapid gene induction is required, for example during 
environmental change or challenge. However, these post-translational mechanisms of control 
rely on the synthesis of a transcription factor, albeit in an inactive state, even when it is not 
required and are thus more demanding in terms of energy usage than those mechanisms that 
only completely synthesise a protein when it is needed.
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There are several ways to modify the activity of a transcription factor post­
translationally and these include the association of transcription factors with small diffusable 
ligands, the covalent modification of factors, the recruitment of accessory proteins, the 
interaction of transcription factors with chromatin or the exclusion of trans-acting factors 
from the nucleus to prevent DNA binding. Each of these methods of control will be discussed 
under the headings which follow.
1.311. The association of transcription factors with small, diffusable ligands.
In many eukaryotes the ability of a transcription factor to bind its target DNA is 
controlled via its association with small, diffusable ligands. The activity of the yeast 
transcription factor, AMTl is regulated in this way. AMTl induces the expression of 
metallothionein genes in response to copper. Activation of AMTl is achieved by a major 
conformational change which is induced by the binding of four copper (+) ions and one zinc 
(2+) ion to two independent sub-domains located in the N-terminal DNA binding region of 
the protein. Although the zinc ion does not affect the ability of AMTl to bind DNA it is 
thought that it may be critical for the transcriptional activation function of the protein 
(Thorvaldsen etal, 1994; Farrell et al., 1995).
Members of the nuclear receptor superfamily, which are responsible for the mediation 
of many extracellular signals into transcriptional responses, can only bind with high affinity to 
their cognate hormone response elements (HRE) via association (through ligand binding 
domains (LED)) with various lipophilic hormonal ligands. Some members of the Orphan 
receptors (a class of nuclear receptors) appear to lack the requirement for these ligands. 
However, it is more likely that a group of novel ligands exist for these receptors which, as yet, 
have not been identified. These ligands include the steroids, retinoids, thyroid hormones and 
vitamin D3 (reviewed in Mangelsdorf et al., 1995). They can pass through the lipid bilayer of 
the cell to interact with their respective receptors where they can act as regulators of 
development, cell differentiation and organ physiology. The classic model for hormonal 
induction of receptor DNA binding postulates that hormone binding induces allosteric 
changes in the receptor which unmasks the DNA binding region of the receptor. This allows
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the hormone-receptor complex to associate with specific DNA sequences and modulate 
transcription.
Studies to date have characterised over 150 members of the nuclear receptor 
superfamily. The superfamily is often sub-divided into the steroid receptor family and the 
thyroid/retinoid/vitamin D (or non-steroid) family. In addition, the superfamily can be 
arranged into four classes based on the ability to dimerise and bind DNA: Class I receptors 
consist of the steroid hormone receptors which, following ligand induction, bind as 
homodimers to DNA half-sites organised as inverted repeats; Class II receptors form 
heterodimers with the retinoid X receptor (RXR) and tend to associate with DNA arranged as 
direct or symmetrical repeats. This class includes all the other known ligand receptors outwith 
the steroid hormone receptor class; Class III receptors exist as homodimers and recognise 
DNA sequences organised as direct repeats; Class IV receptors are monomeric and associate 
with DNA arranged as an extended core. The Orphan receptors tend to fall into either Class 
III or IV and it is thought that a set of novel hormonal ligands may exist for these receptors 
(reviewed in Mangelsdorf and Evans, 1995).
Recently, the structures of unliganded human retinoid X receptor LBD and liganded 
thyroid receptor a LED have been resolved using X-ray crystallography (Bourguet et aL, 
1995; Wagner et al., 1995). The two structures were found to be broadly similar, although 
RXR exists as a homodimer and the thyroid receptor is monomeric. It has previously been 
found that the LBD's of all known ligand-activated receptors comprise a carboxy-terminal 
region of around 225 amino acids. This region is also responsible for dimerisation, hormone- 
dependent transcriptional activation and, in some instances hormone-reversible transcriptional 
repression. The most striking feature to emerge from the crystallisation data was the differing 
arrangement of the receptors respective transcriptional activation domains. The transcriptional 
activation domain of RXR formed an amphipathic alpha helix (termed AF-2) which extended 
into the solvent away from the central core of the LED (containing the putative ligand binding 
site). In contrast, the the equivalent transaclivatron region in the thyroid receptor was packed 
onto the core of the receptor and formed part of the ligand-binding pocket. The ligand itself 
was buried inside the hydrophobic core of the receptor. Therefore, it appears that ligand
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binding probably causes extensive allosteric changes in the receptor which allows the 
complex to bind specific DNA sequences and regulate transcription.
1.312. The covalent modification of transcription factors.
Several transcription factors are regulated post-translationally by covalent 
modifications such as phosphorylation or the addition of O-linked monosaccharides. For 
example, the CREB transcription factor, previously mentioned to undergo regulation through 
alternative splicing (section 1.212), can also be activated by the phosphorylation of a serine 
residue at position 133 via protein kinase A (Gonzalez et al., 1989). Protein kinase A is 
stimulated by cyclic AMP (Nigg et al., 1985) to release its catalytic subunits into the nucleus 
where they can phosphorylate and activate CREB. The serine residue which is phosphorylated 
in CREB is located within a region of the protein known as the phosphorylation-box (P-box) 
or kinase-inducible domain (KID). The P-box is flanked by two transcriptional activation 
domains, Q1 and Q2, the latter domain appears to be more important for activation (Brindle et 
aL, 1993). Phosphorylation of the serine residue in the P-box stimulates Q1 and 
predominantly Q2 to activate the transcription of specific genes.
The precise mechanism of the stimulatory action on Q1 and Q2 is not known. 
However, it has been suggested that like other substrates of protein kinase A, CREB may 
undergo a conformational change following phosphorylation which allows Q1 and Q2 to 
interact with the transcription apparatus and activate gene expression (Brindle et aL, 1993). 
Alternatively, it has been shown that phosphorylation of the P-box can enable CREB to 
interact with a co-activator protein known as CBP (CREB-binding protein) (Chrivia et aL, 
1993). Transfection experiments have demonstrated the ability of CBP to enhance the 
activation of CREB -mediated reporter constructs in vivo in a manner which is dependent on 
protein kinase A phosphorylation of CREB (Kwok etal, 1994). Recently, a domain referred 
to as KIX has been characterised in CBP. KIX was found to bind CREB following 
phosphorylation of CREB at serine 133 and was able to be recruited to a cAMP response 
element. It appears that KIX is co-ordinated through a single arginine residue (Arg-600) to the 
phosphoserine residue in CREB. This association is stabilised by hydrophobic residues in the
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KID of CREB which flank serine 133. It has been proposed that novel motifs such as KIX 
may be responsible for the protein-protein interactions that follow serine/threonine mediated 
signalling (Parker etal, 1996).
The mammalian Jun transcription factor is activated by the phosphorylation two N- 
terminal serine residues (Ser 63 and Ser 73) which are located in the transcriptional activation 
domain of Jun. The Jun N-terminal kinases (JNKs)/stress activated protein kinases (SAPKs), 
members of the family of mitogen-activated protein kinases (MAPK) are responsible for this 
N-terminal phosphorylation. In vitro studies have shown that the JNK/SAPKs can bind to a 
so-called “docking site” in the Jun activation domain from residues 30 to 60. Removal of this 
site from Jun results in a dramatic reduction in the ability of Jun to be phosphorylated in vivo 
in response to a range of JNK/SAPK activators (environmental stress and the 
proinflammatory cytokines)(reviewed in Hill and Treisman, 1995; Karin and Hunter, 1995),
1.313. The of accessory proteins by transcription factors.
Many transcription factors require the presence of a co-activator protein to assist in
the process of transcriptional regulation. This can be illustrated by the interaction between the 
transcription factor Oct-2 and the co-activator, OBF-1. As previously described in section 
1.212 Oct-2 can upregulate immunoglobulin gene expression in B-cells only by binding to an 
octamer motif (ATGCAAAT) in the promoter and enhancer regions of most immunoglobulin 
genes. Substantial evidence exists to suggest that Oct-2 mediates the cell-specific 
transcriptional regulation of immunoglobulin genes by forming a ternary complex with the B- 
cell specific factor, OBF-1 on an octamer motif (Gstaiger etal, 1995; Strubin etal, 1995). 
OBF-1 does not appear to bind the DNA itself but instead associates directly with the POU 
domain of Oct-2. This domain contains two highly conserved regions which mediate the 
transactivating potential of Oct-2 and other transcription factors that comprise the POU family 
(reviewed in Herr etal, 1988). It is thought that OBF-1 may potentiate the activity of Oct-2 
by acting as a bridge between a member of the basal transcriptional machinery and the 
octamer-bound Oct-2.
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As outlined in section 1.211 the transcription factor, SRF (serum response factor) 
requires the coactivator protein, TCF (ternary complex factor) to efficiently induce c-Fos gene 
expression from the serum response element (SRE) in the c-Fos promoter (reviewed in 
Treisman etal, 1995; Hill and Treisman, 1995). TCF forms a ternary complex with SRF at 
the serum response element following treatment with serum growth factors. TCF cannot bind 
the SRE alone. Various studies have indicated that SRF may occupy the SRE in a ternary 
complex with Elk-1 even in the absence of serum (Herrera et al, 1989). This indicates that 
activation of the SRE may involve regulation of transcriptional activation rather than DNA 
binding.
Several cDNAs that encode proteins with TCF-like activity have been identified. 
These include the Ets domain proteins, Elk-1, SAP-la and SAP-2. They are the targets for the 
mitogen activated protein kinases (MAPK), a family of protein kinases whose members 
include the mammalian extracellular signal-regulated kinases ERKl and ERK2. MAP kinases 
are activated through a signalling cascade which is initiated by the stimulation of receptor 
tyrosine kinases. This signalling cascade involves the activation of ras kinase followed by the 
sequential activation of MAPK kinase and ERK-l/ERK-2 (Cobb and Goldsmith, 1995). 
MAPK phosphorylation sites contain a core sequence motif, S/T-P. Such core motifs have 
been identified in the C-terminal transcriptional activation domains of the Elk-1, SAP-la and 
SAP-2 proteins (Price et al., 1995). These motifs are required for activation of the TCF-like 
proteins. ERK-2 can phosphorylate each TCF activation domain in vitro. Furthermore, ERK 
activation in vivo is capable of inducing transcriptional activation in the presence of each TCF 
activation domain. Interestingly, SAP-2 cannot bind DNA or form ternary complexes as 
efficiently as ELK-1 or SAP-la, suggesting that its binding may be regulated through 
mechanisms distinct from these two proteins.
A model has been proposed in which SRF is permanently bound to the SRE in a 
ternary complex with Elk-1. Following exposure to serum MAP kinase phosphorylates Elk-1 
leading to the subsequent induction of c-Fos transcription. An alternative signalling pathway 
for the phosphorylation and subsequent activation of Elk-1has recently been described 
(Whitmarsh et al., 1995). This pathway has been shown to involve phosphorylation of Elk-1
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and a resulting increase in ternary complex formation at the SRE by a group of MAP kinases 
referred to as the JNKs (see section 1.312). The JNKs are activated through a signal 
transduction pathway distinct from that of the ERKs. It would therefore appear that the SRE 
represents an integrative site for two distinct signalling pathways.
1.314. The interaction between transcription factors and chromatin.
In eukaryotes, transcription factors must function in an environment where DNA is 
compacted into a chromatin structure by repeating units (nucleosomes) of five small, basic 
proteins (l l-l(5k^D) called histones (H2A, H2B, H3, H4 and the linker histone). Beyond the 
chromatin level of organisation there also exists a higher order structure comprising of 
chromosomal domains of chromatin fibres (see figures 3 and 4; reviewed in Pruss etal, 1995; 
Wolffe and Pruss, 1996a). As yet, there is little information on the nature of the contacts 
which may contribute to the formation of these domains. However, it can be envisaged that 
large areas of the genome will be rendered inaccessible to transcription factors and also to the 
basic transcription initiation machinery (RNA polymerase and the basal transcription factors 
supporting the minimum levels of transcription) which results in the repression of many 
genes. However, as will be discussed, the effect of chromatin structure on gene transcription 
is not always one of repression.
Substantial genetic evidence exists to show that the histone proteins can influence the 
level of transcription. For example, studies were performed on yeast cells where the wild-type 
histone H4 and H2B genes were replaced with repressed copies which resulted in the 
normally silent PHO5, CUPl and HIS3 genes becoming active (Durrin et aL, 1992; Kim et 
aL, 1988 and Han et al., 1987). Presumably the repression of the histone genes prevented 
normal chromatin assembly and thereby permitted the trans-acting factors and RNA 
polymerase to gain access to the promoter and enhancer regions of the PHO5, CUPl and 
HIS 3 genes so that transcription could proceed.
However, more specific information on the regulatory proteins which interact directly 
with the histones to control gene expression does exist. This includes the SWI-SNF activator 
complex in yeast which is composed of eleven proteins, the sucrose non-fermenting (SNF5,
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Figure 3: The histone fold and DNA binding motifs.
The relative juxtaposition of the two histone heterodimers as viewed "from the 
top"(i.e. along the superhelical axis of the DNA). Histones are colour-coded in the 
following way: H4 (red), H3 (yellow), H2B (blue) and H2A (green). The 
approximate positions of the flexible histone tails are shown by broken lines. Note 
the six regularly spaced domains (double arrows) predicted to be involved in DNA 
binding (taken from Pruss et al, 1995).
Figure 4. The anatomy of the core particle-a view down the superhelical 
axis.
The micrococcal nuclease (MNase) digestion boundaries and sites of 
histone-DNA contact (revealed by crosslinlang) (coloured circles) are shown as 
found on the coding sequence portion of the 5S nucleosome (the numbers of 
"crosslinking circles" roughly indicate the efficiency of crosslinking). For 
simplicity, the DNA is shown as a uniform superhelix. The helical turns are 
numbered relative to the dyad axis (0). GH5, globular region of linker histone H5 
(taken from Pruss et aL, 1995).
SNF6, SNFll) and switch (SWI1, SWI2, SWI3) proteins in addition to other identified 
polypeptides, and is required for the expression of many inducible genes (reviewed in 
Peterson and Tamkun, 1995; Kornberg and Lorch, 1995). SWI-SNF mutations have a 
profound effect on activator function, for example the activity of the GAL4 transcription 
factor can be reduced approximately twenty fold in the absence of either SWI1, SNF5 or 
SNF6. Early clues to the mechanism of transcription factor activation by the SWI-SNF 
complex arrived when it was demonstrated that yeast strains deficient in SWI gene activity 
were still capable of inducible gene transcription. This activity was attributed to mutant forms 
of the sin genes which normally generate proteins which are thought to act like histones 
(Kruger et aL, 1991). Therefore, mutants of these proteins probably failed to compact the 
DNA so that the promoter and enhancer regions of the genes were exposed allowing 
transcription initiation. It was thought that the activator complex may similarly affect the 
integrity of the chromatin structure, unfolding it for transcription initiation.
Biochemical studies using the purified SWI-SNF complex and a derivative of GAL4 
have revealed a direct biochemical relationship between the SWI-SNF complex and 
chromatin (Cote et aL, 1994): the SWI-SNF complex does not result in nucleosome 
displacement although it does directly bind to the nucleosomal DNA, instead it promotes the 
formation of a ternary complex between the GAL4, its DNA recognition site and the histone 
proteins. The SWI-SNF complex uses the energy generated from the hydrolysis of ATP to 
drive this process. The ATPase activity of the complex is thought to reside in the SWI2 
component since it possesses ATPase motifs (similar to the DNA stimulated ATPases) and 
mutations in the protein result in a loss of ATPase activity from the SWI-SNF complex. One 
current "chromatin remodelling" model for the SWI-SNF complex proposes that the SWI- 
SNF complex associates with the nucleosomal DNA and then uses the energy produced from 
ATP hydrolysis to alter DNA-histone interactions thereby promoting the loss of one or both of 
the histone2A-2B dimers from the GAL4 ternary complex (Cote et aL, 1994; Peterson and 
Tamkun, 1995).
Genetic evidence also exists for the role of the higher order chromatin structure 
(chromosomal domains) in transcription initiation control. This can be demonstrated by
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“position effects” in both the fruit fly, Drosophila and the yeast strain, S. cerevisiae. Position 
effects occur when active genes become repressed following their relocation next to inactive 
highly condensed domains of DNA (heterochromatin) as a result of rearrangement or 
recombination. This repression is thought to be brought about by the extention of the 
heterochromatin structure into the previously active gene.
In Drosophila and 5. cerevisiae, the histone proteins (Becker, 1994; Wolffe and Pruss, 
1996b) have been shown to play a role in position effects. These transcriptionally repressive 
effects can be relieved through the hyperacetylation of core histones. This hyperacetylation 
causes an allosteric change in nucleosome conformation which destabilises the higher-order 
chromatin structure and allows transcription factors to gain access to the nucleosomal DNA. 
Recently, a yeast transcriptional activator called GCN5p was shown to function as a histone 
acetyltransferase suggesting the potential for targeted histone modification (reviewed in 
Wolffe and Pruss, 1996b). In addition, a specific family of trans-acting factors in Drosophila, 
including HP1, a chromodomain associated protein (reviewed in Wolffe, 1994) and a factor 
encoded by the Brahma gene (brm) in Drosophila (Tamkin et al., 1992) can also contribute to 
position effects. Brm is related to the ATPase component of the SWI-SNF complex, SWI2 
and assists DNA binding regulatory proteins to overcome the repressive effects of chromatin 
on transcription (reviewed in Peterson and Tamkun, 1995). A recent study has discovered that 
the product of the Drosophila snrl gene (a potential homologue of the SNF5 gene) can form 
a complex with brm indicating that the yeast SWI-SNF complex may be conserved in higher 
eukaryotes (Dingwall etal., 1995).
Finally, several examples exist where nucleosome positioning can positively or 
negatively regulate transcription initiation (reviewed in Grosschedi, 1995). The mouse 
mammary tumour virus (MMTV) promoter is strongly transcribed in response to steroid 
hormones but is almost silent in the absence of hormonal stimuli. Full transcriptional 
activation from the MMTV promoter in the presence of steroid hormones requires the 
association of the hormone receptors to four hormone-responsive elements (HREs), in 
addition to the binding of nuclear factor 1 (NF1) and the octamer transcription factor, Oct-1. 
The low basal activity of the MMTV promoter is believed to result from its organisation in a
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positioned nucleosome where it is wrapped around a histone octamer in a precise rotational 
orientation. This allows access to only two of the HREs by the hormone receptors and 
completely prevents the binding of NFl and Oct-1 to their respective sites. Presumably 
hormone induction remodels the nucleosome allowing the binding of each trans-acting factor 
to its relevant site and transcriptional activation (reviewed in Truss et al., 1995). The 
Drosophila hsp26 and alcohol dehydrogenase promoters are arranged into a 3-dimensional 
structure by nucleosomes (reviewed in Wolffe, 1994). Distant regulatory elements are brought 
into close proximity by nucleosome positioning and it is thought that this may be required for 
efficient transcriptional activation.
Many transcription factors can themselves induce bending in the promoter DNA to 
facilitate the binding of additional transcription factors for transcriptional activation 
(Grosschedi et al., 1995). For example, the LEF-1 protein (a lymphoid specific member of the 
high mobility group (HMG) domain family) binds to a specific site in the centre of the T-cell 
receptor a enhancer (TCRca) and causes the DNA to bend sharply. It is proposed that LEF-1 
acts as an architectural element that allows additional transcription factors which are bound to 
sites flanking the LEF-1 binding region to interact with one another.
1.315. Cytoplasmic localisation of transcription factors in an inactive form.
Many transcription factors can exist in the cytoplasm in an inactive form and can be 
activated by certain stimuli so that they can enter the nucleus to regulate the transcription of 
specific genes. For example, the interferon stimulated gene factor 3 (ISGF3) is a trimeric 
transcription factor which resides in the cytosol in an inactive state (reviewed in Hill and 
Treisman, 1995; Schlinder and Darnell, 1995). It is stimulated in response to treatment of 
cells with the cytokine, interferon a (IFa) via the JAK-STAT signal transduction pathway. 
JAK refers to a family of receptor- associated tyrosine kinases and STAT refers to a family of 
latent cytoplasmic transcription factors, which are activated by tyrosine phosphorylation. 
ISGF3 is composed of an a-interferon inducible component referred to as ISGF3ca and a 48 
kDa constitutively active DNA binding component, which can be induced by y-interferon, 
known as ISGF3y (a member of the IRF-1 family of transcription factors). ISGF3 a is a dimer
21
comprised of two STAT (signal transducers and activators of transcription) proteins , STAT2 
(113kDa) and either STAT 1 a (91 kDa) or an 84kDa C-terminally truncated splice product of 
STAT 1a, referred to as STAT 1p. Following treatment with interferon a the 
cytoplasmically located subunits of ISGF3a (STAT 2 and either STAT 1a or STAT Ip) are 
tyrosine phosphorylated on a specific residue towards their C-termini and associate into an 
active signal transducing factor (STF). The STAT1:STAT2 heterodimer translocates to the 
nucleus where it forms a complex with ISGF3y to yield the mature transcription factor, 
ISGF3. ISGF3 can then bind to a specific sequence which is located in the promoters of 
interferon responsive genes and is referred to as a type I interferon stimulatable response 
element (ISRE).
Tyrosine phosphorylation of the STATl and STAT2 proteins of ISGF3 is achieved 
through the activation of the interferon a receptor following stimulation by the binding of 
IFNa at the extracellular surface. IFNa has been shown to induce rapid phosphorylation of its 
receptors as well as two receptor associated tyrosine kinases, JAKl and TYK2, members of 
the Janus kinase (JAK) family. The JAK kinases appear to be essential for the activation of 
the STAT proteins. Recent evidence has demonstrated that TYK2 can tyrosine phosphorylate 
the IFNa receptor subunit 1. This complex can recruit unphosphorylated STAT2 (via the SH2 
domain of STAT2) to the receptors phosphorylated residues, essentially acting as a docking 
site for the protein (Yan et al, 1996). Further studies have shown a dependence of STATl 
phosphorylation on the STAT2 protein but not vice versa (Leung et al., 1995). It has been 
proposed that STATl may be drawn into the receptor complex through the activated STAT2 
protein and activated by a JAKl/TYK mediated event. The dissociation of the STATl:STAT2 
complex from the receptor is thought to be controlled by the SH2 domains of these proteins. 
After initial binding to the receptor tyrosine motif, the SH2 domain is believed to shift its 
binding specificity to that of the associated tyrosine kinases (JAK1/TYK2) and perhaps to 
additional stabilising domains. Presumably the subsequent activation of the STATs would 
than act to destabilise the kinase interaction, promoting the formation of energetically 
favourable dimers (Gupta et al, 1996).
22
Cytoplasmically located transcription factors can be held in an inactive form via their 
association with so-called inhibitory proteins. Various stimuli can release the factor from this 
protein and permit its translocation to the nucleus where it can participate in DNA binding 
and hence transcriptional modulation. For example, the previously mentioned steroid hormone 
receptors (see section 1.311) when not bound to their respective hormone ligands are held in 
the cytoplasm by a large multiprotein complex of chaperones, including Hsp90 and the 
immunophilin Hsp56 (reviewed in Pratt., 1993; Beato et al., 1995). The receptors are only 
released from their protein anchor by the steroid hormones which allows the receptor to 
dimerise and enter the nucleus where it can bind to specific palindromic DNA sequences and 
transcriptionally activate genes (the mechanism of activation of the mouse mammary tumour 
virus long terminal repeat by the glucocorticoid receptor has already been discussed in section 
1.314).
Hsp90 interacts with the C-terminal region of the glucocorticoid receptor which also 
contains the sequences responsible for steroid binding (Pratt, 1995). Immediately adjacent to 
this region is the DNA binding domain of the receptor and the sequences responsible for 
receptor dimerisation. It is thought that Hsp90 masks these regions when it is bound to the 
receptor and only after Hsp90 is displaced by steroids can the receptor dimerise and bind to 
DNA. It has been demonstrated that disruption of Hsp90 homologues in yeast strains 
expressing the glucoorticoid receptor does not result in an expected constitutive activation of 
the receptor. Instead, the ability of the receptor to be stimulated by hormones is dramatically 
reduced. It has therefore been suggested that the protein chaperones help to maintain the 
function of the steroid hormone receptors. Other chaperones besides Hsp90 have also been 
shown to assist in conserving the functional integrity of the steroid hormone receptors. This 
includes the yeast YDJ1 protein, a member of the DnaJ chaperone family, which can bind to 
unliganded steroid thyroid hormone receptors (Kimura etal., 1995).
In parallel to the steroid hormones there exists a group of transcription factors known 
as the Rel/NF-KB family which are also primarily regulated through inhibitory proteins in the 
cytosol. One of these family members, known as NF-kB has received extensive interest 
because it plays an important role in several diseases and is also involved in controlling the
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expression of many genes including those of the immune and inflammatory responses. NF-kB 
is a ubiquitous transcription factor present in mammalian cells and is activated by exposure of 
cells to a range of stimuli including inflammatory cytokines such as tumour necrosis factor 
(TNF) and interleukin-1 (IL-1), viral infection or the expression of certain viral gene products, 
B or T-cell activation or UV irradiation (reviewed in Liou etal, 1993). Cytosolic activation of 
NF-kB is modulated through the targeted phosphorylation and subsequent degradation of its 
inhibitor protein, IkB which releases NF-kB allowing it to translocate to the nucleus and bind 
specific DNA sequences. There it can regulate the transcription of many viral and cellular 
genes such as those of the human immunodeficiency virus (reviewed in Roulston etal, 1995; 
Baldwin, 1996). The discussion which follows in sections 2 and 3 will be mainly focused on 
NF-kB and its inhibitor protein, IkB although some details of the other Rel/NF-KB family 
members will be given.
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2. THE NF-kB AND iKBa PROTEINS.
2.1. Structure and function of NF-kB.
2.11. Identification and purification of NF-kB.
NF-kB was first identified in mature B-cells as a nuclear factor which bound to a 
specific DNA sequence located in the immunoglobulin K light chain gene transcriptional 
enhancer and referred to as the kB motif (5’ GGGGACTTTCC 3’, the immunoglobulin type 
of kB motif) (Sen and Baltimore, 1986a). Subsequently, NF-kB DNA binding activity was 
found to be inducible in pre-B cells following exposure to lipopolysaccharide (LPS) or the 
active phorbol ester phorbol 12-myristyl 13-acetate (PMA) (Sen and Baltimore, 1986b). In 
addition, it was discovered that NF-kB DNA binding activity was independent of protein 
synthesis since protein translation inhibitors such as cycloheximide could activate DNA 
binding. This indicated that NF-kB may exist in an inactive form prior to stimulation, possibly 
bound to an inhibitor protein. Another significant discovery in this study was that neither NF- 
kB nor its potential repressor protein were confined to the B-cell lineage as previously 
believed: NF-kB could be induced in both T-cell and epithelial cell lines. Subsequent studies 
identified functional NF-kB recognition sites in the promoters and enhancers of several genes 
in cells other than those of the B-cell lineage such as the MHC class I and p2 globulin genes 
(Yano etal, 1987; Baldwin and Sharp, 1988),
The identification of a specific, reversible inhibitor of NF-kB DNA binding activity, 
named the IkB protein clarified the mechanism of NF-kB activation (Baeuerle and Baltimore, 
1988a, b). It was suggested that NF-kB was sequestered in the cytoplasm of cells via its 
interaction with I kB and that various stimuli could disrupt this association thereby allowing 
NF-kB Io enter the nucleus and lransaclivale target genes (reviewed in Liou and Baltimore, 
1993). A detailed discussion of the relationship between NF-kB and IkB will be given under 
the sub-section which deals with the mechanisms of NF-kB regulation.
Early efforts to DNA affinity purify NF-kB from human cell lines using double­
stranded multimers of the kB recognition site (5’ GGGACTTTCC 3’) yielded proteins of 
around 40-60kDa (Kawakami etal, 1988; Lenardo etal, 1988). More definitive biochemical 
analyses revealed that the inducible form of NF-kB was comprised of two polypeptides with
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apparent molecular sizes of 50kD and 60kD, referred to as p50 and p65 (Baeuerle and 
Baltimore, 1989).
2.12. Cloning of NF- KB the emergence of the Rel/NF- KB family of proteins. The 
first subunit of NF-kB to be cloned was that of p50 and resulted from the independent and 
simultaneous efforts of several laboratories (Kieran et aL, 1990; Ghosh etal, 1990: Bours et 
al., 1990). The amino acid sequence of p50 was found to be identical to that of the 
constitutively active nuclear protein, KBF-1 which was previously purified from a mouse T- 
cell line (Yano et al., 1987). In addition, p50 appeared to be generated from the N-terminal 
half of a larger precursor protein known as pl05 (NF-kB 1) which failed to bind DNA. The N- 
terminal region of pl05 was highly homologous to an area in the proto-oncogene product, c- 
Rel (Wilhelrasen et al., 1984; Brownell et al., 1989) and the Drosophila maternal effect 
morphogen protein dorsal which is involved in the critical developmental pathways that 
determine the dorsal-ventral patterning of the Drosophila embryo (Steward, 1987). Further 
investigations led to the isolation of cDNAs encoding the p65 (Rel A) subunit of NF-kB 
(Nolan etal, 1991; Ruben et al., 1991). Like the precursor to p50, the N-terminal region of 
p65 displayed a high level of sequence similarity to the rel proto-oncogene product. Indeed, 
p65 appeared to share more amino acid homology with c-Rel than with either p50 or dorsal. 
Conversely, the amino acid sequence of p50 was more closely related to the Drosophila 
dorsal protein than to either p65 or c-Rel.
The highly conserved N-terminal region present in p50, p65, c-Rel and the Drosophila 
dorsal protein was soon discovered in other proteins. This included the p49 protein (also 
known as p50B or p52) (Schmid et al., 1991; Bours et al., 1992) which shared extensive 
amino acid homology with p50 and like p50 was also generated from the N-terminal half of a 
larger non-DNA binding precursor protein known as pl00/p97 (or NF-kB2) via alternative 
splicing. In addition, the two closely related proteins, murine RelB (Ryseck et al, 1992) and 
human I-Rel (Ruben et al., 1992a) were cloned and found to possess areas of amino acid 
homology to the c-Rel protein. Recently, the Drosophila immune response protein, Dif which 
is involved in the regulation of bacteriocidal genes in response to endotoxin was cloned and
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its amino acid sequence was found to be highly homologous to the dorsal protein (Ip et ah, 
1993).
This group of related mammalian proteins have become collectively known as the
Rel/NF-KB family (see figure 5) and they are characterised by the presence of a Rel homology 
domain (RHD), an N-terminal region of around 300 amino acids in length which displays 
approximately 30 to 61% identity between the various family members. The RHD 
accomodates the areas of sequence which are involved in protein dimerisation (a prerequisite 
for DNA binding), DNA binding, nuclear localisation and interactions with various members 
of the IkB protein family. These functions will be discussed in section 2.14.
The Rel/NF-KB family members can be grouped into two classes on the basis of 
sequences C-terminal to the RHD. The two members of the first class, pl05 (NF-kB 1) and 
plOO (NF-kB 2) which are proteolytically cleaved to yield p50 and p49 respectively, contain 
seven copies of a 33 amino acid repeat called an ankyrin or cell-cycle repeat at their C- 
termini. These ankyrin repeats are known to mediate protein-protein interactions (reviewed in 
Michaely and Bennett, 1992) and are present in the IkB inhibitor proteins of the Rel/NF-KB 
family. The functional significance of these ankyrin repeats in plOO and pl05 will be 
discussed in section 2.23. In addition, the role that proteolytic processing of these proteins 
plays in the regulation of Rel/NF-KB proteins will be dealt with in section 2.236.
Members of the second class of Rel/NF-KB proteins which includes p65 (RelA), c-Rel, 
Rel B, Dorsal, Dif and v-Rel (the retroviral counterpart of the cellular c-Rel protein isolated 
from the avian retrovirus, Rev-T which causes rapid and fatal lymphoma in young birds 
(Gilmore and Temin, 1986; Herzog and Bose, 1986)), have generally unrelated C-terminal 
domains that do not contain ankyrin repeats. They are also characterised by the absence of 
approximately 25 amino acids in the RHD, a length of sequence that is present in the class I 
Rel/NF-KB proteins.
Recently it has been suggested that the NF-AT family of transcription factors may 
also be related to the Rel/NF-KB group of proteins. The NF-AT transcription factors are 
believed to be involved in the inducible transcription of the IL-2 gene and other cytokine 
genes. Several similarities exist between the NF-AT and Rel/NF-KB groups of proteins
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Figure 5: The Rel/NF-KB/Dorsal family.
All the members of this family contain the well-conserved Rel homology domain 
(green box) which is -300 amino acids long and is involved in DNA binding and 
dimerisation. The nuclear localisation signal (NLS) (blue box), a stretch of basic 
amino acids, is also well coserved. (TA) Trans-activation domain present in c-Rel, 
p65, Dorsal, and Dif. Both p50 and p52 are generated by a proteolytic processing 
event of the precursor pl05 and plOO possibly involving the glycine “hinge” (pink
box) region. The carboxy-terminal half of pi00 and pi05 contains the ankyrin 
motif (yellow boxes) (adapted from Verma ei al., 1995).
including their ability to be induced following the stimulation of T-cells and their use of 
cytoplasmic/nuclear partitioning as a mechanism of control. In addition, the DNA binding site 
for NF-AT family members, GGAAAA, resembles one half-site of the kB motif. Most 
significantly, the recent cloning of members of the NF-AT family has revealed a region 
similar to the RHD in the Rel/NF-KB proteins (Nolan et al., 1994; Jain et al., 1995). These 
findings indicate that the Rel/NF-KB proteins may form part of a larger family of transcription 
factors which appear to regulate important areas of immune function.
2.13. NF- kB: a dimer of distinct subunits.
The active, DNA binding forms of the Rel/NF-KB family are dimeric complexes. 
Combinatorial mixing of the different family members yields many homo- and heterodimers 
each with a different affinity for the so-called kB DNA binding site. The general consensus 
sequence for the DNA binding site is a degenerate decamer (GGGRN/NYYCC, where R is 
any purine, N is any nucleotide and Y is any pyrimidine) that essentially contains two half­
sites. The hi-partite nature of the DNA binding site tends to reflect the type of member that 
will associate with each half-site.
The most abundant and extensively studied of all the Rel/NF-KB dimeric complexes is 
NF-kB(p50/ p65(RelA)) which is detectable in most cell types. Other dimers include 
homodimers of RelA or RelA/Rel heterodimers which usually tend to be detected in very low 
levels. It appears that certain dimers do not exist, for example RelB will only dimerise with 
p50 or p52 (Ryseck et al., 1995).
As previously mentioned each dimer type has a preference for a certain kB binding 
site. For example, classic NF-kB binds to the sequence, 5' GGGRNNYYCC 3’ (where R is 
any purine, N is any nucleotide and Y is any pyrimidine), whereas RelA/c-Rel binds to the 
sequence, 5’ HGGARNYYCC 3’ (where H indicates A, C or T; R refers to purine and Y is 
pyrimidine) (Parry et al.., 1994). The two types of subunit comprising NF-kB have been 
shown to vary in their preference for the two half sites which comprise the prototypical 
immunoglobulin (Ig) kB site: p50 binds to the 5’ half site (5’-GGGAC), while the p65 subunit 
tends to associate with the 3’ half site (3’GGAAA, opposite strand) (Urban & Baeuerle, 1991;
28
Kunch et al, 1992). Subsequently, homodimers of p50 prefer to interact with palindromic 
sites consisting of two Ig kB 5’ half sites and p65 homodimers bind with higher affinity to 
duplicated Ig kB 3’ half sites. Such selective recognition of KBbinding sites by the various 
combinations of Rel/NF-KB members increases the number of genes which can be regulated 
by NF-kB dimers. In addition to differences in binding site preference, different combinations 
of the Rel/NF- kB family also exhibit distinct transactivation potentials, kinetics of nuclear 
translocation, interactions with members of the IkB family and activation (reviewed in 
Siebenlist et al, 1994 and discussed in the sections which follow).
2.14. The protein of NF- tK and their functions.
As previously mentioned, the RHD present in all Rel/NF-KB family members is
responsible for DNA binding, dimerisation, nuclear localisation and interactions with the 
various members of the IkB family of proteins. Classical NF-kB (p50/p65) contacts DNA 
through both subunits as described in section 2.11. The crystal structure of the 50kD NF-kB 1 
homodimer bound to a kB site (Ghosh et al., 1995; Muller et al., 1995) has revealed that large 
areas of the RHD constitute the DNA binding surface of the protein and contacts the entire 
major groove of the bound DNA. In addition, the RHD is arranged into two domains, each of 
which contribute to DNA binding. The dimerisation surface of the two subunits of NF-kB 1 is 
formed by the side chains from three p-strands in the C-terminal region of each RHD. 
However, extensive information had been obtained on the mode of NF-kB’s DNA binding 
and the location of the dimerisation domain before the crystal structure of NF-kB 1 had been 
published (reviewed in Grimm and Baeuerle, 1993; Matthews and Hay, 1995). An early study 
had shown that the dimerisation domain of p50 was contained within the N-terminal region of 
the RHD, specifically amino acids 201-367 (Logeat et al., 1991). Furthermore, internal 
deletions within the C-terminal region of the RHD of p50 from amino acids 11-200 prevented 
DNA binding but did not affect homo- or heterodimer formation. An alternatively spliced 
transcript of p65 which lacked amino acids 222-231 (equivalent to residues 279-293 in p50) 
had also been reported and failed to homodimerise or to form heterodimers with p50 (Ruben
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et al., 1992b). Indeed, a complementary study of p50 by Bressler et al in 1993 reported that 
the mutation of residues similar to those missing in the p65 transcript impeded dimerisation.
As described above, DNA binding of p50 was prevented by the internal deletion of the 
N-terminal residues, 22-200 of the RHD (Logeat et al., 1991) which corresponds to the 
information obtained from the p50 homodimer-KB motif DNA co-crystal structures. Other 
studies also demonstrated that the N-terminal region of the RHD was critical for p50 DNA 
binding. This included a study involving the creation of a fusion protein comprised of residues 
35-68 of human p50 and residues 46-309 of human p65 (Coleman et al., 1993). The resulting 
hybrid protein exhibited p50 DNA binding specificity which could be switched to p65 
specific DNA recognition by the introduction of a single amino acid change (H67R) to the 
p50 sequence. Moreover, substituting four residues in the N-terminal region of the p65 
sequence for the corresponding p50 residues, generated a mutant with the ability to bind to kB 
motif and specific p50 DNA sequences but incapable of recognising p65 DNA sites. An 
additional mutagenesis study found that residues 54-70 of human p50 were important for 
DNA binding. This finding agreed with the p50 homodimer-KB co-crystal structure since 
these residues form the start of a loop region in the N-terminal area of the RHD which makes 
several base and backbone DNA contacts (Toledano et al, 1993).
A small region of amino acids at the beginning of the N-terminal section of the RHD 
(the R(F/G)(R/K)YXCE motif) was also found to be essential for p50 DNA binding 
(Toledano et al., 1993) and the p50 homodimer-KB DNA motif co-crystal structure showed 
that this region made direct contact with the major groove of the DNA recognition sequence. 
Site directed mutagenesis of the cysteine residue within this motif (conserved amongst all 
Rel/NF-KB family members) indicated that this amino acid was required for redox regulation 
of DNA binding activity (C35 of v-Rel, Kumar et al., 1992 and C62 of human p50, Matthews 
et al., 1992; Toledano et al., 1993). Indeed, prior to this discovery several other groups had 
suggested that NF-kB DNA binding activity might depend on the redox state of a cysteine 
residue (Toledano and Leonard, 1991; Matthews etal, 1992 and Hayashi etal, 1993). The 
modification of cysteine 62 in p50 by treatment with iodoacetate was found to inhibit p50 
DNA binding. However, attempts to modify p50 and inhibit its DNA binding activity when
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the homodimer was complexed with its specific DNA recognition site failed, indicating that 
the cysteine residue was probably located near to the DNA (Matthews et al., 1993a). This 
suggestion was confirmed by the co-crystal structure of p50 homodimers bound to a kB motif 
which illustrated that cysteine 62 made contact with the DNA backbone (Ghosh et al., 1995; 
Muller et al., 1995). Photocrosslinking studies implicating residue Y60 of p50 as a 
determinant of DNA binding specificity (Liu etal., 1994) were also substantiated by the X- 
ray co-crystal structure of p50 homodimers complexed with the kB motif. The side-chain of 
Y60 was found to donate a hydrogen bond to a DNA phosphate in the kB motif (Ghosh et al., 
1995; Muller etal., 1995).
Partial proteolysis studies have revealed that the binding of p50 to the high affinity 
H2TF1 type kB motif involves conformational changes in the N-terminal region of the protein 
(Hay and Nicholson, 1993). More recent studies using circular dichroism (CD) spectroscopy 
have confirmed that both p50 homodimers and p65 homodimers change conformation upon 
association with specific or non-specific DNA recognition sites (Matthews et al., 1995). 
However, corresponding changes in the conformation of the DNA recognition sites which are 
complexed with either p50 or p65, were limited to only the high affinity type of kB motif. 
Such protein-induced distortion of the DNA at kB motifs was thought to account for the 
change in the alkylation pattern observed upon NF-kB binding in early chemical probing 
studies (Clark et al., 1989, 1990). In contrast, a recent discovery shows that purified p50 
homodimers appear to induce minimal DNA bending in a variety of kB sites (Kuprash et al.., 
1995). This finding was confirmed by the X-ray crystal structures of p50 homodimers 
complexed with the kB motif (Ghosh et al., 1995 and Muller et al., 1995) which indicated that 
the DNA recognition sites were only bent slightly upon p50 binding. Taken together with the 
CD spectroscopy findings (Matthews et al., 1995) the data tends to suggest that a slight 
unwinding of the kB motif duplex probably occurs upon binding of p50 or p65 homodimers.
The Rel/NF-KB family of proteins all possess a nuclear localisation signal (NLS) 
which is located towards the end of the RHD’s C-terminal region. The NLS consists of a 
stretch of positively charged amino acids which are required for nuclear uptake of the protein 
and for interactions with the IkB inhibitor proteins (discussed later) (Blank et al., 1991; Beg
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etal, 1992; Ganchi etal, 1992; Henkel etal, 1992; Matthews etal, 1993b and Zabel etal,
1993).
Members of the Rel/NF-KB family of proteins also contain transcriptional activation 
domains which are found in the carboxyl terminal side of the RHD. The p65 subunit 
(specifically a stretch of 30 C-terminal amino acids) of NF- kB appears to provide most of the 
heterodimers transactivation function. Homodimers of p50 fail to activate gene expression 
whereas p65 homodimers and p50/p65 heterodimers (NF-kB) show strong activation 
(Schmitz and Baeuerle, 1991). However, there has been some evidence that, in certain 
circumstances p50 homodimers can activate transcription. For example, when p50 binds to 
certain types of the kB motif in vitro, such as the high affinity H2TF1 site and adopts a 
chymotrypsin resistant conformation, the protein acts as a strong transcriptional activator 
(Fujita et al., 1992). Transcriptional activation by p50 is believed to be dependent on the IkB 
protein, Bcl-3 which is thought to act as a coactivator by forming a ternary complex with p50 
homodimers at the promoter region of the gene to be activated (see section 2.233).
Other members of the Rel/NF-KB family including RelB and the closely related I-Rel 
(thought to be the human homologue of murine RelB) protein are not capable of binding kB 
sites as homodimers but can act as potent transcriptional activators as heterodimers with, for 
example p50 (Bours et al, 1994; Ryseck et al, 1992). In contrast, the full length mouse c-Rel 
protein when fused to GAL4 is a relatively poor transcriptional activator (Bull et al, 1990) 
and has been shown to interfere with p65 DNA binding resulting in the inhibition of 
transactivation by p65 homodimers (Doerre et al, 1993). However, fusing the C-terminal 
residues of c-Rel residues to GAL4 leads to transcriptional activation and it is thought that the 
N-terminal region of the full length protein may, in some way mask this potential 
transactivation domain (Bull etal, 1990).
The Rel/NF-KB family of transcription factors like all transcription factors can act as a 
rate limiting step in the assembly of the basal transcription machinery (see chapter 1). 
Available evidence has shown that c-Rel, p65 and dorsal can interact with the TATA binding 
protein (TBP) in vitro. It appears that the N-terminal 50 residues of c-Rel can also maintain 
this interaction in vivo. In contrast, v-Rel, p50 and p52 fail to associate with TBP but p50 and
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e-Rel can interact with the basal transcription factor, TFIIB in vitro (Kerr et al, 1993). More 
recently, it has been demonstrated that the C-terminal transactivation domain of p65 can 
interact with TBP, TFIIB and at least one coactivator protein, PCI in vitro (Schimtz et al., 
1995). One model has been proposed in which p50/p65 or p50/c-Rel heterodimers once 
associated with their kB recognition sites, could bind to TBP via p65 or c-Rel and then 
promote the assembly of the preinitiation complex by interacting with TFIIB via p50 and / or 
c-Rel.
2.15. Interactions between NF-kB and other cellular transcription factors.
NF-kB is capable of interacting with other transcription factors and there is evidence 
to suggest that this affects the ability of NF-kB to selectively mediate the transcription of 
target genes. As detailed in the section above, NF-kB can associate with members of the basal 
transcription machinery but interactions with transcription factors such as the high mobility 
group protein HMGI(Y), the CCAAT/enhancer element binding protein (C/EBP) and Spl 
have also been demonstrated, to name but a few.
Both NF-kB and HMGl are essential for activation of the human interferon (3 gene 
(IFNp). The human IFNp gene is stimulated by viral infection or by treatment with double­
stranded RNA. HMGI(Y) has been shown to stimulate the binding of NF-kB to a kB site in 
the promoter of the IFN p gene by associating with the central core of this site and promoting 
the binding of NF-kB to the outer sequences of the kB site. In addition, it has been 
demonstrated that HMGI(Y) can interact directly with both the p50 and p65 subunits of NF- 
kB (reviewed in Baldwin, 1996; Lin etal, 1995; Thanos and Maniatis, 1995).
Avian lymphoid cells contain complexes of C/EBP and NF-kB proteins which are 
capable of binding DNA and a recent study has suggested that such interactions may be 
important for the regulation of avian leukosis virus LTR (long terminal repeat) driven 
transcription (avian leukosis virus induces B-cell lymphomas in chickens following 
integration of the proviral LTR enhancer sequences adjacent to the c-myc proto-oncogene) 
(Bowers et al., 1996). An NF-KB/Rel related factor was found to be a component of the LTR 
binding complex (which activates transcription) and immunoprecipitation studies on cells
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demonstrated that the NF-KB/Rel factor could bind to a C/EBP factor referred to as Al/EBP. 
In addition, in vitro analyses of NF-kB/ C/EBP interactions have indicated that both p50 and 
p65 can bind to Al/EBP. Furthermore, p65 was able to activate LTR CCAAT/enhancer 
element transcription.
The transcription factor Spl, a constitutively expressed protein present in a wide range 
of cell types which binds to GC-rich sequences in the promoters of many viral and cellular 
genes, can interact with NF-kB to stimulate HIV-1 transcription. Interestingly the two 
transcription factors associate with one another through their respective DNA binding 
domains which allows cooperative DNA binding of each transcription factor to their specific 
sites in the HIV-1 long terminal repeat. The HIV-1 LTR contains two kB sites in close 
proximity to three Spl sites and it is assumed that this permits NF-KB-Spl interaction 
(Perkins etal., 1994).
2.2. The IkB proteins.
2,21.Identification and purification of I tKB oe
IkB was first discovered in 1988 by Baeuerle and Baltimore (a,b) as an inhibitor of 
NF-kB DNA binding activity. It appeared that NF- kB could be prevented from binding target 
DNA sequences by its association with IkB in the cytoplasm of cells. Furthermore, NF-kB 
was not associated with IkB in the nucleus indicating that the inhibitory action of IkB on NF- 
kB DNA binding was exerted in the cytoplasm (Baeuerle and Baltimore, 1988a,b). Therefore, 
IkB appeared to be able to exert a twofold effect on NF-kB: inhibition of both NF-kB nuclear 
translocation and DNA binding.
Initial attempts to purify the IkB protein(s) associated with NF-kB (from cytosolic 
fractions of the human placenta) yielded two chromatographically distinct forms of IkB: A 
35-37kDa species, termed iKBa and a minor form (constituting approximately 20-30% of the 
placental inhibitory activity) named iKBp of 43kDa (Zabel and Baeuerle, 1990). Both forms 
of IkB were capable of inhibiting the DNA binding activity of NF-kB but not of p50 
homodimers. In addition, both IkB(3 and iKBa were shown to dissociate NF-kB from a high 
affinity DNA binding site.
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2.22. Cloning of IK a and the f^em^e^r^en^^ce of a family of IK proteins.
The cDNA encoding the IKBa protein (or MAD-3; 36-38kDa) was isolated in 1991 
from mRNAs which were induced following adherence of human monocytes (Haskill etal, 
1991). The IkBcx protein could prevent NF-kB and c-Rel DNA binding in vitro but could not 
inhibit DNA binding of p50 homodimers. Furthermore, iKBa was found to contain six copies 
of the 33 amino acid ankyrin repeat, previously shown to be present at the C-terminal end of 
the pl05 precursor to p50 and to be responsible for its inability to bind DNA (Kieran etal, 
1990; Ghosh et al., 1990). This suggested that the ankyrin repeats may play an important role 
in the functioning of IkB proteins.
The cloning of IKBa was soon followed by the isolation of a cDNA encoding an avian 
homologue of iKBa , termed pp40 (Davis et al., 1991). Like iKBa, pp40 was able to inhibit 
the DNA binding activity of p65 or c-Rel containing complexes (NF-kB, p50/c~Rel and c-Rel 
homodimers). A rat homologue of human iKBa and chicken pp40, termed RL/IF-1 
(regenerating liver inhibitory factor), was identified by Tewari et al in 1992 and was found to 
inhibit the DNA binding of NF-kB, c-Rel/p50, RelB/p50 but not homodimers of p50 in vitro. 
Another homologue of IkB a was discovered in pigs and is known as ECI-6 (deMartin et al, 
1993). This protein displays both functional and structural similarities to the other iKBa 
homologues.
Several other functionally related IkB proteins have since been identified which 
contain a number of copies of the ankyrin repeat region. These include mammalian IkB., Bcl- 
3, IkBR, IkBL and Drosophila cactus. IkB. is a 70kDa protein which is detected in cells of a 
lymphoid lineage and is the product of an alternatively spliced RNA transcribed from the 
pl05 gene (this gene also generates the p50 protein-see section 2.12). IkB. corresponds to the 
C-terminal ankyrin repeat region of the full-length pl05 protein. IkB. was originally shown to 
be capable of inhibiting the DNA binding of p50 homodimers, NF-kB and c-Rel in vitro 
(Inoue etal, 1992). However, subsequent studies using an independently expressed carboxy­
terminal region of pi 05 (which corresponds to Ik By ) have suggested that Ik By has an 
inhibitory specificity for p50 homodimers ( Liou etal, 1992).
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The Bcl-3 protein, encoded by a proto-oncogene, was originally discovered in 1990 
and found to contain seven tandem copies of the ankyrin repeat region (Ohno et al, 1990). 
Later studies established Bcl-3 as an iKB-like protein through its ability to inhibit the DNA 
binding of p50 homodimers {in vitro) via its ankyrin repeats (Hatada et al, 1992). The Bcl-3 
protein has been found to be selective for both p50 homodimers and p52 homodimers (Nolan 
etal, 1993). In addition, Bcl-3 is thought to act as a coactivator of p50 and p52 homodimers 
(section 2.233). However, it has been reported that the protein can also inhibit the DNA 
binding of NF-kB (p50/p65) (Kerr et al., 1992) although titration experiments have shown 
that this inhibitory capacity is minimal when compared to the inhibition exerted on p50 
homodimers by Bcl-3 (Nolan etal, 1993).
The cloning of the Drosophila cactus gene and the sequencing of its maternal 
transcript revealed areas of homology to the mammalian IkB genes (Geisler etal, 1992 ;Kidd 
et al., 1992). The predicted protein sequence showed a set of seven ankyrin repeats and the 
bacterially expressed protein was capable of inhibiting the DNA binding activity of the 
Drosophila NF-kB/ Rel related protein, dorsal (Geisler et al, 1992). Indeed, previous studies 
had demonstrated that cactus activity was required to retain dorsal in the cytoplasm of cells.
A cDNA representing the gene which encodes the IkBR protein (iKB-related) was 
isolated from human epithelial cells by Ray et al.. in 1995. The IkBR protein sequence is 
highly homologous to other IkB proteins, exhibiting greatest sequence similarity to the 
Drosophila protein, Cactus and containing three carboxy-terminal ankyrin repeats. IkBR was 
able to inhibit the DNA binding activity of both NF-kB and p50 homodimers in vitro but 
failed to prevent DNA binding of p65 homodimers. In addition, co-transfection of a vector 
over-expressing the IkBR protein with an NF-kB dependent luciferase expression vector into 
a murine embryonal carcinoma line (F9), resulted in inhibition of NF-kB-mediated activation 
of luciferase expression. It is thought that IkBR may regulate the activity of NF-kB and 
perhaps other unidentified target proteins in epithelial cells.
The cDNA encoding a protein referred to as IkBL also exhibits homology to the other 
IkB proteins. IkBL possesses two complete ankyrin repeats together with a third incomplete 
repeat and its gene is located in the major histocompatibility complex (Albertella etal, 1994).
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The gene encoding the mammalian iKBp protein was cloned in 1995 (Thompson et 
al., 1995) and together with iKBa represents one of the most abundant forms of the IkB 
proteins identified so far in mammalian cells. iKBp (around 45kDa) was shown to inhibit the 
DNA binding activity of NF-kB in vitro . Furthermore, co-transfection of Cos7 cells with 
vectors expressing iKBp and either p50 and p65 or p50 and c-Rel demonstrated the ability of 
IkBP to inhibit the DNA binding of both p65 and c-Rel (although the inhibitory effect 
observed was weaker with respect to c-Rel). Recombinant IkBP was also shown to interact 
equally well with p65 and c-Rel but the protein failed to associate with p50.
The proteins described above constitute the IkB family of proteins (figure 6) and 
include the NF-kB precursor proteins, pl05 and pl00, previously mentioned in section 2.12. 
Both pl05 and pl00 have been found complexed with p50, p65 or c-Rel in vivo and can retain 
these proteins in the cytoplasm of cells (Rice et al., 1992; Mercurio et al, 1993; Rice and 
Ernst, 1993 and Miyamoto et al., 1994). The IkB proteins are characterised by the presence of 
several copies of a 30-35 amino acid ankyrin repeat, generally located in the centre of the IkB 
protein and their ability to interact with members of the NF-KB/Rel family of transcription 
factors. Ankyrin repeats can also be found in yeast cell-cycle proteins (Breeden and Nasmyth, 
1987) and human erythrocyte ankyrin (Lux etal, 1990) although they vary from the distinct 
sequence of the IkB ankyrin repeats (Nolan and Baltimore, 1992). The ankyrin repeats are 
required for protein-protein interactions, in effect they enable the individual members of the 
IkB family to bind to their respective NF-KB/Rel dimeric complexes.
2.23. Regulation of NF-kB byOxBa.
The primary role of IkB a is to regulate the activity of the transcription factor, NF-kB 
and there are several ways in which IkB a can achieve this control. For example, through the 
inhibition of both NF-kB DNA binding activity and nuclear translocation, in addition to those 
mechanisms which mediate the transient loss and resynthesis of iKBa itself. The following 
headings outline the various control mechanisms exerted on NF-kB via iKBa.
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Figure 6: The IkB family.
The IkB proteins are characterised by the presence of ankyrin repeats (yellow boxes) 
whose numbers vary among the various family members (3 to 7). The ankyrin repeat 
domains are essential for protein-protein interactions. IkBy is generated by alternative 
splicing from pi05 mRNA. Cactus is the functional IkB homologue in 
Drosophila (adapted from Verma et al., 1995).
2.23 L Interaction of IkB a with NF-kB and the mechanisms of NF-kB cytoplasmic 
retention.
A combination of mutational analyses and protease sensitivity studies have allowed 
the identification of regions within IKBa which are important for interacting with NF- kB and 
for the cytoplasmic retention of NF-kB. Several observations have indicated that iKBa 
preferentially inhibits the DNA binding activity of the p65 rather than the p50 subunit of NF- 
kB (reviewed in Grimm and Baeuerle, 1993). For example, the addition of p65 homodimers 
to an inactive complex of NF-kB bound to iKBa results in the release of active NF-kB. 
Furthermore, an excess of p65 but not p50 homodimers can block the inhibition of NF-kB 
DNA binding activity by iKBa (Urban and Baeuerle, 1990). In addition, the inhibitory 
specificity exhibited by iKBa is for p65 homodimers and p50/p65 (NF-kB) heterodimers but 
not for p50 homodimers (Baeuerle and Baltimore, 1989; Urban et al., 1991). Therefore, most 
of the information which follows on the interaction between iKBa and NF-kB concerns the 
association between the p65 subunit of NF-kB and iKBa.
Structurally, iKBa can be divided into three distinct regions: an N-terminal region of 
70 amino acids, an internal domain of 205 amino acids that is comprised of ankyrin repeats, 
and a C-terminal acidic region of 42 amino acids. Early studies demonstrated that the C- 
terminal region and the ankyrin repeats of IkB a were required for binding to members of the 
NF-KB/Rel family. For example, a report on the avian form of iKBa (pp40) and its association 
with Rel in vitro showed that a mutant- lacking amino acids 253-317 failed to interact with Rel 
(Inoue etal, 1992). Furthermore, mutation of individual pp40 ankyrin repeats revealed that 
all but ankyrin repeat 3 were essential for association with c-Rel. In addition, co-transfection 
of a vector expressing a pp40 mutant containing an altered fifth ankyrin repeat (which could 
not bind c-Rel) with an NF-kB-dependent reporter plasmid resulted in a failure of the mutant 
to inhibit transcription from the reporter (i.e. through the binding of NF-kB in the cytoplasm). 
In contrast, removal of the N-terminal 51 amino acids did not affect either pp40-c-Rel, pp40- 
p65 or pp40-p50 interaction. A later study to determine the minimal domains of human IKBa 
(MAD-3) and pl05 required for interaction with members of the NF-KB/Rel family revealed 
that a deletion of only three amino acids (71-73) at the start of the first ankyrin repeat of
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iKBa could markedly reduce its affinity for p65 (Hatada et al, 1993). Also, removal of the 
C-terminal amino acids, 280-317 and the N-terminal amino acids, 1-70 of iKBa resulted in a 
loss of interaction with p65 in vitro, whereas deletion of only the N-terminal residues from 1­
70 had virtually no effect on lKBa-p65 binding. In parallel with iKBa, a deletion mutant of 
pl05 lacking the C-terminal acidic region together with the seventh ankyrin repeat (not 
present in iKBa) failed to associate with p50. Surprisingly, a pl05 deletion mutant lacking the 
seventh ankyrin repeat exhibited a weak interaction with p50.
In contrast, other more recent mutational studies have found that the acidic C-terminal 
residues from 279-317 of IkB a are dispensible for association with NF-kB. Ernst etal. (1995) 
generated a C-terminal IkB a mutant lacking amino acids 279-317 which was capable of 
interacting with p65 both in vitro and in vivo. Moreover, immunofluorescence analysis of 
cells cotransfected with vectors expressing p65 and the C-terminal deletion mutant illustrated 
that p65 could still be retained in the cytoplasm of cells by mutant iKBa. A possible 
explanation for this discrepancy exists in the nature and origin of the iKBa mutant generated 
in the earlier study (Hatada et al., 1993). Firstly, Hatada et al generated a mutant that lacked 
the potential stabilising influence of the N-terminal residues (1-70) as well as the C-terminal 
amino acids, 280-317. Secondly, the mutant was expressed in, and isolated from bacteria, 
whereas Ernst et al performed studies on either in vitro translated proteins or proteins 
expressed in mammalian cells.
Interestingly, it appears that the association between IkB a and v-Rel, the oncogenic 
viral counterpart of c-Rel, does require the C-terminal region of iKBa as well as the ankyrin 
repeat region. The C-terminal region also appears to be required for cytoplasmic retention of 
v-Rel by iKBa. In contrast, the C-terminus of IkB a is dispensible for its association with c- 
Rel and for the cytoplasmic retention of c-Rel. This was discovered in a recent study using the 
yeast two hybrid system where a fusion protein of v-Rel and the Gal4 DNA binding domain 
was analysed for its ability to activate Gal-4 dependent p-galactosidase expression in the 
absence or presence of either a C-terminal iKBa deletion mutant lacking amino acids 300-317 
or 281-317 fused to the Gal4 activation domain. High level p-galactosidase expression was 
observed in the presence of the C-terminal deletion mutant, 300-317 but expression did not
39
increase above background levels in the presence of the mutant devoid of residues 281-317 
(Rottjakob et al., 1996). In addition, an IkBcc Gal4 (the activation domain) fusion mutant 
containing a deletion of 142 amino acids in the ankyrin did not associate with v-Rel (in fusion 
with the Gal4 DNA binding domain) in yeast. Immunofluoresence analysis of cells co­
transfected with a vector expressing either the C-terminal deletion mutant, 281-317 or an 
IKBa mutant containing three substituted residues at position 288-290 and a vector expressing 
v-Rel revealed that neither of the mutants could retain v-Rel in the cytoplasm. This indicated 
that distinct regions within the C-terminal region of pp40 were required for the cytoplasmic 
retention of v-Rel.
The above study also revealed that certain mutant forms of both c-Rel and v-Rel (for 
example a v-Rel mutant containing an amino acid substitution in a consensus protein kinase A 
site (S275 to A275) and a C-terminally truncated c-Rel protein containing a serine to cysteine 
substitution at position 26) could associate with pp40 but failed to be retained in the 
cytoplasm of cells when overexpressed with pp40. This suggested that the association of pp40 
with Rel proteins was not sufficient for their cytoplasmic retention and that some other 
contributory factor was involved, possibly post-translational modifications of either Rel or 
pp40.
A role for the low homology sixth ankyrin repeat of IKBa in p65-lKBa association has 
recently been suggested through protease sensitivity studies of IkBoc (Jaffray et al., 1995). 
This report describes the protection of residues 251 (Y), 258 (W) and 275 (E) from proteolytic 
cleavage in the low homology sixth ankyrin repeat of IkBoc when the protein is bound to p65. 
A more recent study using deletion mutants of IkBcc has indicated that the removal of residues 
263-317 prevents p65-lKB a interaction in vivo. Furthermore, immunofluorescence assays 
using the overexpressed IKBa deletion mutant (265-317) revealed that it could not localise 
overexpressed p65 in the cytoplasm of transfected cells. This correlated with the inability of 
the overexpressed mutant to inhibit NF-KB-dependent transcription from a reporter plasmid in 
transfected cells (Sun et al., 1996). Similarly, another report demonstrated that the deletion of 
either amino acids 261-317 or 269-317 in IkBoc abolishes binding to p65 in vivo (Beauparlant 
etal., 1996).
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The interaction of iKBa with heterodimeric complexes containing either p65 or c-Rel 
results in the localisation of these complexes in the cytoplasm of cells. It has been shown that 
both iKBa and the ankyrin repeat region of pl05 can interact with, and shield the nuclear 
localisation signal (NLS) located at the C-terminal end of the RHD of some NF-KB/Rel 
family members. An early report investigated the effect of removing or substituting the 
residues corresponding to the NLS’s of p50, p65 and c-Rel on their interaction with iKBa. It 
was discovered that the mutant proteins could not interact with iKBa. In addition, 
overexpression of the p65 NLS mutant from a transfected vector in cells revealed that the 
mutant was exclusively cytoplasmic, unlike transfected wild-type p65 which was found in 
high levels within the nucleus. However, fusion of a second NLS derived from the SV40 large 
T-antigen to the p65 mutant resulted in its nuclear localisation, indicating that the iKBa could 
not interact with the new NLS and therefore failed to retain the mutant within the cytoplasm 
(Beg et al., 1992). Around the same period, a report on the pl05 protein emerged which 
demonstrated that its NLS could not bind an anti-p50 NLS-antibody (Henkel etal, 1992). 
Indeed earlier experiments using a pl05 mutant lacking the C-terminal acidic region (between 
the sixth and seventh ankyrin repeats) had shown 10% nuclear localisation (whereas wild-type 
pl05 was not found in the nucleus) and it was suggested that this region may interact with the 
NLS in the full-length pl05 protein, preventing nuclear localisation (Blank etal., 1991).
A later study demonstrated that when iKBa was associated with NF-kB, antibodies 
specific for regions which overlapped the NLS of both p50 and p65 failed to recognise their 
epitopes on these proteins (Zabel et al, 1993). In contrast, an additional report on iKBa 
showed that whilst iKBa could block the binding of antibodies to the p65 NLS, an antibody to 
the p50 NLS was still able to immunoprecipitate p50. However, the p65-NLS antibody could 
co-immunoprecipitate p50 and p65 following the co-translation of their mRNA’s. It was 
suggested that when p50 and p65 were associated (i.e. as NF-kB) iKBa was able to contact 
both of their NLS’s (Zabel et al., 1993). The discovery that p50 alone (i.e. p50 homodimers) 
did not interact with iKBa through its NLS was supported by the finding that a complex of 
p50 and iKBa was accessible to proteolytic cleavage by trypsin, which initially cuts at 
sequences in or near to the NLS of p50. However, when the C-terminal region of pl05
41
(corresponding to iKBy) was bound to p50, digestion with trypsin was blocked. Furthermore, 
p50 failed to be immunoprecipitated with an antibody recognising the NLS in the presence of 
the pl05 C-terminus (Matthews etal., 1993b).
It appears that the NLSs of the c-Rel protein and its oncogenic counterpart, v-Rel are 
not required for association with pp40. Fusion of c-Rel and v-Rel mutant proteins, containing 
deleted NLSs (residues 298-303) with the Gal4 DNA binding domain did not affect P~ 
galactosidase expression in yeast cells when tested with a Gal4 activation domain-pp40 fusion 
protein. However, replacing wild-type pp40 with a C-terminal deletion mutant lacking 
residues 282-317 reduced P-galactosidase expression in the presence of the v-Rel NLS 
mutant. This indicates that removal of the NLS from c-Rel renders the protein dependent on 
the pp40 C-terminal region for c-Rel-pp40 association. Furthermore, it was demonstrated that 
only a two amino acid difference between c-Rel and v-Rel (amino acids 286 and 302) 
appeared to be responsible for the pp40 C-terminal requirement in v-Rel-pp40 interactions 
(Rottjakob etal., 1996).
2.252. Inhibition of NF- kB DNA binding activity and nuclear translocation by IkB ot
The inhibition of NF-kB DNA binding by IkBoc has been shown in vitro to be 
controlled by certain regions of I KBa. Numerous mutational studies have demonstrated that, 
although the ankyrin repeats are required and sufficient for binding IkB a to NF-kB (as 
discussed in section 2.231) they cannot alone maintain inhibition of NF-kB DNA binding 
activity. Inhibitory activity appears to additionally require the presence of the acidic C- 
terminus of IKBa. An early report on the avian form of IKBa, pp40 demonstrated that altering 
the individual ankyrin repeats of pp40 prevented the protein from inhibiting the DNA binding 
of NF-kB in vitro. However, a pp40 mutant containing the ankyrin repeats only (devoid of 
both N- and C-termini) and a mutant lacking the C-terminus and a section of the sixth low 
homology ankyrin repeat (residues 253-317) also blocked the inhibitory capacity of the 
protein, whereas an N-terminal pp40 deletion mutant was still able to inhibit NF-kB and c-Rel 
DNA binding (Inoue et al., 1992). Interestingly it appeared that those mutants which were 
unable to inhibit the DNA binding of c-Rel (the ankyrin repeat only and C-terminal deletion
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mutants) also failed to associate with c-Rel. It was suggested that the association of pp40 with 
p65 and c-Rel may contribute to the inhibition of their DNA binding activity.
Additional experimental evidence for the inhibitory role of the C-terminus of I KBa 
was presented by Rodriguez et al (1995) where the C-terminal residues, 257-317 were deleted 
resulting in a failure of IKBa to inhibit either p65 or NF-kB DNA binding activity. A similar 
result was obtained from a study using IKBa mutants lacking either residues 261-317 or 269- 
317 which also failed to inhibit NF-kB DNA binding activity (Beauparlant et al., 1996). In 
addition, these mutants were only able to interact weakly with p65. A combined loss of the 
N- and C-termini of I KBa has also been shown to prevent the inhibition of p65 DNA binding 
activity and interaction with p65 (Hatada et al., 1993). The possible molecular mechanisms 
involved in the inhibition NF-kB DNA binding activity by the acidic C-terminus of IKBa will 
be detailed in the discussion
It is interesting to note that, as well as inhibiting NF-kB DNA binding activity, IKBa 
can also disrupt preformed NF- kB-DNA complexes (Zabel and Baeuerle, 1990). This finding 
originally led to the suggestion that I KBa may limit the transcriptional activation by NF-kB 
through actively removing the complex from its DNA binding site. In vivo, this would require 
the presence of IKBa in the nucleus and indeed many recent studies have indicated that this 
may be the case. For example, an early investigation on the pp40 protein in REV-T 
transformed chicken lymphoid cells demonstrated the presence of the protein in complex with 
pp59v~Rel within the nucleus (Davis et al., 1990). Further studies on the pp40 protein 
indicated that it could form complexes with members of the NF-KB/Rel family in both the 
cytoplasm and nucleus of WEHI-231 murine lymphoma cells (Kerr et al., 1991). Later reports 
demonstrated the localisation of human IkB a in the nucleus and cytoplasm of a variety of 
mouse tissues and cell types when the protein was overexpressed from a transfected vector or 
microinjected into the cytoplasm (Cress and Taub, 1993; Zabel etal., 1993).
In a more recent study it was shown that newly synthesised I KBa (which follows NF- 
KB-dependent transcription of the IKBa gene-see section 2.237) could accumulate in the 
nucleus of untransfected HeLa cells following treatment with TNF where it was found in 
association with NF-KB/Rel complexes. Furthermore, the localisation of IKBa in the nuclear
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compartment was accompanied by a reduction in NF-kB DNA binding and NF-KB-dependent 
transcription. In addition, a massive reduction in the amount of nuclear p50 was observed 
suggesting that after NF-kB has associated with newly synthesised iKBa the complex is 
exported out of the nucleus (Arenzana et al., 1995). Interestingly, an investigation using in 
vitro synthesised proteins microinjected into Xenopus oocytes has recently demonstrated that 
nuclear iKBa can disrupt NF-kB-DNA interaction and then export NF-KB/Rel complexes out 
of the nucleus. Located in the C-terminus of iKBa is a nuclear export signal (NES-residues 
265-277) which appears to mediate the nuclear export of NF-KB/Rel complexes (see figure 7). 
The fusion of this sequence onto a reporter protein allows the fusion protein to be exported 
out of the nucleus. Moreover, the NES has been found to be homologous to the NES of 
protein kinase I and HIV-1 Rev (Arenzana etal, 1996, submitted for publication).
Other IkB proteins have also been found in the nucleus of cells. A species known as 
p56 which appeared to be identical to the Bcl-3 protein was discovered in both nuclear and 
cytoplasmic extracts of HeLa cells. A related proteolytically cleaved protein, p38 was also 
found, but it appeared to be present exclusively in the nucleus (Kerr et al, 1992). Conflicting 
reports on the localisation of Bcl-3 in the nucleus of cells transfected with a vector expressing 
the protein have since been published. One report claims that Bcl-3 can localise in the nucleus 
(Bours et al., 1993) whereas another investigation could only detect Bcl-3 in the cytoplasm 
(Naumann et al., 1993). A more recent study using transgenic mice constitutively expressing 
Bcl-3 in thymocytes has demonstrated that Bcl-3 is associated with endogenous p50 and p52 
in nuclear extracts from the transgenic mice (Caamo etal, 1996).
2.233. IkB (a as a transcriptional activator-co-operation v^iiti NF-kB.
It has been demonstrated that the human (MAD-3) and avian (pp40) forms of IkBa in 
addition to the C-terminal region of pl05 (corresponding to Ik By) and c-Rel can act as 
transcriptional activators when fused to the Gal4 DNA binding domain and transiently 
transfected into chicken cells or yeast (Morin and Gilmore, 1992; Morin etal, 1993), It was 
found that the transcription activation domain of pl05 was contained within C-terminal 
residues, 727-806 (located between the sixth and seventh ankyrin repeat). Interestingly this
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region consists of highly negatively charged amino acids, a feature shared with several other 
transcription activation domains. The transcription activation domain of pp40 was located 
between residues 49-229. Surprisingly, a Gal4 fusion protein containing the negatively 
charged C-terminus, low homology sixth ankyrin repeat and part of the fifth ankyrin repeat 
(residues 229-318) failed to activate transcription (Morin and Gilmore, 1992).
Since the pp40 ankyrin repeats are required for interaction with c-Rel or p65 
containing dimeric complexes, it was suggested that pp40 may activate transcription by 
associating with endogenous c-Rel or p65 containing complexes. Several findings appeared to 
indicate that this proposal was correct. For example, a pp40 mutant fused to a Gal4 DNA 
binding domain which failed to interact with c-Rel was not able to activate transcription in 
chicken embryonic fibroblasts. However, a pp40 mutant capable of binding to c-Rel, strongly 
activated transcription. In addition, coexpression of the wild-type pp40 Gal4 fusion protein in 
chicken embryonic fibroblasts with a c-Rel protein devoid of its transcriptional activation 
region failed to activate transcription. It was possible that the pp40 mutant which was unable 
to interact with c-Rel was in a conformation which rendered it inactive in the assays. 
Similarly, the association of the c-Rel deletion mutant with the wild-type Gal4 fusion protein 
may have altered the conformation of the pp40 fusion protein to interfere with the pp40 
transcriptional activation domain. Alternatively, binding of the mutant c-Rel protein to Gal4- 
pp40 may have prevented interaction of Gal4-pp40 with some other non-Rel protein (Morin et 
al., 1993). Significantly, coexpression of p65 or p50 mutant proteins lacking their 
transcriptional activation domains with the previously described minimal transcriptional 
activation domain of pl05 (residues 727-806) did not inhibit transcriptional activation by the 
pl05 protein. However, coexpression of the wild-type p65 protein with Gal4 pl05 (727-806) 
reduced activation ten fold. This indicated that pl05 was a genuine transcriptional activator, 
probably interacting with a coactivator identical to p65.
Bcl-3 is believed to act as a transcriptional coactivator since it appears to be capable of 
superactivating p50B (also known as p49 or p52) (Bours et al, 1993) and p50 (Fujita etal, 
1993) homodimers during in vitro transcription from int^r^^^<^i^^(3, immunoglobulin and H2K^ 
kB sites. More recently a report describes that nuclear extracts prepared from the thymocytes
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of transgenic mice constitutively expressing Bcl-3 exhibit a ten fold increase in p50 DNA 
binding activity but no change in p52 binding compared to cells lacking constitutively 
expressed Bcl-3. In addition, it appeared that the observed increase in p50 DNA binding was 
dependent on the phosphorylation of Bcl-3. Furthermore, both p52 and p50 were found to be 
complexed to Bcl-3 in thymocyte nuclear extracts (Caamano et al., 1996). Bcl-3 is thought to 
form a ternary complex with either p50B and p50 homodimers and their kB motifs to regulate 
the transcription of target genes through the promoter region. Ternary complexes have also 
been shown to exist for avian pp40, where the protein was detected in nuclear extracts 
prepared from WEHI-231 cells as part of a complex comprised of c-Rel and other unidentified 
kB binding proteins (Kerr et al., 1991). Many in vitro studies and transient transfection 
experiments have described an alternative mechanism of Bcl-3 mediated transcriptional 
activation where Bcl-3 has been shown to dissociate p50 homodimers from DNA, thus 
allowing transcriptional activation to occur through NF-kB (Franzoso et al, 1992, 1993; 
Naumann etal, 1993).
2.234. Indue er-mediated phosphorylation, ubiquitination and degradation of IkB a: a 
mechanism for inducible NF- kB activation.
Early in vivo studies revealed that inducer-mediated stimulation of NF-kB DNA 
binding activity was accompanied by the rapid, transient hyperphosphorylation and 
degradation of IkB (a (Beg et al, 1993; Brown et al, 1993; Cordle et al, 1993; Henkel et al, 
1993; Mellits er al, 1993; Rice and Ernst, 1993; Sun et al, 1993). Indeed, it was also reported 
that the activation of NF-kB DNA binding activity was correlated with a slow, transient 
phosphorylation of pl05 and a slow, sustained phosphorylation of both p50 and p65 (Mellits 
et al, 1993; Mercurio et al, 1993). In addition, the use of certain stimuli such as TNF and 
double-stranded RNA caused an increase in the processing of the precursor protein, pl05 to 
p50(Mellits etal, 1993).
The observation that inducibly phosphorylated IkB a did not accumulate but appeared 
only as a transient species immediately after the stimulation of cells led to the proposal that 
the inducible phosphorylation of IkBcx served as a marker for IkB<x degradation. An
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alternative proposal was made following the observation that NF-kB bound IkB a was highly 
stable compared to free, unbound iKBa. In this model it was proposed that inducer-mediated 
phosphorylation of iKBa caused the dissociation of I KBa from NF-kB leading to the rapid 
proteolysis of iKBa via constitutively active proteases and the translocation of NF-kB to the 
nucleus (Beg et al., 1993; reviewed in Siebenlist et al, 1994). However, subsequent reports 
have revealed that inducibly phosphorylated I KBa is still able to interact with NF-kB 
demonstrating that signal-induced phosphorylation does not dissociate I KBa from NF-kB. 
Furthermore, a critical role for the proteases involved in I KBa degradation emerged after the 
discovery that the protease Inhibitors referred to as the peptide aldehydes were able to block 
the signal induced degradation of iKBa and nuclear translocation of NF-kB but failed to 
prevent inducible phosphorylation of I KBa (Finco et al., 1994; Miyamota et al., 1994; 
Palombella eg(Z., 1994; Traenckner etal, 1994; Alkalay etal, 1995a; Didonato etal, 1995; 
Lin et al., 1995). Therefore, it would appear that the inducible phosphorylation of Ik B (a tags 
the protein for proteolytic degradation which then leads to its dissociation from NF-kB (see 
figure 8 for overview).
Two residues within the N-terminus of I KBa, specifically serine 32 and serine 36 have 
been shown to be targeted for inducible phosphorylation (Brown etal, 1995; Traenckner et 
al., 1995). In addition, it appears that serine 19 and serine 23 of IkB (3 are required for 
inducible phosphorylation of the protein (Didonato etal, 1996). For the studies on I KBa, a 
vector expressing an IKBa mutant containing serine to alanine substitutions at positions 32 
and 36 was transfected into either mouse EL-4 lymphocytes or HeLa cells and failed to be 
inducibly phosphorylated or degraded. Furthermore, cotransfection of the mutant with an NF- 
kB dependent reporter plasmid Into cells, followed by induction of cells with either TNF or 
PMA resulted in the inhibition of NF-kB mediated transcription. An investigation involving 
human T-cell leukaemia virus type 1 Tax transactivator protein Induction of iKBa, has yielded 
similar results (Brockman et al., 1995). Phosphopeptide mapping has also been used to show 
that the two serine residues at positions 32 and 36 are phosphorylated in response to various 
activators of NF-kB (DiDonato et al., 1996). In addition, two homologous sites in IkBP at 
positions 19 and 23 have also been shown to be important for the inducible degradation of the
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protein: substitution of both for alanine blocks stimulation dependent degradation of IkBP. 
These findings indicate that the N-terminal phosphorylation of both IkB a and IKBp is 
essential for their inducible degradation and hence subsequent activation of NF-kB.
However, sequences in and around the C-terminus of iKBa has also been shown to be 
important for the signal induced degradation of I KBa (Brown et al., 1995; Rodriguez et al., 
1995; Beauparlant et al, 1996; Sun et al, 1996). The highly negatively charged C-terminus of 
MBa is comprised of a proline, glutamic acid/aspartic acid, serine and threonine rich PEST 
sequence. Such sequences have been found in other proteins and are associated with rapid 
protein turnover. Brown et al (1995) reported that a deletion mutant lacking 41 C-terminal 
residues (1-276) was resistant to inducible degradation when a vector expressing the mutant 
was transfected into mouse EL4 T-lymphocytes. However, the mutant was phosphorylated 
indicating that the C-terminus is not a target for inducible phosphorylation.
Similarly, deletion mutants of IkB a consisting of either residues 1-256 (Rodriguez et 
al., 1995), 1-268 or 1-260 (Beauparlant et al., 1996) have been shown to be resistant to signal 
induced degradation. In addition, mutants 1-268 and 1-260 inhibited NF-KB-dependent 
transcription in cells cotransfected with vectors expressing either of the mutants and a kB 
dependent reporter plasmid. However, a deletion mutant corresponding to residues 1-277 was 
reported by another group to be degraded in response to TNFa (Sun et al., 1996). 
Furthermore, a mutant comprised of residues 1-287 has also been shown to undergo 
proteolysis in response to TNFa induction. This group has suggested that the PEST sequences 
located in the final 40 amino acids of the C-terminal region of I KBa are not involved in the 
signal induced degradation of IkB a. Instead a glutamine and leucine region in the sixth 
ankyrin repeat from residues 264-276 is proposed to participate in signal induced degradation 
(Sun et al., 1996). Results corresponding to this report have recently been published by 
another group in which the PEST sequences were found to be dispensable for inducible 
degradation (Aoki etal, 1996).
Several studies have indicated that the 26S multicatalytic proteinase or proteasome is 
involved in the signal induced degradation of I KBa. Experimental evidence for this 
suggestion includes the use of a peptide aldehyde inhibitor specific for the chymotrypsin like
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activity of the 26S proteasome which prevents the signal induced degradation of I KBa and 
activation of NF-kB and also leads to the accumulation of hyperphosphorylated iKBa 
(Traenckner etal, 1994; Palombellaef aZ., 1994).
The 26S proteasome is a multicatalytic, ubiquitous proteinase complex mediating non­
lysosomal degradation of ubiquitin-conjugated polypeptides in cells (reviewed in 
Hochstrasser, 1995; Ciechanover, 1994; Rubin and Finley, 1995). The ability of the 
proteasome to degrade target proteins generally depends on the substrate having multiple 
copies of covalently bound ubiquitin (a small, highly stable protein) and requires ATP. 
However, proteins which are not conjugated to ubiquitin have also been shown to undergo 
proteasomal dependent degradation including the enzyme, ornithine decarboxylase (Rubin 
and Finley, 1995).
Ubiquitin dependent proteolysis involves two main steps: The protein is first "marked" 
by the covalent attachment of multiple molecules of ubiquitin and the secondly the protein is 
degraded. Degradation is accompanied by the release of free ubiquitin to be reused in 
subsequent reactions. The addition of ubiquitin to proteins consists of three main stages. 
Ubiquitin must first be activated by the ubiquitin-activating enzyme, El which catalyses the 
ATP dependent activation of the C-terminal glycine of ubiquitin to a thiol ester intermediate. 
The second step makes use of the ubiquitin-conjugating enzyme, E2. E2 transfers activated 
ubiquitin molecules to the substrate which is anchored to a ubiquitin protein-ligase, E3. 
Finally, an isopeptide bond is formed between an e-amino group of a lysine residue in the 
target protein and the C-terminal glycine of ubiquitin. In subsequent reactions the activated 
ubiquitin molecule is attached to lysine 48 of the previously protein-conjugated ubiquitin 
molecule, eventually leading to the production of a polyubiquitin chain. The 26S proteasome 
then degrades the substrate protein and this releases free ubiquitin which can be reused in 
subsequent reactions. It should be noted that E2 can transfer ubiquitin to the protein substrate 
itself. However, this is only thought to occur for the addition of single molecules of ubiquitin 
to the target protein and does not signal the protein for degradation (reviewed in Ciechanover, 
1994; Hochstrasser, 1995).
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The 26S proteasome comprises a 20S catalytic core referred to as the proteasome. The 
proteasome appears to require the presence of a 19S particle which is thought to mediate the 
ATP-dependent recognition of ubiquitinated substrates through its 5S subunit (reviewed in 
Rubin and Finley, 1995). ATP may also be required for peptide bond cleavage of the protein 
substrate and for translocation of the substrate along the enzyme from the 19S particle to the 
20S catalytic core. In addition, the release of cleavage products during the degradation of the 
protein in the catalytic core probably utilises ATP. It is thought that the proteasome must 
unfold the protein substrate in order for it to be efficiently passed through narrow channels 
into the central cavity of the enzyme which houses the active sites. It has been suggested that 
the protein substrate is unfolded by the 19S particle since it directly contacts the proteasome 
channels which open into the central cavity. This view is supported by the observation that the 
19S particle contains multiple ATPases. These ATPases could directly contact the protein and 
destabilise the folded conformation by exhibiting a greater affinity for the unfolded protein.
Degradation of the protein allows free ubiquitin to be regenerated by special de- 
ubiquitinating enzymes (or ubiquitin carboxy C-terminal hydrolases) (Hochstrasser, 1995). 
This group of enzymes fall into two distinct families: a set of small proteins which generally 
remove ubiquitin from small substrates including peptides and lysine, and a set of larger 
proteins which cleave ubiquitin from a wide variety of protein substrates in vitro. It appears 
that ubiquitin chains are continuously being attached and cleaved from protein substrates so 
that the regulation of both the enzymes involved in the addition and removal of ubiquitin is 
vitally important for the process of protein degradation.
Several recent in vivo and in vitro studies have detected the presence of ubiquitinated 
forms of iKBa that can be degraded by purified preparations of proteasomes (Chen et al, 
1995; Li et al, 1995; Roff et al, 1996; Alkalay et al, 1995b). In addition, it has recently been 
demonstrated that IkBP can undergo inducible ubiquitination (DiDonato etal, 1996). In one 
study, ubiquitinated forms of iKBa were shown to accumulate following TNFa induction of 
HeLa S3 cells transfected with a vector expressing iKBa and pre-treated with a proteasome 
inhibitor (Roff et al., 1996). Under the same conditions, an IxBa mutant containing serine to 
alanine substitutions at positions 32 and 36 failed to be ubiquitinated. An in vitro translated C-
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terminal deletion mutant of IkBcx lacking the final 75 amino acids when incubated with HeLa 
cell extracts was shown to be successfully ubiquitinated (Chen et al, 1995). Since 
ubiquitinated forms of IxBa were only detected when cells were pre-treated with the 
proteasome inhibitor it is likely that such species are relatively transient, reminiscent of 
inducibly phosphorylated .IkBcx. It can be envisaged that, following induction of cells, IkBcx 
complexed to NF-kB is phosphorylated on residues 32 and 36 which then targets the protein 
for ubiquitination and then degradation.
Indeed, only a small proportion of IkBcx accumulates when proteasomal degradation is 
blocked. It has been suggested that this is a direct result of the action of multiple-C-terminal 
hydrolases which remove ubiquitin bound to target proteins and are responsible for processing 
the primary products of polyubiquitin gene mRNA translation (Roff et al., 1996). 
Alternatively, it is possible that both a ubiquitin-independent and dependent mechanism of 
degradation exists.
Immunoprecipitation studies to determine whether or not ubiquitinated IkBcx can 
associate with NF-kB includes one report where attempts to immunoprecipitate ubiquitinated 
forms of transfected IkBcx from HeLa S3 cytoplasmic cell extracts with an antibody specific 
for p50 failed (Roff et al., 1996). However, another investigation showed that ubiquitinated 
forms of in vitro translated IkBcx incubated in HeLa cell cytoplasmic extracts could be 
immunoprecipitated with an antibody specific for p65 (RelA) (Chen et al, 1995). Clearly a 
direct comparison of both studies is difficult since the origin of the expressed IkBcx proteins 
was different and this may explain the apparent contradictory results. Furthermore, the 
antibodies used to immunoprecipitate IKBca were each for different subunits of NF-kB. It is 
possible that ubiquitinated forms of IkBcx do not associate with p50 but are capable of binding 
to p65.
Another report isolated a ternary complex of p50, p65 and newly phosphorylated IKBa 
from stimulated T-lymphocytes pre-treated with a peptide aldehyde proteasome inhibitor. 
Both inducibly (hyper-) and basal phosphorylated IKBa were detected but only the 
hyperphosphorylated form could be degraded in vitro. In addition, two fractions obtained 
from reticulocyte extracts, one of which was Known to contain the 26S proteasome and
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several of the ubiquitin-conjugating enzymes (including the ubiquitin- activating enzyme 
(El), many of the ubiquitin-conjugating enzymes and three known B3 ubiquitin ligases) and 
one of which was comprised of ubiquitin and a few components of the ubiquitin system were 
only capable of degrading hyperphosphorylated iKBa when they were combined (Alkalay et 
al., 1995b). Therefore, it appeared that the 26S proteasome required the presence of ubiquitin 
and other components of the ubiquitin system to achieve degradation of hyperphosphorylated 
iKBa . In vivo analysis of the ubiquitin dependence of hyperphosphorylated IKBa degradation 
revealed that a cell line containing a temperature sensitive mutation in the El ubiquitin­
activating enzyme could not support efficient stimulation induced degradation of iKBa at 
temperatures known to inactivate El in the cell line. The report indicated that inducible 
degradation of hyperphosphorylated IkBa involved the ubiquitin-proteasome pathway 
(Alkalay et at, 1995b).
Having established that ubiquitinated forms of IxBa exist many groups have 
investigated the possible target residues for ubiquitination. Protein ubiquitination is known to 
occur on lysine residues and therefore studies have concentrated on identifying candidate 
lysine residues around the inducibly mediated phosphoacceptor sites at positions 32 and 36 in 
the N-terminus of iKBa . It has been demonstrated that the substitution of lysine 21 and 22 for 
arginine in the N-terminus of iKBa can almost completely block signal induced ubiquitination 
and degradation of the protein whereas stimulation dependent phosphorylation remains 
unaffected (Rodriguez et al, 1996; Baldi et al, 1996; Didonato et al, 1996). In addition, NF- 
kB dependent transcription was drastically reduced following induction of cells cotransfected 
with a vector expressing the lysine to arginine iKBa mutant and an NF-kB dependent reporter 
plasmid.
Although it would appear that lysine 21 and 22 are the primary targets for 
ubiquitination, a more thorough mutational analysis of the N-terminal lysine residues of iKBa 
revealed that the mutation of lysine residues 38 and 47 together with lysine 21 and 22 
completely blocked ubiquitination and NF-kB-dependent transcription whilst still retaining 
the ability to be inducibly phosphorylated (Rodriguez et al, 1996). However, a mutant 
containing only substituted lysine 38 and 47 was ubiquitinated but not as extensively as the
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wild-type protein. Therefore, it has been proposed that lysines 38 and 47 represent the 
secondary targets for ubiquitination. These findings taken together suggest that after the 
signal-induced phosphorylation of I kB a on serine 32 and 36, lysine 21 and 22 are 
ubiquitinated (and to a lesser extent lysine 38 and 47) which targets the protein for proteolytic 
degradation.
2.235. Basal phosphorylation and degradation oflkBa,
Although the activation of NF-kB is dependent on the inducible phosphorylation and 
degradation of IkB a, I kB a is also constitutively phosphorylated and turned over in cells. 
Recent evidence strongly indicates that casein kinase II may be responsible for the 
constitutive phosphorylation of iKBa in its C-terminal region (Barroga et al, 1995; 
McElhinny et al., 1996; Lin et al., 1996; Schwarz et al., 1996). Studies have demonstrated 
that mutating casein kinase II phosphorylation sites in the C-terminus of iKBa block not only 
constitutive phosphorylation of iKBa but also the basal degradation of the protein. This aspect 
of IkBregulation will be detailed in the discussion.
2.236. Inducible phosphorylation, ubiquitination and degradation of the NF-kB 
subunits: an additional level of control for NF-kB.
Although IkBa appears to be the primary target for modification by various activating 
signals it has been demonstrated that the subunits of NF-kB and the pi 05 and pi 00 precursors 
can also be modified. Early studies showed that protein kinase A (PKA) was responsible for 
the rapid inducible phosphorylation of the Drosophila, dorsal protein (reviewed in Siebenlist et 
al., 1994) and the pl05, p50 and p65 proteins were shown to become phosphorylated in 
response to activation (Mellits et al., 1993). It appeared that the phosphorylation of pl05, p50 
and p65 was slower than that observed for iKBa. Furthermore, the phosphorylated p50 and 
p65 proteins were not short lived like phosphorylated pl05 and IkBcx, but were detectable 45 
minutes after cell stimulation. In addition, activation of cells also appeared to enhance the 
processing of the pl05 to p50, although this conversion exhibited slower kinetics than the loss 
(degradation) of iKBa (Mellits et al., 1993; Mercurio et al., 1993). The cytokine induced
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transient phosphorylation of p65 homodimers has been described more recently (Diehl et al, 
1995). As suggested in one report a role for this inducible phosphorylation may be to enhance 
the DNA binding of p65 containing dimers (Naumann et al., 1994). However, it could equally 
be required for the release of IKBa, nuclear translocation or for transcriptional activation.
Later investigations demonstrated that the in vitro processing of pl05 to p50 was 
dependent on ATP and was accompanied by the degradation of the C-terminus of pl05 
(Pallombella etal, 1994; Donald etal, 1995). Moreover, ubiquitinated forms of pl05 were 
detectable in vitro in the presence of a non-hydrolyzable analogue of ATP Known as ATPyS 
which stabilises ubiquitinated proteins but blocks degradation via the proteasome pathway. 
The proteasome was also shown to be required for pl05 processing in vitro and inhibitors of 
the proteasome also blocked pl05 processing both in vivo and in vitro and prevented the 
activation of NF-kB. Therefore, it appeared that pl05 processing and/or degradation was 
mediated by a ubiquitin-dependent proteasome pathway. Indeed, the ubiquitin-carrier protein, 
E2-F1, which participates in the conjugation and degradation of p53, and a novel species of 
ubiquitin-protein ligase have both been shown to be required for limited processing of the 
pl05 precursor protein to p50 (Orian etal., 1995).
The processing signal of pl05 has recently been identified and consists of a 23 amino 
acid glycine rich region (GRR) (residues 372-398) (Lin and Ghosh, 1996). It appears that the 
endoproteolytic cleavage of pl05 to p50 occurs downstream of this glycine rich sequence. 
When the C-terminus of pl05 was removed (residues 404-917) and replaced with the C- 
terminal region of IkB a, the processing of the fusion protein in vivo (in Cosl cells) yielded 
p50 and an intact C-terminal IKBa region. It has been proposed that pl05 processing involves 
an initial GRR-dependent endoproteolytic cleavage event followed by a rapid degradation 
step.
The PEST sequences (specifically the serine residues) of pl05, located in the final 150 
C-terminal residues appear to be phosphorylated in response to activation of JurKat T cells 
with either PMA (phorbol 12-myrlstate 13-acetate)/ionomycin or oKadaic acid (a 
serine/threonine phosphatase inhibitor and activator of NF-kB). This has been shown to be 
accompanied by an increase in the proteolytic processing of pl05 to p50. Deletion of the C-
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terminal 68 residues of pl05 (i.e. part of the PEST-like region) results in a failure of pl05 to 
be phosphorylated or for its processing to p50 to be increased in response to stimulation of 
cells with PMA/ionomycin (MacKichan et al, 1996). Moreover, the signalling pathway 
which leads to the phosphorylation and processing of pl05 after PMA/ionomycin treatment 
appears to be have elements distinct from that which controls iKBa phosphorylation and 
degradation. For example, pre-treatment of Jurkat cells with antioxidants followed by 
activation with PMA/ionomycin blocks phosphorylation and degradation of iKBa but does 
not affect either pl05 phosphorylation or processing.
Notably, Epstein-Barr immortalised cells contain nuclear pl05 complexed to p65. 
Mitomycin C, which activates NF-kB has been shown to induce processing of pl05 to p50 in 
the nucleus whereas the steady-state levels of both pl05 and iKBa in the cytoplasm remain 
constant. In contrast, phorbol ester induction of cells stimulated the degradation of 
cytoplasmic pi05 and iKBa but did not affect pi05 protein levels in the nucleus (Baldassarre 
et al, 1995). Therefore, it appears, at least in the cell type examined that nuclear processing 
of pi05 to p50 can contribute to the activation of NF-kB.
2.237. MuCtud Control ofNF- iK3 and IkBoo
As detailed in the previous sections iKBa activity can be mediated through 
phosphorylation and ubiquitin dependent proteolysis and this in turn controls the activity of 
NF-kB. However, both iKBa and NF-kB are also regulated at the level of transcription. Early 
studies demonstrated that the induced loss of iKBa and subsequent translocation of NF-kB to 
the nucleus was accompanied by an increase in the level of iKBa mRNA (Sun et al, 1993; 
reviewed in Siebenlist etal, 1994). Later investigations demonstrated that the transfection of 
a vector expressing p65 into cells resulted in increased levels of iKBa mRNA. Following the 
identification of several NF-kB binding sites in the promoter of the gene encoding iKBa it 
was proposed that NF-kB must stimulate the transcription of the gene encoding iKBa (Chiao 
et al, 1994; LeBail etal, 1993). Therefore, a feedback mechanism exists in the NF-KB-lKBa 
system whereby newly synthesised iKBa generated through NF-kB mediated transcriptional 
activation of the iKBa gene, acts to restore NF-kB in the inhibited state in the cytoplasm of
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cells. However, more recent experimental findings have indicated that iKBa mRNA levels can 
be increased via a transcription-independent event during adherence (Lofquist et al, 1995).
Indeed, it appears that the gene promoters of pl05 and pl00 are also similarly 
regulated by NF-kB since they too contain kB binding sites. Cotransfection experiments 
demonstrated that p50 homodimers, p65 homodimers and p50/p65 heterodimers (i.e. NF-kB) 
could activate the promoter of pl05 (and hence p50) (Ten et al, 1992). In addition, the levels 
of plOO mRNA and protein were increased by nuclear p65 (Sun et al, 1994). The structural 
and functional characterisation of the NF-kB2 (pl00) gene promoter regions has indicated 
that p65 can enhance the activity of these regions, whereas NF-kB2 p52 can negatively 
regulate promoter activity (Lombardi et al, 1995). Prior to processing both pl00 and pl05 
can act as inhibitors of NF-kB/Rcl proteins in the cytoplasm of cells ensuring, like iKBa a 
rapid but transient activation of NF-kB. Interestingly, the gene promoter of p65 does not 
possess any kB elements and has only been shown to be stimulated slightly following 
induction of cells (reviewed in Siebenlist et al., 1994). It is thought that p65 expression is 
essentially constitutive.
2.3. transduction pathways involved in ttie activation of NF-kB.
2.31. Second messengers, kinases and phosphatases implicated in the activation of 
NF-kB.
NF-kB DNA binding activity can be stimulated by a multitude of agents including 
cytokines such as tumour necrosis factor a, isterleukin-1 (IL-1) and interleukin-2, bacterial 
lipolysaccharide (LPS), virus infection (HIV-1, HTLV-1 (human T-cell leukaemia virus) and 
hepatitis B virus)), viral proteins (tax, X and El A), phytohaemagglutinin (a mitogenic lectin), 
ultraviolet light, calcium ionophores, phorbol esters, hydrogen peroxide and nitric oxide 
(Matthews etal, 1996), to name but a few (reviewed in Siebenlist etal, 1994).
A common secondary messenger has not been identified for the range of signals which 
activate NF-kB, suggesting that several different signalling pathways may regulate NF-kB. 
However, pretreating cells with antioxidants such as V-acetyl-L-cysteine appears to block the 
majority of these activating signals as demonstrated through the inhibition of NF-kB DNA
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binding activity (SchrecK et al, 1991) and the suppression of transcriptional activation from 
the HIV-1 LTR (Staal et al, 1990). Many of the agents which activate NF-kB are thought to 
do so by generating reactive oxygen intermediates such as the superoxide anion O2" and the 
hydroxyl radical OH . For example, the protein phosphatase inhibitor oKadaic acid is thought 
to inhibit a phosphatase of IkBa indirectly through the production of reactive oxygen 
intermediates (Schmidt etal., 1995). These reactive oxygen intermediates could result in the 
activation of various proteases and the degradation of the IkB proteins (Baldwin et al, 1996). 
Indeed, a recent report has suggested that intracellular reactive oxygen species can mediate 
the phosphorylation of IKBa in response to TNFa, induction of cells (Kretzremy et al, 1996). 
This study showed that the overexpression of glutathione-peroxidase in cells followed by 
stimulation with TNFa resulted in the accumulation of the inducibly phosphorylated form of 
iKBa.
Thioredoxln, a protein involved in redox regulation within cells, can also activate NF- 
kB and its expression can be increased by the NF-kB-activators, hydrogen peroxide and 
ultraviolet light. Therefore, it is possible that these stimuli may lead to the activation of NF- 
kB via thioredoxin (Baldwin etal., 1996; Matthews and Hay, 1995).
Ceramide has also been implicated as second messenger in the pathway to NF-kB 
activation following stimulation of cells with either TNF and IL-1. It has been proposed that 
the association of TNF with its receptor on the surface of cells leads to the production of 
ceramide through the activation of sphingomyelinase by diacylglycerol (generated by a 
phosphatidylcholine-specific phospholipase C). Sphingomyelinase is capable of inducing the 
degradation of I kB a in vitro and may be involved in the activation of a specific Kinase 
capable of phosphorylating IKBa (reviewed in Baldwin, 1996). However, evidence against 
ceramide involvement in NF-kB activation does exist. This includes a report on cells 
chronically activated with PMA. Such activation inhibited the ceramide pathway, however 
TNF induction of cells still resulted in NF-kB activation (WestwlcK etal, 1994).
Several Kinases have been implicated in the signalling pathways which lead to the 
activation of NF-kB. For example, inactivation of the interferon-inducible or double-stranded 
RNA-dependent protein Kinase, PKR in cells results in the failure of double-stranded RNA to
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induce the DNA binding activity of NF-kB and this is believed to be mediated through the 
phosphorylation of iKBa (Maran et ah, 1994). Protein kinase C when overexpressed in NIH 
3T3 cells, causes the persistent translocation of NF-kB to the nucleus. Furthermore, a 
dominant negative mutant (devoid of kinase activity) of protein kinase C £ when 
cotransfected into cells with an NF-KB-dependent reporter plasmid results in a reduction in 
transcription from the reporter (Diaz-Meco, 1993). A more recent study has shown that 
protein kinase C £is involved in the activation of NF-kB in human immunodeficiency virus- 
infected monocytes (Folgueira et al, 1996). The v-abl tyrosine kinase (a viral transforming 
protein) was shown to negatively regulate NF-kB activity in pre-B cells through a post­
translational mechanism which increased the stability of IkB (a (Klug et al, 1994). The Src 
family of tyrosine kinases have also been implicated in the activation of NF-kB in response to 
ultraviolet light (Devary etal, 1993).
Transfection of vectors constitutively expressing the Raf-1 serine/threonine kinase into 
cells was shown to stimulate transcriptional activation from a KB-dependent reporter plasmid. 
In addition, when the endogenous activity of Raf-1 was blocked in cells treated with a range 
of known NF-kB activators by the overexpression of a dominant negative mutant of Raf-1, a 
reduction in KB-dependent transcription was observed (Finco and Baldwin, 1993). Indeed, the 
upstream effector, Ras of the so-called Ras-Raf pathway, has also been shown to activate kB- 
dependent transcription and a recent report has demonstrated that both Ras and Raf-1 are 
activated in human immunodeficiency vims infected monocytes and stimulate DNA binding 
of NF-kB (Folgueira et al., 1996). The mitogen-activated protein kinase kinase kinase, 
MEKK, which stimulates the stress-activated protein kinases/jun kinase-1 (SAPKs/JNKl) was 
recently shown to participate in the activation of NF-kB through the degradation of iKBa 
following stimulation of cells with TNFa (Hirano et al, 1996). An additional report has 
demonstrated that the downstream kinase, JNK-1 and c-Rel can interact in vivo but that JNK- 
1 does not phosphorylate either c-Rel, NF-kB or iKBa in vitro . It has been proposed that c- 
Rel may act as a "docking site" for JNK-1 thereby permitting the kinase to phosphorylate Rel- 
associated proteins (Meyer et al., 1996).
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A novel ubiquitin-dependent protein kinase activity has been discovered in HeLa cell 
cytoplasmic extracts which specifically phosphorylates IkB a on the N-terminal serine 
residues at positions 32 and 36 (the targets for inducible phosphorylation). Interestingly the 
kinase activity appears to require the ubiquitin activating enzyme (El), a specific ubiquitin 
carrier protein (E2) and ubiquitin. A ubiquitination step for kinase stimulation is essential and 
it has been proposed that ubiquitination occurs on a factor associated with the Kinase complex. 
Moreover, this step takes place before the site specific phosphorylation of IkB a on residues 
32 and 36 (Chen et al, 1996). Another iKBa associated Kinase has been found in the human 
monocytic cell line, THP-1, which can bind to and phosphorylate IkB a on C-terminal serine 
and threonine residues (Kuno et al, 1995). A report has recently claimed that neither Raf-1 
nor the isozymes of protein Kinase C (including Q are capable of directly phosphorylating 
IkB a . Instead Raf-1 associates with casein kinase II and casein kinase II together with other 
unidentified kinases phosphorylate the C-terminal region of iKBa (Janosch etal., 1996).
Phosphatases are also thought to participate in the pathway leading to NF-kB 
activation by either dephosphorylating upstream effectors of the signalling cascade or by 
acting directly on iKBa. For example, an inhibitor of the Ca^-dependent phosphatase 
calcineurin referred to as FK506 prevented the activation of c-Rel in both B and T cells 
(Venkataramas etal., 1995). In addition, the overexpression of calcineurin in T cells from a 
transfected vector resulted in the activation of NF-kB in T-cells (Franz et al., 1994). 
Experimental evidence has suggested that the Ca2+ -dependent pathway involving calcine^urin 
can synergise with the protein kinase C-dependent and -independent pathways to regulate the 
phosphorylation and degradation of I kB a (Steffan et al., 1995). The possibility of direct 
dephosphorylation of IkB a by the serine/threonine protein phosphatase 2A (PP2A) has been 
suggested through the treatment of human T cells with an inhibitor of PP2A known as 
calyculin A. Such treatment resulted in the phosphorylation of IkB a at protein phosphatase 
2A sensitive sites and activation of NF-kB (Sun et al., 1995). Finally, another study has 
indicated that a protein-tyrosine phosphatase(s) may participate in the upstream regulation of 
the TNF signalling pathway which leads to the degradation and subsequent activation of NF- 
kB (Menon etal, 1995).
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2.32. Viral proteins and the (wtwaaion of NF-kB.
Several studies have revealed the importance of NF-kB in the activation of viral gene 
expression particularly those genes whose products are required for viral replication. 
Consequently many viruses regulate the activation of NF-kB through certain viral proteins, a 
few of which are discussed below.
Recently many studies have focused on the role of the human T-cell leukaemia vims 
type 1 (HTLV-1) tax protein in NF-kB activation. Tax potently activates transcription from 
the HTLV-1 long terminal repeat and is also involved in increasing the expression of several 
viral and cellular genes including the genes encoding c-Fos and interleukin-2. Tax is believed 
to be essential for the transforming properties of HTLV-1. Numerous routes have been 
proposed for the activation or suppression of NF-kB by tax. One of these involves pl00 (NF- 
kB2) which has been reported to interact with Tax thereby disrupting Tax mediated activation 
of NF-KB(Kanno et al, 1994; Murakami et al., 1995). Another occurs through Tax induction 
of the pathway leading to the degradation of IkB<x and IkBP and the passage of NF-kB to the 
nucleus (Brockman etal, 1995; Good etal, 1996; McKinsey etal, 1996).
The viral transactivator protein Tat of the human immunodeficiency virus-1 (HIV-1) is 
thought to interact with NF-kB at the HIV-1 long terminal repeat in order to maintain the 
elevated level of viral expression which is observed in U937 monocytes infected with HIV-1 
(Jacque etal, 1996). The 13S splice variant of the adenovirus type 5 El A regulatory protein 
has been shown to activate NF-kB by two routes. The first occurs through the activation of 
the p65 subunit of NF-kB by 13S El A. This involves the stimulation of the p65 
transcriptional activation domain by direct association of 13S ElA with this region (as 
demonstrated in vitro). The second route leads to the production of reactive oxygen 
intermediates, phosphorylation of IkB a via serine residues 32 and 36 and the degradation of 
IkB<x. The DNA binding activity of NF-kB can also be inhibited through the adenovirus ElB 
19K (19 Kilodalton) protein, presumably to counteract the immune stimulatory and apoptotlc 
effects of persistent NF-kB activation (Schmitz etal, 1996).
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2.33. Inactivation of NF- kB via spetific compounds: a rouUe towards the eluddatton 
of signal transduction pathways and disease therapies.
Many compounds have been shown to inhibit the activity of NF-kB and these provide 
a useful tool for gaining knowledge on the activation pathways involved in NF-kB 
stimulation. Moreover, they may enable the identification of possible therapies for those 
diseases which involve the persistent activation of NF-kB.
Glucocorticoids are powerful anti-inflammatory and immunosuppressive agents and 
their involvement in NF-kB inhibition has been known for some time (Baldwin, 1996). 
However, the mechanism of this inhibition was unclear until fairly recently. It now appears 
that glucocorticoids can block the activation of NF-kB in two ways. Firstly, the receptor for 
glucocorticoids (a ligand-activated transcription factor), has been reported to interact directly 
with NF-kB and interfere with the activation of NF-KB-dependent gene expression. The 
second mechanism of inhibition was discovered following studies on monocytes and 
lymphocytes and involves the induction of iKBa protein synthesis by glucocorticoids. Newly 
synthesised IkBa retains NF-kB in the cytoplasm of cells, even after induction with TNF 
(since degraded iKBa will be quickly replaced by newly synthesised iKBa) (Auphan et al, 
1995; Scheinman et al, 1995). It is believed that the suppression of NF-kB DNA binding 
activity decreases the level of cytokine secretion thereby preventing stimulation of the 
immune system. However, it appears that in certain cell types such as endothelial cells 
glucocorticoid-mediated inhibition of NF-kB does not involve an increase in the rate of iKBa 
protein synthesis (Brostjan etal., 1996).
Nitric oxide acts as a repressor of the immune and inflammatory responses and 
appears to inhibit the activation of NF-kB in a similar way to the glucocorticoids i.e. through 
the induction of iKBa protein synthesis (Peng etal, \995).In vitro studies have demonstrated 
that nitric oxide can inhibit the DNA binding activity of NF-kB (Matthews et al., 1996). 
Furthermore, NF-kB can activate nitric oxide synthase II (iNOS) gene expression suggesting 
the existence of a negative feedback loop, whereby nitric oxide (generated by iNOS) can 
reduce expression of iNOS by inhibiting the DNA binding of NF-kB (Baldwin, 1996).
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Many more inhibitors of NF-kB exist including the immunosuppressive fungal 
metabolite, gliotoxin (Pahl et al., 1996). Gliotoxin is generated as a toxic metabolite in 
Aspergillus infections, a serious condition often observed in immunocompromised patients. It 
appears that gliotoxin cannot inhibit the DNA binding activity of NF-kB at physiological 
concentrations. Instead, it was discovered that gliotoxin acted to inhibit the activation of NF- 
kB by preventing the degradation of IkB a in intact T cells. The results suggest that the 
inhibition of NF-kB activity may be important for the immunosuppressive effect of gliotoxin 
when it is synthesised in during Aspergillus infections.
2.4. NF-kB mediaaed genes and the pllysiologicat rde of NF-kB.
2.41. Genes regulated by NF-kB.
NF-kB is responsible for mediating the activity of a plethora of genes, in particular 
those which encode proteins that are critical for the immune, inflammatory and acute-phase 
responses (reviewed in Baldwin , 1996; Siebenlist etal, 1994). For example, transcription of 
the gene encoding the co-stimulatory molecule B7.1 (involved in T cell activation ) (Zhao et 
al., 1996) is controlled by NF-kB together with the genes encoding the proteasome subunit, 
LMP2 and the peptide transporter, TAPI (Wright et al, 1995). NF-kB has also been 
implicated in the control of many cytokine and growth factor genes, such as G-CSF, IL-2, IL- 
6 and IL-8 (reviewed in Baldwin, 1996).
Extensive studies have been performed on the regulatory role of NF-kB in the 
expression of genes encoding cell adhesion molecules. The activity of the gene encoding the 
vascular cell adhesion molecule-1 (VCAM-1), a member of the immunoglobulin superfamily, 
is controlled in part through NF-kB. Following treatment of endothelial cells with TNF, IL-1 
or LPS (lipopolysaccharide) VCAM-1 is seen to accumulate on the cell surface. VCAM-1 has 
been implicated in the recruitment of monocytes and lymphocytes which express a4pl or 
a4^7 integrins to an area of tissue injury as well as playing a role in the development of the 
central nervous system. The promoter of the VCAM-1 gene contains two binding sites for 
NF-kB (Ahmad et al., 1995) as well as a binding site for IRF-1 (endothelial interferon 
regulatory factor 1), a phosphoproteiii transcription factor implicated in the activation of the
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IFN-p gene and other cytokine inducible genes (Neish et al, 1995). NF-kB is necessary but 
not sufficient for complete cytokine-mediated transcriptional activation of the VCAM-1 gene. 
However, IRF-1 is cytokine inducible and recombinant IRF-1 and NF-kB can physically 
interact. Furthermore, IRF-1 can synergise with NF-kB to activate VCAM-1 in vivo. 
Therefore, IRF-1 is thought to interact with NF-kB in order to promote VCAM-1 expression.
The apg gene encoding the a-1-acid glycoprotein/enhancer binding protein (AGP/EBP 
or C/EBPp) is also regulated in part through NF-kB. AGP/EBP is a member of the C/EBP 
family of transcription factors and plays a Key role in the induction of a wide variety of genes 
including a number of those expressed during the acute-phase response. NF-kB, together with 
a phosphoprotein transcription factor, termed Noppl40 have been shown to interact with two 
forms of AGP/EBP (possibly generated through alternative translation start sites) which 
results in transcriptional activation of the agp gene via an AGP/EBP-binding motif. In 
addition, apg gene expression can be stimulated following exposure to external stimuli which 
are Known to be inducers of NF-kB (Lee etal, 1996).
NF-kB can also regulate the transcription of genes whose products are essential for 
processes outwith the immune and inflammatory responses. For example, the genes encoding 
proteins which are important for cell growth such as c-myc (LaRosa et al, 1994). Many viral 
genes are also mediated by NF-kB including those of the widely studied human 
immunodeficiency virus (HIV) (reviewed in Roulston etal, 1995).
2,42. Gene knockout studies.
During 1995 and 1996 gene knockout studies have confirmed the important role that 
the Rel/NF-KB family members play in immune function. In addition, these experiments have 
resulted in a number of unpredicted discoveries, some of which are summarised below.
NF-kB 1: Knockout of the gene encoding pl05/p50 (or NF-kB 1) in mice resulted in normal 
development but an impaired immune response due to the failure of B-cells to both proliferate 
normally in response to LPS or secrete antibodies (Sha et al, 1995). More recently, defects in 
the maturation of B-cells to immunoglobulin secretion together with IgE, IgA and IgG3 class
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switching have been observed in p50 deficient mice (Snapper et al., 1996). This indicates that 
p50 may be involved in immunoglobulin class switching. In the earlier study by Sha et al 
(1995) mice were not able to clear Listeria and Streptococcus infections but they were more 
resistant to infection with murine encephalomyocarditis (EMC). Resistance to EMC was 
correlated with an increase in IFNp (known to be an antiviral protein). Therefore, in wild-type 
mice, p50 may act to inhibit the activity of IFN p.
RelB: RelB deficient mice developed normally but abnormalities existed in the animals 
immune and hematopoietic systems (Burkly et al., 1995; Weih et al., 1995). It was found that 
mice lacking RelB showed an impaired development of dendritic cells and hence a defective 
antigen-presenting function (since dendritic cells from the bone marrow are the primary 
antigen-presenting cells in the activation of the T-lymphocyte response). Furthermore, the 
differentiation of thymic medullary epithelial cells was also defective. These cells are very 
similar to dendritic cells, participating in antigen presentation to T-cells. They have also been 
implicated in regulating the negative selection of developing thymocytes (Burkly etal, 1995). 
In previous studies RelB had been implicated in the constitutive expression of kB regulated 
genes in lymphoid tissues. Weih et al (1995) discovered that mice lacking RelB exhibited a 
large reduction in the level of constitutive KB-dependent DNA binding activity in the spleen 
and thymus. These mice were also seen to have phenotypic defects including splenomegaly 
(due to extramedullary haematopoiesis) and reduced cellular immunity. Hence it appears that 
RelB performs an essential role in immune function as well as in the development of dendritic 
and thymic medullary epithelial cells. It is also clear that no other member of the Rel/NF-KB 
family is able to replace the loss of RelB function indicating that RelB performs functions 
distinct from other family members.
p65(RelA): Disruption of the relA locus in mice resulted in embryonic lethality which was 
thought to be a result of liver degeneration. In addition, mice deficient in p65 lost TNF- 
mediated inducibility of NF-kB (p50/p65) as well the inducibility of NF-KB-mediated genes 
such as those encoding iKBa (Beg et al., 1995). The degeneration of the liver observed in
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mice lacking p65 occurred through apoptosis and this is similar to the results obtained from 
studies on c-Jun deficient mice (see Beg et al., 1995). Therefore, it is possible that both p65 
and c-Jun both perform overlapping roles in normal liver development.
c-Rel: c-Rel is known to be expressed in high levels within hemopoietic cells. Interestingly, 
mice containing an inactivated c-Rel gene developed normally and showed normal 
hematopoietic cell differentiation. However, the mature B and T cells of c-Rel -/- mice failed 
to be stimulated (to proliferate) by various mitogenic stimuli (Kontgen et al., 1995). More 
recently, it has been discovered that Rel is required by T-lymphocytes for the production of 
IL-3 and granulocyte macrophage colony stimulating factor (GM-CSF). However, in Rel-/- 
lipopolysaccharide macrophages the levels of GM-CSF were higher than normal indicating 
that in normal cells c-Rel acts as a negative regulator of GM-CSF production (Gerondakis et 
al., 1996). Mice deficient in c-Rel also exhibited a reduction in T-cell dependent humoral 
immunity. However, the impaired proliferative response of T-cells to certain membrane 
receptor mediated stimuli could be overcome by co-activating phorbol-ester and the calcium 
ionophore (Kontgen et al., 1995). This indicates that T-cell proliferation can be achieved via 
both c-Rel-dependent and -independent mechanisms.
I KBa & Bcl-3: IKBa (-/-) mice appeared to be normal at birth but exhibited skin defects 
and extensive granulopoiesis soon after birth, followed by a cessation of growth by 3 days and 
death by 8 days. The nuclear levels of NF-kB in hematopoietic tissues (the spleen and 
thymus) were high in IKBa deficient mice and the expression of some NF-kB regulated genes 
(VCAM-1) was also increased. This suggests that I KBa is predominant in the spleen and 
thymus of wild-type mice. These phenotypic abnormalities were due to NF-kB elevation 
because mice deficient in both p50 and I KBa did not develop these abnormalities as rapidly 
IkB a (-/-) only mice and consequently lived longer. Interestingly, embryonic fibroblasts 
failed to show abnormally high levels of nuclear NF-kB, indicating that the cytoplasmic 
retention of NF-kB is mediated by other members of the IkB family of proteins. Indeed, 
IkB a deficient fibroblasts were also responsive to TNFa treatment, showing NF-kB
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activation through the targeted degradation of IkB2. However, these cells were not able to 
reduce post-induction levels of nuclear NF-kB as rapidly as cells with iKBa. This signifies the 
requirement of IkB a for the post-induction repression of nuclear NF-kB (Beg et al, 1995;
Klement et al,, 1996).
Initial work on bcl-3 gene knockout mice has indicated that mice develop normally 
and do not show any immunological defects (Baldwin, 1996).
2.43. The of NF- kB in disease.
NF-kB has been implicated in many diseases including arthritis, atherosclerosis, 
cancer and several neurological disorders. Hence an understanding of the mechanisms of 
activation and regulation of NF-kB represent critical targets for possible therapeutic 
intervention in these various diseases (reviewed in Baldwin, 1996). NF-kB also plays an 
important role in the activation of HIV gene expression (reviewed in Roulston etal., 1995). 
Several other viruses are also partially dependent upon the activity of NF-kB, these include 
SV40, CMV and influenza virus
Atherosclerosis is a condition which is related to lipid oxidation in low density 
lipoproteins (LDLs). NF-kB becomes activated when the oxidised lipids accumulate in the 
extracellular matrix of the subendothelial space. This results in the stimulation of genes which 
encode proteins participating in the inflammatory response. Furthermore, atherosclerosis leads 
to the proliferation of the vascular wall, a process thought to be mediated in part by the serine 
protease, thrombin through the activation of NF-kB (reviewed in Baldwin, 1996).
Since NF-kB is involved in mediating responses to inflammatory cytokines it is 
perhaps not surprising that it performs a role in the development of acute inflammatory 
conditions such as arthritis. Indeed, recent experimental evidence has demonstrated that NF- 
kB is activated in the arthritic synovium (Baldwin, 1996). In addition, many of the treatments 
which are used for arthritis have been shown to inhibit the activation of NF-kB including gold 
compounds (Yang etal, 1995).
Recent experimental evidence has strongly indicated that NF-kB performs a crucial 
function in neurodegenerativs processes such as Alzheimer’s disease. In Alzheimer's disease
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a toxic derivative of the p-amyloid precursor protein known as amyloid P-peptide 
accumulates in plaques in the brain. Studies have shown that the neurotoxicity of amyloid p- 
peptide is linked to a mechanism which involves the stimulation of reactive oxygen species 
(ROS) and high levels of free intracellular Ca2+. Experimental findings have indicated that 
TNFa and TNFP can prevent degeneration of hippocampal neurons by amyloid P-peptide 
through the suppression of ROS and Ca2+ levels and that kB-dependent transcription can 
mediate this effect (Barger et al., 1995). Furthermore, NF-kB can be activated by the P~ 
amyloid precursor protein (Barger and Mattson, 1996). These findings suggest that NF-KB- 
dependent gene expression, induced by cytokines may be required to protect neurons against 
the amyloid p-peptide.
A similar protective function for NF-kB in the process of apoptosis has recently been 
reported in B-cells. It was discovered that following stimulation of B-cells with transforming 
growth factor-p 1 (a factor known to induce apoptosis in several cell types (including B-cells)) 
a reduction in both NF-kB DNA binding activity and c-myc gene expression was detected 
together with an increase in I KBa gene expression and protein levels (Asura et al., 1996).The 
c-myc gene has been previously implicated in mediating cell death in a range of cell types. In 
B-cells, suppression of c-myc gene expression is correlated with an induction of apoptosis, 
whereas in myeloid and fibroblast cells an increase in c-myc gene expression has been 
associated with apoptosis. NF-kB is known to stimulate c-myc gene expression through two 
kB binding sites (reviewed in Baldwin, 1996). Therefore, it has been proposed that in 
response to treatment of B-cells with transforming growth factor-p 1, apoptosis is induced by 
inhibiting NF-kB activity through an increase in Ik Ba protein levels which prevents the 
translocation of NF-kB to the nucleus and stimulation of c-myc gene expression. Presumably 
in the absence of apoptotic stimuli NF-kB maintains c-myc levels to avoid cell death.
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MATERIALS AND METHODS
1.11. Materials.
Human recombinant TNFa was provided by the MRC ADP reagent programme. The 
proteasome inhibitor, Z-LLL-H (carbobenzoxyl-leucin-leucin-leucinal) was synthesised as 
described by Fehrentz et al. in 1985 and isolated by reverse phase HPLC (>95% purity). The 
structure was confirmed by NMR spectroscopy.
1.12. Recombinant proteins.
Human recombinant p65 (amino acids 12-317), GST-p65, p50 (35-381), GST-p50 and 
wild-type IkB a c-tag were generously supplied by E.Jaffray and J.Nicholson (St.Andrews 
University). The proteins were expressed as glutathione-S-transferase (GST) fusions in E.coli 
JM101 and cleaved with thrombin as described in Jaffray et al., 1995 and Matthews et al., 1992.
1.13. Bacterial strains.
E. coli K12 strains; XL-1 blues (in house supply) [genotype->rec Al, end Al, gyr 
A96, thi -1, hsd R17, sup E44, rel Al, lac , {F' pro AB, lac I9ZAM15, Tn 10 (tetr)}] or Top 10s 
(Invitrogen Corporation) [genotype->mcr A, A(mrr-hsd RMS-mcr BC), 08OA/ac AM 15, Alac 
X74,deo R,rec Al, end Al, ara D139, A(ara,, leu ) 7079, gall], gal K, r/zsL(Strr), nup G] were 
used for routine propagation of plasmids. Bacteria were grown in Luria-Bertani (LB) broth with 
antibiotics added when required.
1.14. Mammalian tissue culture cells and antibodies.
293 cells (transformed human embryonic kidney cells) at low passage number (no. 28) 
for efficient transfection were a kind gift from F. Graham (McMaster University). 293s were 
cultured in GMEM supplemented with 10% FCS (GMEM-10F) and passaged weekly. Cos-7s 
(transformed African Green-monkey kidney cells) were generously donated by F. Arenzana-
68
Seisdedos (Institut Pasteur) and passaged twice weekly in GMEM-10F. The monoclonal antibody 
SV5-P-k (Anti-Pk) recognising an epitope on SV5 phospho (P) and V proteins (Randall et al., 
1987 and Southern et al., 1991) was supplied by Dr. R.E. Randall, St. Andrews. The monoclonal 
antibody 10B MAD3 which recognises an epitope between amino acids 21 and 48 of human 
IkBoc (Jaffrey etal., 1995) was prepared by M. Roff (University of St. Andrews).The polyclonal 
antibody raised against p65 was purchased from Santa Cruz and recognises an epitope between 
amino acids 531-550 of human p65. Rabbit antiserum raised against p50 (35-381) was prepared 
by J.Thompson (St. Andrews University).
1.15. Plasmids.
Plasmid pGEX2T was donated by E. Jaffray (University of St.Andrews) and plasmid 
pGEXcPk was obtained from R.E. Randall (University of St.Andrews). The transient mammalian 
expression vector pcDNA3 was purchased from Invitrogen Corporation. Plasmid pCT7Bgal 
which encodes the 13-galactosidase gene under the hCMV promoter/enhancer was generously 
donated by M.O'Reilly (University of St.Andrews). The luciferase reporter vectors 
3EnhConALuc (NF-kB dependent) and LTRAkBLuc (NF-kB independent) were a kind gift from 
F. Arenzana-Seisdedos (Institut Pasteur). The 3EnhConALuc vector is driven by three synthetic 
copies of the NF-kB consensus sequence from the immunoglobulin kappa chain promoter. The 
LTRAkBLuc promoter contains regions U3 and R regions of the HIV-1 LTR deleted of the NF- 
kB consensus sequences.
1.16. Agarose-gel electrophoresis.
DNA samples were separated via horizontal agarose-gel electrophoresis using a mini­
gel (10cm x 10cm) apparatus (Bioscience 101). T.B.E. or T.A.E. buffer was used depending on 
the particular application. The agarose (molecular biology grade, Sigma) concentration ranged 
from 0.8% to 2% depending on the size of the DNA fragments to be separated. Gels were ran at 
varying voltages and for differing times, again depending on the application. The DNA was 
subsequently analysed by ethidium bromide staining and visualisation under U.V.
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1.17. Extraction of DNA fragments from agarose-gels.
DNA fragments were separated on an agarose-gel prepared from TAE buffer. Gel 
fragments containing the DNA band of interest were excised from the agarose gel and processed 
using Qiaquick gel-extraction spin-columns (Hybaid Ltd.) according to the manufacturers 
recommendations. To assess recovery of the DNA fragments, Vioth aliquots (5jils) were 
visualised after electrophoresis through agarose-gels.
1.18. DNA linkers and primers.
Oligonucleotides used for the generation of mutant I KBa genes were synthesised in­
house using an Applied Biosystems oligonucleotide synthesiser. Oligonucleotides were purified 
via ethanol precipitation as described in Molecular Cloning by Sambrook, Fritsch and Maniatis. 
Oligonucleotides used for the generation of Pk-tag-linkers were synthesised and H.P.L.C. purified 
by OswelTs DNA service (Chemistry department, University of Edinburgh).
Oligonucleotides of positive and negative sense for the generation of the C-terminal 
Pk-tag linker were -> Pkpos 5 '-AAT TCT AGG AAA GCC GAT CCC AAA CCC TTT GCT 
GGG ATT GGA CTC CAC CTA AGC - 3" and Pkneg 5 '-CCC CGC TTA GGT GGA GTC 
CAA TCC CAG CAA AGG GTT TGG GAT CGG CTT TCC TAG- 3. The two 
oligonucleotides were annealed together and 5' phosphorylated using standard protocols 
(Manniatis etal). Underlined sequences correspond to the Pk-oligonucleotide sequence.
Primers annealing to the non-coding and coding strands of the human I KBa gene for 
the generation of mutant IKBa genes, designated FOR (forward) and BACK (backwards) are as 
follows;
Two "Universal oligonucleotides" :FOR 5' - ATT GTA GGA TCC ATG TTC CAG GCG GCC 
GAG CGC - 3'. BACK 5' - GCC AGG AAT TCC TAA CGT CAG ACG CTG GCC TCC - 3'.
Mutants: W258v. FOR 5' - TAG CAG CTC ACC TAC GGC CGC CCA - 3'. E275q. FOR 5' - 
CAG CTG ACA CTA CAG AAC CTT CAG - 3'. E275s, FOR 5' - CAG CTG ACA CTA TCG 
AAC CTT CAG -3'. EDE284-286qnq. FOR 5 ’-CTG CCA GAG AGT CAG AAT CAG GAG
AGCTAT-3'. EDE284-286sss„ FOR 5' - CTG CCA GAG AGT TCG TCG TCG GAG AGC
TAT -3'. EDE300-302qnq. FOR 5' - ACG GAG TTC ACA CAG AAT CAG CTG CCC TAT -
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3'. EDE300-302SSS. FOR 5' - ACG GAG TTC ACA TCG TCG TCG CTG CCC TAT - 3'. ^°- 
317. FOR 5' - ATT GTA GGA TCC ATA CAG CAG CAG CTG GGC CAG - 3’. 275-317. FOR
5' - ATT GTA GGA TCC GAA AAC CTT CAG ATG CTG CCA - 3'.
Underlined, bold script refers to the mutant type (e.g. W258v. W= original amino 
acid, 258 = amino acid location within IkB a and y = amino acid after mutation) and the bold 
letters within the primers represent the areas of mutated sequence.
1.19. Generation of cDNA mutant IkBcc c-tag proteins.
A P.C.R. mutagenesis technique was employed (Landt et al, 1990) to generate the
cDNA molecules encoding mutant iKBa c-tag proteins. This method used one internal 
mutagenising primer and two external "Universal" primers (used for all the mutants) in a two 
step P.C.R.. The first P.C.R. contained lOOng of the linearised (obtained by digestion of the 
template with EcoRV and dephosphorylation with calf-intestinal alkaline phosphatase) "template" 
DNA i.e. pGEXcPk+Wild-type IkBcc (amino acids l-317)-c-tag (14 amino acids), 1pM of the 
"C-terminal" (3') primer BACK 5’ - GCC AGG AAT TCC TAA CGT CAG ACG CTG GCC 
TCC - 3' (lpl of 100|xM stock), lpM of the mutant primer (l|Ll of lOOgM stock), lOx dNTP 
(lOpl of a stock containing 0.5mM of each dNTP), lOx P.C.R. reaction buffer ( 10(tl;xl(final): 
lOmM Tris-Cl pH8.8, 1.5mM MgCl2, 50mM KCl and 0.1% Triton X-100) and lpl of Dynazyme 
DNA polymerase (Finnzymes Ltd.) - this mixture was made to a total of 100pi with sterile water 
and then overlaid with 50pl of liquid paraffin to minimise evaporation. The P.C.R. conditions 
were as follows: 30 cycles of; 94°C for 1.5 minutes, 50®C for 1.5 minutes and 72°C for 2 
minutes with the last cycle being 72°C for 7 minutes. The P.C.R. product was purified using the 
Qiaquick gel-extraction spin-columns (Hybaid Ltd.) as previously described. However, if the 
P.C.R. product was around 100 base pairs (the spin columns' limit for small fragments) it was 
loaded onto a 5% polyacrylamide gel (29:1, acrylamide:bisacrylamide) in 6x loading buffer 
(0.25% bromophenol blue, 0.25% xylene cyanol FF and 30% glycerol in sterile water) and ran at 
150V in lxT.B.E. until the marker dyes had separated (2-3 hours). The gel was stained in 
ethidium bromide (0.5pg/ml in lx T.B.E.) and the P.C.R. product was excised and eluted from 
the gel overnight at room temperature in 1-2 volumes of elution buffer (0.5M ammonium acetate,
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lOmM magnesium acetate, ImM EDTA, 0.1% SDS). The following day the DNA was recovered 
by adding 2 volumes of -20° C ethanol and centrifuging at 14, 000 rpm, 4°C for 30 minutes. The 
DNA was dissolved in lQpl of sterile water and the concentration was checked on a 1% agarose
gel.
The second P.C.R. also contained lOOng of linearised pGEXcPk+Wild-type IKBa , 
lpM of the '"N-terminal" (5') primer FOR 5' - ATT GTA GGA TCC ATG TTC CAG GCG GCC 
GAG CGC - 3" (1 pi of lOOpM stock), 40ng of the P.C.R. product from the first cycle, lOx 
dNTP (lOpl of a stock containing 0.5mM of each dNTP), lOx P.C.R. reaction buffer 
(U0ptl;xl(^f'inal): lOmM Tris-Cl pH8.8, 1.5mM MgCl2, 50mM KCl and 0.1% Triton X-100) and 
lpl of Dynazyme DNA polymerase (Finnzymes Ltd.)- this mixture was made to a total of lOOpl 
with sterile water and then overlaid with 50pls of liquid paraffin to minimise evaporation. The 
P.C.R. conditions were as follows: 32 cycles of; 94°C for 1.5 minutes, 55°C for 1.5 minutes and 
72°C for 2 minutes with the last cycle being 72°C for 7 minutes. The P.C.R. product was 
Qiaquick gel-extracted using spin-columns (Hybaid Ltd.) as previously described. The product 
(the mutant IkB(X DNA) was then digested with the appropriate restriction endonucleases 
(BamHl and EcoRl) for 10-16 hours according to the vendors instructions. The digested products 
were purified as before and used for subsequent ligations.
1.20. DNA llgations.
Depending on the size of DNA fragments to be ligated, an approximate 3:1 (large 
DNA inserts, >500bp) to 15:1 (small DNA inserts, <100bp) molar ratio of insert to vector 
fragments were combined in a total of 10-20pl of ligation buffer (xl: 50mM Tris-Cl pH7.8, 
lOmM MgCl2, lOmM DTT, lmM ATP and 25mgml-l BSA) where upon 200-1000U of T4 
DNA ligase (New England Biolabs) were added and the ligation reaction incubated at 16°C for 
10-16 hours. Half of the ligation reaction was used for subsequent transformation of competent 
bacteria.
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1.21. Preparation of competent bacteria.
• E. coli strains were made chemically-competent using MgCl2 and CaCl2 as follows:
A 100ml bacterial culture was grown to an OD6OO = 0.4-0.6, cooled on ice and centrifuged at
SOOOrpm in a Beckman JA20 rotor for 10 minutes at 4®C. The pellet was gently resuspended in 
10ml of ice-cold, sterile, O.1M MgCl2 and left on ice for approximately 3minutes. The
suspension was centrifuged as above and the pellet resuspended in 2ml of ice-cold, sterile, O1M 
CaCl2-The competent bacteria were used for transformation after approximately lhour and were 
optimally competent 12-24 hours after preparation.
1.22. Transformation of competent bacteria.
200pl of competent cells were incubated with lOpl of ligation reaction, on ice, for 30­
60 minutes with periodic mixing end-over-end. lng of pUC19 or no DNA were added to 
competent cells as positive and negative controls respectively (typically 10^ to 10^ transformants 
per pg of DNA was observed). After incubation, the bacteria were heat-shocked for 1.5 minutes 
at 42®C and returned to ice for 5 minutes. The transformation mix was added to 0.8ml of LB- 
broth and incubated at 37®C for lhour, to allow expression of B-lactamase for ampicillin 
selection, after which the transformed bacteria were plated on LB-agar containing relevant 
antibiotics.
1.23. Colony hybridisation.
A 9cm diameter nylon membrane (Hybond-N, Amersham International) was placed 
on top of the agar plate containing the colonies arising from the transformation of DNA ligation 
reaction into competent E. coll. The membrane was left to moisten for approximately 3 minutes, 
carefully peeled off the plate and placed, for 2 minutes, colony-side up onto a 3MM Whatman 
filter pre-soaked in lysis solution (10% SDS). The membrane was then transferred for 2 minutes 
colony-side up, onto a 3MM Whatman filter pre-soaked in denaturing buffer (0.5M NaCl, 1.5M 
NaCl). Next, the membrane was again transferred colony-side up onto a 3MM filter pre-soaked in 
neutralisation buffer (lM Tris/HCl, l.SMNaCl) for 5 minutes, this step being repeated once more. 
Once the neutralisation step was completed the nylon membrane was washed in 2xSSC (0.3M
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NaOH, 0.03M Na citrate}. The denatured DNA was cross-linked onto the membrane by 
illuminating the lysed colonies with U.V light for approximately 2-3 minutes. The membrane was 
then incubated in pre-hybridisation buffer (6xSSC, 5x Denhardts, 0.1% SDS and 50pg/ml single
stranded DNA) for 4 hours at 55 °C. A radiolabelled oligonucleotide was prepared by mixing 
lOOng (2pi) of oligonucleotide, 2pi lOx kinase buffer, 3.5ml y^2p ATP and 11.5pi sterile H2O 
and incubating at 37 °C for 30 minutes. The labelled solution of oligonucleotide was diluted by 
adding it to 10ml of hybridisation buffer (6xSSC, 5x Denhardts, 0.1% SDS and 50pg/ml single 
stranded DNA) and the incubation was continued overnight at 55°C. The following day the filter 
was washed as follows: 6x SSC, 0.1% SDS for 30 minutes at 50°C, 2x SSC, 0.1% SDS for 30 
mins at 50°C, 0.2x SSC, 0.1% SDS for 30 minutes 50 °C, 0.2x SSC, 0.1% SDS for 30 minutes at 
50°C and 2x SSC briefly. The filter was exposed to X-ray film overnight at -70°C.
1.24. Preparation of plasmid DNA.
Small-scale preparations of DNA, mini-preps., were prepared using the alkaline-lysis 
method of Birmboim and Doly (1979). Large-scale preparations, maxi-preps., were prepared by 
utilising Qiagen DNA maxi-prep, ion- exchange columns (Hybaid Ltd.) as used according to the 
manufacturer. Quality and quantity of DNA was analysed by spectrophotometric readings at 
260nm & 280nm and by visualisation on an agarose-gel (Manniatis et al.).
1.25. DNA sequencing.
DNA sequencing was performed on double stranded plasmid DNA templates using 
the dideoxy chain-termination procedure. Plasmid DNA for sequencing was prepared using 
Qiagen plasmid preparation columns (Hybaid Ltd.), as above. 5gg of plasmid DNA per primer- 
reaction were sequenced using the Sequenase° version 2.0 sequencing kit (Amersham 
International), [a^SjdATP (10^ Ci.mmoH; Amersham International) and used exactly 
according to the vendor's recommendations.
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1.26. Glutathione-agarose and FPLC Mono-Q column purification of I KBa c- 
tag from bacterial culture.
A.Triton X-100 method.
A single bacterial colony from a Luria agar plate containing lOOpg/ml ampicillin and 
12.25p.g/ml tetracycline was used to inoculate 50ml of LB-broth containing 100p.g/ml amp and 
12.25jig/ml tet overnight at 37 °C with shaking. 25 -50ml of the overnight culture was then added 
to 500ml of LB-broth (tet/amp) and incubated with shaking at 37°C until an ODgOOnm of 0.4-0.6 
was reached. The culture was induced with ImM IPTG for 3-4 hours at 25°C with shaking. The 
cells were harvested by centrifugation at 10,000rpm, 4 °C on a JAH Rotor in a Beckman J2-21 
Centrifuge for 10 minutes and resuspended in 30ml PBS, 0.5MNaCl, 2mM EDTA, ImM PMSF 
(Sigma) and 2mM benzamidine (Sigma). The cells were sonicated 6x30 second pulses (and 
placed on ice between sonications) until homogenous. 10% Triton X-100 was added to a final 
concentration of 1% and the mixture was centrifuged for 30 minutes at 17,000 rpm, 4°C on a 
JA17 or JA20 rotor in a Beckman J2-21 Centrifuge. Both the pellet and supernatant were 
retained.
The supernatant was loaded in a cold room at 4°C onto a 10ml glutathione agarose 
column (prewashed with 1 column volume of 0.2% NaOH and 6 column volumes of PBS/0.5M 
NaCl) using a pump at a flow rate of lml/min. The column flow-through was retained and the 
column washed with 2 column volumes of PBS, 0.5MNaCl, 2mM EDTA, ImM PMSF and 2mM 
benzamidine. The GST-protein was eluted with lOmM glutathione, 0.5M NaCl and 50mM 
Tris/HCl pH8.0 and collected in 20xlml fractions.The protein peak was found using a Bradford’s 
assay (see next method) and an aliquot of each fraction was ran on a 10% SDS polyacrylamide 
gel and stained with Coomassie Bluestain (2% PAGE blue 83, 40% methanol, 10% acetic acid) to 
check for purity .The peak fractions were pooled and treated with thrombin (from Sigma, 0.5 
units/0.24mg of GST-IkBoc) for 1-2 hours at 25°C. The reaction was stopped with ImM PMSF.
The thrombin cleaved GST and IkB a were diluted by half into 50mMTris/HCl 
(filtered) and then separated on an FPLC Mono-Q column across a salt gradient ranging from 
250mMNaCl in 50mMTris/HCl pH8.0 (filtered) to 1M NaCl in 50mM Tris/HCl pH8.0 (filtered). 
30x1 ml fractions were collected and an aliquot of each of the peak protein samples were checked
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on a 10% SDS polyacrylamide gel (as described in the next method). The concentration of each 
of the peak fractions to be retained was estimated using the A 280 in a quartz cuvette, whereby 
10D=2mg/ml protein. The protein peaks were then aliquoted and stored at -70OC.
B.Triton X-100 and Sarkosvl method.
Overnight cultures were grown, induced with IPTG and harvested by centrifugation as 
for the Triton X-100 method. After centrifugation the cells were resuspended in 30 ml PBS, 0.5M 
NaCl, 2mM EDTA, lmMPMSF, 2mM benzamidine and 100|xg/ml of lysozyme (Sigma) and 
incubated on ice for 15 minutes. This was followed by the addition of dithiothreitol (DTT) to 
5mM, N-laurylsarcosine to 1.5%, MgSO4 to lM and DNase (NEB) to 2mg/ml. This mixture was 
incubated at 37 °C for 15 minutes. The lysate was then clarified by centrifuging for 25-30 minutes 
at 14, 000 rpm, 4°C on a JA17 or JA20 rotor in a Beckman J2-21 centrifuge. The supernatant and 
pellet were both retained. The supernatant was transferred to a clean tube and Triton X-100 was 
added to a final concentration of 2% and EDTA to a final concentration of 8.2mM. The mixture 
was then centrifuged at 14, 000 rpm, 4°C for 10 minutes on a JA14 rotor in a Beckman J2-21 
centrifuge.
The supernatant was diluted 1 part supernatant to 5 parts PBS, 0.5M NaCl, 5mM DTT 
and 1% Triton X-100. The diluted sample was recirculated overnight on a 25ml glutathione 
agarose column (prewashed with 1 column volume of 0.2% NaOH and 6 column volumes of 
PBS/0.5M NaCl) in a cold room at 4°C using a pump set at a flow rate of approximately 
1ml/minute. The following morning the column was washed with lOOmls PBS, 0.5M NaCl and 
then the protein was eluted in 20x5ml fractions with lOmM glutathione, 0.5M NaCl and 50mM 
Tris/HCl pH8.0. The remainder of the procedure was carried out as for the Triton X-100 method.
1.27. Quantitation of
Protein concentrations were determined using either the method of Bradford (1976) or the 
BCA protein assay system as purchased from Pierce. The Bradford's assay was performed on 
protein samples where DTT was present, as this interferes with the BCA assay. For the Bradford's 
assay protein samples of 10ml were mixed with 990ml of Bradford's reagent (lOOmg coomassie
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blue G250, 100ml orthophosphoric acid and 50ml of 100% ethanol made up to 1 litre with 
distilled water), incubated at room temperature for 5 minutes and the absorbance at 595nm was 
measured on an LKB Biochrom Ultrospec II spectrophotometer. Protein absorbances were 
converted to mg/ml concentrations using a standard curve constructed by measuring the 
absorbances of a range of bovine serum albumin (BSA) concentrations after incubating with 
Bradford's reagent. The BCA assay was used according to the microtiter plate method in the 
manufacturers instructions (the BSA standards used for the Bradford's assay were also used for 
the BCA assay).
1.28. SDS-PAGE and Western blot analysis.
Protein samples were resuspended in disruption buffer (xl; 2% w/v SDS, 5% v/v 6- 
mercaptoethanol, 2.5% v/v glycerol and 0.25 % w/v bromophenol blue) boiled for 5 minutes and 
separated through a 10-12% SDS-polyacrylamide gel (29:1, acrylamide: bisacrylamide) using 
thin (0.75 mm) mini-slab gels of the Bio-Rad mini-protean II electrophoresis system (gel 
composition varied slightly for some methods but this has been indicated). Separated 
polypeptides were transferred (transfer buffer for semi-dry blotting- 48mM Tris, 39mM glycine, 
20%v/v methanol and 0.0375% SDS. Transfer buffer for wet blotting- 192mM Tris, 25mM 
glycine, 20%v/v methanol) onto nitrocellulose or P.V.D.F. filters using a semi-dry gel 
electroblotter (CBS Scientific Co.) or a Wet-blotter (Biorad Systems). The filters were blocked 
with PBS containing 5% (w/v) skimmed milk powder and 0.1% (v/v) Tween 20 then incubated 
with monoclonal or polyclonal antibodies diluted 1:200 to 1:1000 in blocking buffer. After 
washing in blocking buffer, bound antibodies were detected using HRP-conjugated anti-mouse 
(for monoclonal primary antibodies) or anti-rabbit (for polyclonal primary antibodies) antibodies 
(Amersham International) diluted in blocking buffer, washed as above, then developed by the 
enhanced chemiluminiscence (ECL; Amersham International) protocol according to the 
manufacturers recommendations.
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1.29. Stripping of nitrocellulose or P.V.D.F. membranes.
The membranes were transferred to strip buffer (0.15ml p-mercaptoethanol, 2.00ml 
20% SDS, 1.25ml lM Tris pH6.7, 16.6ml sterile H2O) and incubated in a hybridisation oven at 
72®C for 30 minutes. The membranes were washed xl quickly (5 mins) and x3 (15 mins) in 
250ml PBS containing 0.1% (v/v) Tween 20. The membranes were blocked for 1 hour in PBS 
containing 5% skimmed milk powder and 0.1% (v/v) Tween 20 and the membranes were probed 
as explained in the previous method. N.B. after E.C.L. development the membranes may be 
soaked in PBS containing 0.1% (v/v) Tween 20 and 0.1% NaN3 and sealed in a polythene bag at 
4®C.
1.30. Preparation of a radioactively labelled double stranded DNA probe.
Oligonucleotides were 5' end labelled using the T4 polynucleotide kinase (NEB).
5pmoles (1 pl) of the bottom strand of an oligonucleotide representing the kB motif present in the 
HlV-1 enhancer was mixed with 1 pl lOx kinase buffer (200mM Tris/HCl pH 7.6, 0.1MgCl2, 10 
mM dithiothreitol, lmM spermidine HCl, lmM EDTA (pH 8.0)), 20pCi "32p)ATP ( 2jxl from a 
stock of 3000 Ci/mmol, Amersham lnternational), 10 units of T4 polynucleotide kinase (NEB-2pl 
from a stock of 10, 000 Units/ml) and 4pl sterile water and heated to 100®C for 2 minutes. 
lmmediately after heating 5 pmoles (lpl) of the top kB oligonucleotide strand was added to the 
mixture. This was allowed to cool over 2 hours in a water bath. DNA dyes (0.25% bromophenol 
blue, 30% glycerol in sterile water) were added and the mixture was ran on a 12% 
polyacrylamide (29:1 acrylamide:bisacrylamide) gel. X-ray film was exposed to the gel for 3 
minutes in order to detect the position of the radioactively labelled DNA probe. The appropriate 
gel band was cut out and eluted overnight in 200pl of TEN JOO at room temperature. The probe, 
was decanted the following morning and stored at 4°C.
(kB 16 - mer Oligonucleotide = 5'-CTGGGGACTTTAGG-3')
1.31. Gel electrophoresis DNA binding assay.
l|X of diluted sample (p65-amounts given in results and discussion) was added to 19pl 
of binding buffer (85mM NaCl, 8.5% v/v glycerol, 22mM Hepes pH 7.5, 1.3 mg/ml BSA, 0.17%
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NP-40, 3.6mM spermidine, 0.85mM DTT, 0.85mM EDTA, 6.1mM MgCl2) which contained a 
r radiolabelled double-stranded 16-mer kB oligonucleotide 5’-CTGGGGACTTTCCAGG-3’
(top strand) derived from the human immunodeficiency virus type 1 enhancer. This mixture was 
left at room temperature for 15 minutes after which the iKBa inhibitor protein was added. This 
was left for a further 15 minutes at room temperature. 4pl of dye mix (50% glycerol, lOmM 
Hepes pH 7.5, 0.1% bromophenol blue) was added and each sample was applied to a 6% non­
denaturing polyacrylamide (44:0.8, acrylamide bisacrylamide) before electrophoresis at 200Vfor 
approximately 1 hour. The gel was dried onto DEAE paper and exposed to X-ray film overnight 
at -70°C to determine the positions of the radioactive species.
1.32. In Viiro plho^ipho^r^luliim msay tu^iing Casein kinase I and II.
Casein kinase assays were performed on mutant and wild-type iKBa c-tag purified 
proteins, BSA (used as a negative control) and purified casein kinase (Sigma-used as a positive 
control). The casein kinase 1 reaction mix was prepared as follows for 10 reactions; lOpl lOx 
casein kinase 1 reaction buffer ( 10x-50mMTris/HCl pH7.5, 10mMMgCl2, 5mMDTT), 
1.18rnMATP (0.2jil of a lOOmM stock), 4pCi of y(^^P)ATP (0.4pi from a stock of 3000 
Ci/mmol, Amersham International) and 6,300 units of casein kinase 1 (NEB-6.3pl from a stock of 
1x10^ Units/ml). 1.69 pi of this mix was added to each of 10 tubes containing 0.22 pmoles of the 
appropriate protein (protein dilutions were made in 20mM Tris/HCl pH8.0, 0.5MNaCl) in a 
volume of no greater than 8.31 pi. The final mixture of protein and casein kinase 1 reaction mix 
was made up to a total of lOpl with 20mM Tris/HCl pH8.0, 0.5MNaCl and incubated at 30OC for 
1 hour. The reaction was quenched in each tube by the addition of 5 pi of disruption buffer and 
the samples were boiled for 2-3 minutes. The contents of each tube were loaded onto a 10% 
polyacrylamide gel (29:1, acrylamide: bisacrylamide) and ran at 150V for 1 hour. The gel was 
dried onto DEAE paper and exposed to X-ray film overnight at -70° C to determine the positions 
of the radioactive species.
The casein kinase 11 reaction mix was prepared for 10 reactions as follows; lOpl lOx 
casein kinase 11 reaction buffer (10x-20mMTris/HCl pH7.5, 50mMKCl, 10mMMgCl2), 
1.18mMATP (0.2pi of a lOOmM stock), 4pCi of y(^^P)ATP (0.4pi from a stock of 3000
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Ci/mmol, Amersham International) and 210 units of casein kinase II (NFB-0.42pl from a stock of 
O.SxlO^Units/ml). 1.1 pi of the casein kinase II reaction mix was added to each of 10 tubes 
containing 0.22 pmoles of the appropriate protein (protein dilutions were made in 20mM 
Tris/HCl pH8.0, 0.5MNaCl) in a volume of no greater than 8.9pl. The final mixture of protein 
and casein kinase I reaction mix was made up to a total of 10 pi with 20mM Tris/HCl pH8.0, 
O.5MNaCl and incubated at 30®C for 1 hour. The reaction was stopped with 5pl of disruption 
buffer and the samples were processed as for the casein kinase I samples.
1.33. Protein association experiment.
lmg of GST fusion protein (GST-p65 or GST-p50) was dialysed overnight against 
PBS, 0.5M NaCl in a cold room at 4®C. 0.4mls of Glutathione-agarose (Sigma) was centrifuged 
in a 1.5 ml eppendorf tube at 14, 000 rpm for 30 seconds on a microfuge. The supernatant was 
removed and the beads were washed once with PBS, 0.5M NaCl. The supernatant was removed 
and the overnight dialysed protein sample or 0.5mg of GST were added to the beads and rotated 
in a cold room at 4®C for 2-3 hours. The mixture was then centrifuged for 1 minute in a 
microfuge at 14, 000 rpm and the supernatant was removed followed by x5 washes with PBS, 
0.5M NaCl. The beads with bound GST protein were then stored at 4®C in 0.2ml of PBS, 0.5M 
NaCl, 0.1% sodium azide.
40pl of the agarose beads with bound GST protein in PBS, 0.5M NaCl, 0.1% sodium 
azide (i.e. 20pl of beads) were pipetted into an eppendorf tube and centrifuged for 1 minute at 14, 
000 rpm in a microfuge. The supernatant was discarded and the beads were washed with 1ml of 
Solution A (for the assay with an [NaCl] variant :- 12mMTris/HCl pH8.0, 1mg/ml protease-free 
bovine serum albumin (PF- BSA), 0.1% NP-40 and either 60mM, 120mM, 240mM, 480mM or 
960mM NaCl. For the assay with pH as the variant :- 12mMMFS (free acid) pH5.5, 6.0 or 6.5 or 
12mMBis/Tris/propane pH6.5, 7.0, 7.5, 8.0, 8.5 or 9.0, 1mg/ml protease-free bovine serum 
albumin (PF- BSA), 0.1% NP-40 and 60mM NaCl). The supernatant was discarded and the 
following components were added to the remaining 20pl of beads; 20pl of lOmg/ml BSA, 160pl 
of Solution B (12mM Tris/HCl, 0.1%NP-40 and either 60mM, 120mM, 240mM, 480mM or 
960mM NaCl) and 2pg of protein sample. This was rotated for 1-1.5 hours at room temperature
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and then 1ml of solution A was added. The mixture was centrifuged for 1 minute at 14, 000 rpm, 
the supernatnt was removed and the beads were washed x4 with 1ml of solution A. This was 
followed by x2 washes with 1ml of solution B. The supernatant was removed and the beads were 
resuspended in 20|il of sterile water and 20jli1 of disruption buffer. The sample was then boiled 
for 2-3 minutes, centrifuged at 14, 000 rpm for 1 minute and 5 jxl of the supernatant was ran on a 
10-12% polyacrylamide gel.
1.34. Preparation of cationic liposomes for DNA transfection.
Lipofectamine for transfection of Cos 7 cells was purchased from Gibco-BRL. 
However, lipids for transfection of 293’s were prepared using the following procedure , kindly 
given by R. Elliott (MRC Virology, Glasgow) and yields a lipid mixture equivalent to Gibco- 
BRL's TransfectACE. Briefly, 1ml DOPE (dioleoyl L-a-phosphatidyl ethanolamine, Sigma) was 
pipetted into a glass universal where-upon 4mg of DDAB (dimethyldioctadecyl ammonium 
bromide, Sigma), w/w ratio of 1:2.5 DDAB:DOPE, were added and briefly vortexed till 
dissolved. The chloroform was evaporated using a stream of nitrogen whilst rotating the universal 
to ensure an even film of lipid dispersed around the walls. The dried lipids were resuspended in 
10ml of sterile distilled water by a 10-15 minute sonication in a sonicating waterbath. Once 
resuspended, the turbid mixture was sonicated with a soniprobe (15 microns amplitude) using 30 
second pulses and incubating on ice in between, until clear (approximately 20-40 minutes). Lipids 
were tested against previous batches for transfection efficiency using a 8-galactosidase expressing 
plasmid, pCT78gal, then stored in 500jxl aliquots at 4°C.
1.35. Staining protocol for detection of B-galactosidase expressing cells.
Transfected cells were washed once with PBS then fixed for 5 minutes at room 
temperature by the addition of 1ml of fixative (2% formaldehyde, 2% glutaraldehyde in PBS ) for 
3.5cm diameter dishes. The fixative was removed and the cells washed with PBS. 1ml of freshly 
prepared staining solution ( 5mM potassium ferricyanide, 5mM potassium ferrocyanide, 2mM 
MgCl2 and 0.5mgmW X-gal, in PBS) was added to the washed cells which were then incubated 
at 37 °C for approximately 4 hours or overnight.
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1.36. Transient DNA transfections.
Expression from the human CMV 1 . E. promoter/enhancer.
Mammalian cells were passed into 25cm 2 flats or individual wells of a 6-well plate to 
obtain 60-70% confluency the next day. Plasmid DNA was introduced into cells using a 
liposome-mediated procedure. Briefly, for one 3.5 cm diameter well, l-3[ig of DNA was added to 
O.5mls of optimem 1 (Gibco-BRL) and gently mixed. lOpl of the liposome mixture was added to 
the DNA/optimem 1, gently mixed, briefly vortexed and left to stand for 10-15 minutes at room 
temperature. The volume of the liposome/DNA mixture was adjusted to 1 ml by the addition of 
0.5ml of optimem 1 (All steps were carried out in polystyrene tubes due to the affinity of the 
liposomes for polypropylene). The optimem 1/liposome/ DNA mixture was left on the cells for 
12-16 hours after which the cells were washed once with GMEM-1OF and incubated for a further
24-72 hours in GMEM-1OF.
1.37. Coupling of SV5-P-k (Anti-Pk) antibody to Protein A Sepharose.
250mg of Protein A sepharose beads were swollen in 2ml PBS, 0.1% sodium azide 
(this yielded a bed volume of 1ml of beads). One hour later 500^l of Protein A sepharose beads 
were mixed with 1ml of Anti-Pk for 2 hours at room temperature (using a rotator). The mixture of 
beads and antiserum were centrifuged at 2500rpm on a benchtop centrifuge for 5 minutes, then 
the supernatant was removed and the beads+bound Anti-Pk were washed x2 in 200mM borate 
buffer, 3M NaCl pH9.0. After the second wash the beads+bound Anti-Pk were resuspended in 
1ml of 20mM dimethylpimelimidate (in 200mM borate buffer, 3M NaCl pH9.0-prepared fresh) 
and rotated for 30 minutes at room temperature. The beads were then centrifuged for 5 minutes at 
2500rpm on a benchtop centrifuge and the supernatant was removed. This was followed by x2 
washes in 200mM borate buffer, 3M NaCl pH9.0 and xl wash in 200mM ethanolamine. The 
beads were resuspended in 1ml of 200mM ethanolamine and rotated for 2 hours at room 
temperature followed by centrifugation at 2500rpm for 5 minutes in a benchtop centrifuge. The 
beads were then washed x2 in PBS, x2 in 200mM glycine (pH2.5), x2 in PBS and the beads were 
stored in 500pi of PBS+0.1% sodium azide.
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1.38. Immunoprecipitation using the Protein A Sepharose beads coupled to 
antiserum.
200|U of lysis buffer (see preparation of cytoplasmic extracts - no protease inhibitors) 
were added to 20p,l (i.e.lOpl of bed volume) of Protein A sepharose beads (Sigma-1.5g of 
beads/12ml PBS/0.1% sodium azide) coupled to anti-PR. 50-100[ig of cell lysate were added to 
the beads and buffer and the mixture was rotated for 90 minutes at room temperature. The beads 
were then centrifuged for 1-2 minutes on a benchtop centrifuge at 14, 000 rpm and the 
supernatant was removed. The beads were washed x3 with lysis buffer and then resuspended in 
lOjil of disruption buffer (xl; 2% w/v SDS, 5% v/v 6-mercaptoethanol, 2.5% v/v glycerol and 
0.25 % w/v bromophenol blue) and boiled for 10 minutes. The samples were then ready to be 
loaded on a polyacrylamide gel.
1.39. Luciferase assays.
Cos 7 or 293 cells were grown to 50% confluency in 25cm^ flats and co-transfected with l[ig 
(for Cos7s) or 5pg (for 293s) of an NF-kB dependent (3FnhConALuc) or independent 
(LTRAkBLuc) luciferase reporter vector and an equal amount of the mutant or wild-type ikB<a in 
pcDNA3cPk plasmid using lipofectamine (for Cos7s) or cationic liposomes (for 293s). Fourty 
hours later the cells were activated with TNFa (lOng/ml final in medium) for eight hours and 
then harvested as follows; the cells were washed once with PBS and then trypsinised (for Cos 7 s) 
or treated with versene (for 293s). This was neutralised with GMFM-10 and the cells were 
pipetted into eppendorfs and centrifuged at 1-2,000 rpm, 4®C for 4 minutes. The supernatant was 
discarded and the cells were washed once with 1ml of ice cold PBS followed by lysis in 200|xl of 
luciferase lysis buffer (25mMTris phosphate pH7.8, 8mMMgCl2, ImMDTT, 1% Triton X-100, 
15% glycerol) to yield the cytoplasmic extract. Following a thorough vortex 100pf of the 
cytoplasmic extract was removed and added to 100pi of luciferin buffer (ImM ATP, 0.25mM 
luciferin, 1% BSA prepared in luciferase lysis buffer) and the luciferase activity was immediately 
measured using a luminometer (Lumat LB 9501, Berthold). A Bradfords' assay was performed on 
the remainder of the extract to determine the protein concentration. The results were expressed as 
relative luciferase units (RLU) per pg of protein. This was determined by subtracting the
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background signal from each of the luminometer readings and divising this figure by the amount 
of cytoplasmic protein contained in the sample.
1.40. Signal-1'nduced Degradation Assay for iKBa c-tag.
293 cells were grown on 35mm 6 well plates until 50% confluent and then transfected for 12­
15 hours with l-3pg of mutant or wild-type iKBa in pcDNA3cPk as described previously for 
transient transfections. 36 hours after the transfection had begun the cells were pretreated for 5 
minutes with lOOpg/ml cycloheximide (Sigma). The cells were then either induced 
(cycloheximide was maintained in culture until the end of the induction) with lOng/ml TNFa for 
15 or 45 minutes or not induced with TNFa at all. The cells were harvested directly into 125 pi 
lysis buffer (50mM sodium phosphate buffer pH 7.5, 0.5% NP40 and the protease inhibitors 
(added immediately before use) - 1pM leupeptin, 1pM pepstatin, 1mM pefablock, 20pM TPCK, 
40pg/ml bestatin). The cells were centrifuged at 6,000 rpm, 4®C for 10 minutes. The supernatant 
was removed as the cytoplasmic extract and a BCA assay was used to determine the protein 
concentration of each sample. 10-20pg of protein was loaded in disruption buffer onto a 10-12% 
polyacrylamide gel (29:1 acrylamide: biacrylamide) and then a Western blot was carried out as 
previously described (membranes were probed with either the monoclonal Anti-Pk or lOB 
antibody).
1.41. Signal-1nduced phosphorylation assay of IkB(s c-tag.
293 cells were grown as for the degradation assay on 35mm 6 well plates until 50% confluent 
and then transfected for 12-15 hours with l-3pg of mutant and wild-type 1tcBa + pcDNA3cPk as 
described previously for transient transfections. 36 hours after the transfection had commenced 
the cells were pretreated with 25pM z-LLL-H for 15 minutes (this was maintained until the end 
of the culture). The cells were then either induced with 250nM Okadaic acid (OKA from Sigma) 
alone for 45 minutes or with 250nM Okadaic acid for 45 minutes followed by lOng/ml TNFa for 
15 minutes or not induced with OKA or TNFa. The cells were harvested into 125pi of lysis 
buffer (as above but with the following phosphatase inhibitors added~50mM sodium fluoride, 
5mM tetra sodium pyrophosphate, 1mM sodium orthovanadate, 10 mM p-glycerophosphate and
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2 mM EDTA) and centrifuged at 6,000 rpm, 4°C for 10 minutes. The supernatant was removed 
as the cytoplasmic extract and a BCA assay was used to determine the protein concentration of 
each sample. 20-30gg of protein was loaded in disruption buffer onto a large 16.5% 
polyacrylamide/9.4% glycerol gel (48:1.5, acrylamide:bisacrylamide and gel buffer-3MTris/HCl 
pH8.45, 0.3% SDS) ran in a buffer gradient (Anode buffer-0.2M Tris/HCl, pH9.0. Cathode 
buffer-O.lM Tris, 0.1M Tricine, 0.1% SDS, adjusted to pH8.25) for 8 hours at lOOVfor the first 
hour and then 150V thereafter. The gel was then blotted overnight at 50mA on a semi-dry blotter 
or for 4 hours at 70mA. The gel was probed with Anti-Pk and ECL developed as described 
previously.
1.42. Analysis of ubiquitination patterns of I KBa c-tag.
293 cells were grown in 35mm 6 well plates until 50% confluent and were transfected for 12- 
15 hours with 1-3 jig of mutant and wild-type I KBa + pcDNA3cPk as described previously for 
transient transfections. 36 hours after the start of transfection the cells were pretreated with 25|iM 
z-LLL-H for 15 minutes (this was kept in culture until the cells were harvested) and then either 
induced with lOng/ml TNFa for 45 minutes or not induced with TNFa. The cells were harvested 
in 125p.1 of lysis buffer (with phosphatase inhibitors and fresh lOmM iodoacetamide). The 
iodoacetamide was quenched 30 minutes later with lOmM DTT and the extracts were centrifuged 
at 6, 000 rpm, 4 °C for 10 minutes. The supernatant was removed as the cytoplasmic extract and a 
BCA assay was performed to determine the protein concentration. 100-200jig of extract in 
disruption buffer was loaded onto a 12.5% polyacrylamide gel (12.5% acrylamide: l.Omg/ml 
bisacrylamide) and a Western blot was carried out as described previously to detect high 
molecular weight bands corresponding to covalently bound ubiquitin-lKBa complexes.
1.43. Circular Dichroism Spectroscopy.
CD spectra were recorded using a Jasco J-600 spectropolarimeter for a range of 
molecules corresponding to the C-terminal region of IKBa by Dr S. Kelly, Stirling University. 
These were as follows; a chemically synthesised peptide kindly supplied by Francoise Baleux, 
Institut Pasteur corresponding to amino acids 275-317 of IkB a and containing a chemical
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blocking group (CH2NHCOCH3) at position 308 (a cysteine group which could cross-link
molecules of the peptide if it remained unblocked) and three bacterially expressed, 
glutathione/FPLC purified C-terminal fragments of IkB a - amino acids 265-217 + c-tag (14 
amino acids) represented as 265-317c-tag, amino acids 265-317 represented as 265-317 and 
amino acids 275-317 represented as 275-317.
The dried peptide was resuspended to a concentration of 0.5mg/ml in a solution of 
50mM sodium fluoride and lOmM sodium phosphate ranging in pH from 6.0-8.0. The CD 
spectrum of the peptide at each pH was measured in the far ultraviolet (UV) region (190-260nm). 
At pH 7.0 the CD spectrum was also measured in the presence of 50% trifluoroethanol (TFE).
The three C-terminal fragments of IkBcc, 265-317 c-tag (0.51mg/ml), 265-317 
(0.2mg/ml) and 275-317 (0.2mg/ml) were dialysed overnight against 50mM sodium fluoride, 
lOmMsodium phosphate pH7.0, 0.5mM DTT. Additionally, 1ml aliquots of 265-317 and 275-317 
were dialysed overnight against 50mM sodium fluoride and lOmM sodium phosphate pH5.6, 
pH6.4 (275-317 only), pH7.0 and pH8.0, 0.5mM DTT. Their CD spectra were measured in the 
far UV region (190-260nm) in the presence and absence of 50% TFE.
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RESULTS
CHAPTER 1. CONSTRUCT1ON, EXPRESS1ON AND PUR1F1CAT1ON
OF W1LD-TYPE AND MUTANT IkBcs C-TAG PROTE1NS.
Studies performed on deletion mutants of the human iKBa protein (note: there are
several homologues of iKBa but in general human iKBa or MAD-3 is referred to as iKBa 
and it is the human form which is the subject of this study) had revealed that the highly 
negatively charged C-terminus was required for the association of iKBa with the p65 subunit 
of NF-kB and for inhibition of p65 DNA binding (1noue et al., 1992; Hatada et al., 1993). 
These reports indicated that specific residues in the C-terminal region may be contributing to 
these functions but that the changes in activity observed in the deletion mutants had perhaps 
arisen from a conformational change in the mutated proteins. Therefore, it was reasonable to 
predict that the substitution (rather than deletion) of a smaller number of residues could 
reduce the probability of inducing a conformational change and may also allow a specific 
function to be assigned to these residues.
1n order to identify suitable target amino acids in the C-terminus of iKBa for 
mutation, the areas of contact between the p65 subunit of NF-kB and 1 kB a had to be 
considered. 1t had been shown that iKBa could mask the nuclear localisation signal (NLS) of 
p65 (Ganchi et al, 1992; Zabel et al., 1993 ). 1n addition, it had also been suggested that 
iKBa may bind to this signal sequence since mutation of the 4 basic residues which compose 
the NLS abolished binding of iKBa (Beg et al, 1992). Available evidence also implied that 
positive charges residing in the DNA binding region of the related v-Rel protein may 
contribute to the binding in vitro of the chicken homologue of mammalian iKBa, pp40 
(Kumar and Gelinas, 1993). 1t was possible that the binding of iKBa to p65 involved an ionic 
interaction between the negatively charged C-terminal region of 1kB a and the positively 
charged NLS and DNA binding region of p65. An ionic interaction between iKBa and p65 is 
supported by the finding that the anionic detergent deoxycholate can dissociate an inactive 
iKBa-NF-KB complex (Baeuerle and Baltimore, 1988b). Comparison of the C-terminal 
amino acid sequence of human 1kB a (MAD-3) with the equivalent acidic regions in the
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avian (pp40), porcine (ECI-6) and rat (RL/IF-1) homologues of IkB a and the related 
proteins, IkBP and IkBy revealed two distinct areas of negatively charged conserved 
residues, glutamic acid (E) 284, aspartic acid (D) 285 , glutamic acid (E) 286 and glutamic 
acid (E) 300, aspartic acid (D) 301, glutamic acid (E) 302 (figure 9). The location of E286 
was analogous to that of E302 in that it was adjacent to aspartic acid at position 285 and then 
glutamic acid at position 284. These amino acids were therefore obvious candidates for 
mutagenesis and it was decided that amino acids 284-286 and 300-302 should be changed to 
either three serine (S) residues or their uncharged equivalents, glutamine (Q), asparagine (N), 
glutamine (Q). The nature of the altered amino acids were critical and “safe” amino acid 
substitutions were selected so that any disturbance of protein folding, both locally and 
globally, was minimised (Bordo and Argos, 1991). For this reason two different mutants 
were generated at each site to enable a comparison of the substituted residues effect (if any) 
on the function of I KBa.
In addition to the construction of C-terminal mutants of I KBa, a second set of mutants 
within the sixth ankyrin repeat or linker region of the protein were generated. This work 
followed a report on the protease sensitivity of I KBa and its sites of interaction with p65 
(Jaffray et al., 1995). While the central 5 ankyrin repeats and C-terminal domain of IKBa 
were found to be relatively resistant to proteolysis, the sixth, low-homology ankyrin repeat 
and the N-terminal region were both susceptible to proteolysis. However, in the presence of 
bound p65, proteolysis was blocked at tyrosine (Y) 251, tryptophan (W) 258 and glutamic 
acid (E) 275 in the low homology ankyrin repeat suggesting their involvement in the 
interaction between I KBa and p65. It was proposed that the sixth ankyrin repeat may exist as 
a flexible linker region between the highly structured 5 ankyrin repeats and the acidic C- 
terminal domain of IKBa. W258 and E275 were targeted for mutation and as previously 
described for the C-terminal mutants, amino acid substitutions were chosen to minimise 
disruption of iKBa’s conformation. W258 was changed to tyrosine and E275 was substituted 
with either serine or glutamine.
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Figure 9. Comparison of the amino acid sequence of human IKBa (MAD-3) 
with related proteins.
The deduced amino acid sequence of human IkB a (MAD-3) (Haskill et al., 
1991) compared with the deduced amino acid sequences of avian IkB a (pp40) (Davis et 
al, 1991), porcine IkB a (ECI-6) (deMartin et al, 1993), rat IkB a (RL/IF-1, 
regenerating liver Inhibitory factor) (Tewari et al., 1992), mouse iKBy (MusIkBg) 
(Inoue et al, 1992) and mouse IkB3 (MusIkBb) (Thompson et al., 1995). Amino acids 
are numbered to the left of the figure. Dashes indicate spaces Introduced to optimise 
sequence identity during alignment. The amino acids are colour coded according to 
their charge: Red, acidic (DE); blue, basic (HKR); yellow, non-polar (AILVPFWM) 
and green, uncharged polar (GSTYCNQ).
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Both the C-terminal and linker IkBoc c-tag (the origin and relevance of the c-tag 
region will be discussed in section 1.2) mutants are represented diagrammatically in figure 
10.
1.1. Construction of IkBoc c-tag mutant proteins.
The C-terminal (EDE284-286qnq, EDE284-286sss, EDE300-302qnq, EDE300- 
302sss) and linker (W258y, E275q, E275s) IkBoc c-tag mutant proteins were generated by the 
PCR mutagenesis technique (Landt et al., 1990) represented schematically in Figure 11. This 
method utilised one internal mutagenic primer and two external “universal” primers (used for 
all mutants) in a two-step PCR (described in detail in the Materials and Methods section) as 
follows:
The first PCR contained the mutagenic primer and the 3’ universal primer (this 
possessed an EcoRI restriction site) which were used to generate a partial length product 
from the linearised template DNA, pGEXcPk + wild-type IkBoc (pGEXcPk will be described 
in section 1.2). The first PCR product was purified from contaminating primers, nucleotides 
and PCR by-products and then used as a primer for the second PCR in addition to the 5’ 
universal primer (containing a BamHI restriction site) and the linearised template DNA, 
pGEXcPk + wild-type IkBoc. The final C-terminal and linker mutant PCR products were 
analysed by separation through a 0.8% agarose gel and revealed that all had the expected size 
of approximately 951 base pairs (data not shown).
Finally, the mutant DNA was digested with the restriction endonucleases, BamHI and 
EcoRI, purified and ligated into the pGEXcPk vector (also digested with BamHI and EcoRI) 
and transformed into competent E.coli (XL-blue). Tetracycline and ampicillin resistant E.coli 
transformants were isolated and small scale preparations of their DNA (mini-preps.) were 
prepared and used as double stranded DNA templates to sequence the cDNA surrounding the 
sites of mutation (i.e. around the C-terminal region), the N-terminal region and some of the 
surrounding ankyrin repeats using the dideoxy-chain termination procedure. Figures 12 and 
13 show the sequencing data obtained for the cDNA surrounding the areas of mutagenesis 
only (including the Pk tag region) for the C-terminal and linker mutants respectively and
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Figure 10. Schematic representation of IKBa C-terminally linked to 
the epitope Pk-tag and derivative mutant proteins with amino acid 
changes in the linker and C-terminal regions.
Wild-type iKBa c-tag is shown with the amino acid sequences, 276 to 
317 and 243 to 275 corresponding to the C-terminal and low homology ankyrin 
repeat or linker regions respectively. The amino acid changes performed in each 
of the regions to produce the mutant IkB a c-tag proteins are alsoindicated in 
addition to thennkyrm repeats ( ), low homology repeat ( ), acidic
domain ( ) (-this forms most of the C-terminal domain), the Pk-tag
epitope ( ) and the anti-Pk antibody ( I ).
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Figure 11. Schematic presentation of the PCR mutagenesis 
method.
In the first PCR (a) the mutagenesis primer (1) and the 3' primer 
(2) (containing an EcoRI site E) were used to generate the product (3) from 
the template DNA (T). Following a purification step (3) was taken as the 
primer (3a) together with the 5' primer (4) (containing a BamHI site B) and 
the template DNA (T) in the second PCR b) to yield the products (5) and 
(3b). Product (5) was purified and in a final step c) the mutant gene 
product (5a) was obtained by cleavage of (5) with the restriction enzymes 
BamHI and EcoRI and ligated into the appropriate vector (V). Any possible 
contamination from product (3b) during subcloning in step c) was reduced 
because of the size dependent purification of product (5a) from an agarose 
gel before step c) and the absence of a BamHI restriction site in 3b) which 
would yield a digested product (3c) non-viable for the subcloning step in 
step c).
Figure 12. Sequence confirmation of the C-terminal IkB a c-tag 
mutants.
The dideoxy chain-termination procedure was used to yield the coding 
DNA strands shown opposite for each of the following C-terminal IkB a c-tag 
mutants (named at the top of each seguence): EDE284-286qnq i.e. the mutation 
of amino acids 284-286 where glutamic acid, aspartic acid and glutamic acid 
were changed to glutamine, asparagine and glutamine (translated from 
TCA/GAA/TCA); EDE284-286sss i.e. the mutation of amino acids 284-286 
where glutamic acid, aspartic acid and glutamic acid were changed to three serine 
residues (translated from TCG/TCG/TCG); EDE300-302qnq i.e. the mutation of 
amino acids 300-302 where glutamic acid, aspartic acid and glutamic acid were 
changed to glutamine, asparagine and glutamine (translated from 
CAG/AAT/CAG) and EDE300-302sss i.e. the mutation of amino acids 300-302 
where glutamic acid, aspartic acid and glutamic acid were changed to three serine 
residues (translated from TCG/TCG/TCG). The coding DNA sequences are read 
from bottom to top (5' to 3' on the coding DNA) and the lane location of each 
DNA base is shown at the top of the gel (A= adenine, C= cytosine, G= guanine 
and T= thymine). The position and sequence of each mutation is boxed. The 
DNA sequence for Pk-tag and the restriction site for EcoRI are also indicated.
aa 284-286 Glu (E) Asp (D) Glu (£)► 
Gin (Q) Asn (N) Gin (Q)
Coding strand 
A C G T
aa284-286 Glu (E) Asp (D) Glu (E) 
Ser (S) Ser (S) Ser(S)
Coding strand 
A C G T
aa300-302 Glu (E) Asp (D) Glu (E) -► 
Gin (Q) Asn (N) Gin (Q)
Coding strand 
A C G T
0<LQJ
aa300-302 Glu (E) Asp (D) Glu (E)
Pk-tag
aa275 Glu (E)»-^ln (Q) 
Coding strand 
A C G T
aa275 Glu (E)»-Ser (S) 
Coding strand 
A C G T
aa25 Trp (W) ►Tyr (Y) 
Coding strand 
A C G T
i
Figure 13. Sequence confirmation of the linker IkB<x c-tag mutants.
The dideoxy chain-termination procedure was used to yield the coding 
DNA strands above for each of the following IkB a c-tag linker mutants (named 
at the top of each sequence): E275q i.e. the mutation of amino acid 275 where 
glutamic acid was changed to glutamine (translated from CAG); E275s i.e. the 
mutation of amino acid 275 where glutamic acid was changed to serine 
(translated from TCG) and W258y i.e. the mutation of amino acid 258 where 
tryptophan was changed to tyrosine (translated from TAC). The coding DNA 
sequences are read from bottom to top (5' to 3' on the coding DNA) and the lane 
location of each DNA base is shown at the top of the gel (A= adenine, C= 
cytosine, G= guanine and T= thymine). The position and sequence of each 
mutation is boxed. The DNA sequence for Pk-tag and the restriction site for 
EcoRI are also indicated.
indicates that the mutagenesis procedure had generated the expected products with no 
inadvertent mutations being produced over the region of readable sequence (approximately 
150-200 base pairs). The N-terminal region of sequence and ankyrin repeats also showed no 
inadvertent mutations. It should be noted that the use of Pfu DNA polymerase (purchased 
from Stratagene) in the polymerase chain reactions minimised the possibility of DNA 
mismatches because of its 3’ to 5’ proofreading activity.
1.2 Expression and purification of wild-type and mutant C-terminal and 
linker I KBa c-tag (aa l-317) proteins in E.coli.
For the expression and purification of wild-type and mutant C-terminal and linker 
IkB(X c-tag proteins in E.coli (XL-blues ) the glutathione-S-transferase (GST)-fusion 
expression system was used (Smith and Johnson., 1988). The vector employed in this study 
was pGEXcPk (Hanke et al, 1992) which was generated from the pGEX-2T expression 
vector (Promega) and allowed the production of high levels of protein with a cleavable N- 
terminally fused 26 kD enzyme, glutathione-S-transferase (GST) and a 14 amino acid C- 
terminally fused Pk-tag linker. Generally proteins fused to GST are more soluble in E.coli 
and can be easily recovered from bacterial lysates by affinity chromatography using 
glutathione bound to agarose. The C-terminally fused Pk-tag linker is recognised by a 
monoclonal antibody termed SV5-Pk (anti-Pk) and therefore allowed IxBa c-tag to be easily 
detected by Western blotting. Pk-tag was originally derived from amino acids 95-108 of the 
phospho (P) and V proteins of simian virus 5 (S V5). The Pk-tag linker DNA and amino acid 
sequences are shown below in figure 14.
gly lys pro ile pro asn pro leu leu gly leu asp ser thr 
GGA AAG CCG ATC CCA AAC CCT CTG CTG GGA TTG GAC TCC ACC 
CCT TTC GGC TAG GGT TTG GGA GAC GAC CCT AAC CTG AGG TGG
Figure 14 The oligonucleotide linker coding for Pk-tag. Coding and non-coding 
DNA strands are shown and the amino acids in bold represent those derived from 
SV5 P and V proteins.
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Screening for the over-expression of the 63 kD glutathione-S-transferase-wild-type 
and mutant IKBa c-tag fusion proteins from the pGEXcPk vector was carried out as follows: 
1ml overnight cultures of the positively identified wild-type and mutant iKBa c- 
tag/pGEXcPk E.coli (XL-1 blue) clones (i.e. the clones which when sequenced exhibited the 
expected changes) were diluted the following day, 1:100, into 1ml of LB-broth and grown 
until an OD6oOnm was reached. The cultures were then induced with IPTG for 3-4 hours and 
the cells were harvested by centrifugation, resuspended in PBS/0.5M NaCl and disruption 
buffer, boiled and then separated through a 10% polyacrylamide gel. An uninduced culture 
was included as a control. The coomassie blue stained gels were used to identify clones 
possessing a protein band of around 63kD (corresponding to the GST-IixBa c-tag fusion 
protein). 1ml overnight cultures of clones positive for the fusion protein were diluted 1:100 
into 1litre of LB-broth and grown at 37°C to the appropriate density before induction with 
IPTG to yield the fusion protein.
The individual fusion proteins were then purified by glutathione-agarose column 
chromatography using either the tritonX-100 method or the tritonX-100 and sarkosyl method 
(see materials and methods). The tr^t^<^^n^^100 method was used for the purification of the C- 
terminal mutants, EDE300-302qnq and EDE300-302sss only and a supply of tr^^<^^!^-100 
purified wild-type iKBa c-tag was kindly provided by Ellis Jaffray (University of 
St.Andrews). This method used the mild non-ionic detergent tr^i^<^^Z^^100 to achieve protein 
solubilisation before the protein sample was applied to a glutathione-agarose column. 
However, the remainder of the GST-fusion mutants (EDE284-286qnq, EDE284-286sss, 
W258y, E275q and E275s) failed to be solubilised by tr^it<^^1^^100 alone and a method which 
employed both tritonX-100 and the stronger ionic detergent, sarkosyl was required 
(Frangioni et al., 1993). This procedure achieved protein solubilisation through the 
denaturing action of sarkosyl. The addition of tritonXIOO was then thought to orient sarkosyl 
into micelles thereby allowing the GST-fusion protein to refold (and remain solubilised) and 
bind to glutathione-agarose. Wild-type IxBa c-tag was also purified using the tritonX-100 
and sarkosyl method to act as a direct comparison between wild-type and mutant proteins 
purified under the same conditions in the experiments which follow In chapter 2.
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Finally, the purified GST-fusion proteins were cleaved with thrombin and the wild- 
type and mutant IKBa c-tag proteins were recovered using ion exchange FPLC on a mono Q 
column. This purification strategy separated proteins on the basis of charge-the more 
negatively charged the protein the greater its affinity for the column. The wild-type and 
mutant IKBa c-tag proteins possessed a highly negatively charged C-terminus and could 
therefore bind to the column. GST was uncharged and would not bind to the column, it was 
present in the initial flow-through. Proteins were eluted from the column using a 
concentration gradient of sodium chloride (250mM to 1M). An additional glutathione- 
agarose purification step was included if the FPLC purified protein sample contained any 
undigested fusion protein (which can bind to the FPLC mono-Q column). The fusion protein 
was absorbed onto the column whereas the thrombin cleaved protein was passed through the 
column to yield the final wild-type and mutant IkB a c-tag proteins.
Figures 15 and 16 show the results of the purification steps. The thrombin cleaved 
fusion protein (i.e. the FPLC column load), the FPLC column flow-through (i.e. GST), FPLC 
column washes and the optional glutathione-agarose purification step are not shown. The 
polyacrylamide gels illustrate that the glutathione-agarose affinity chromatography yielded 
virtually pure GST-IkBoc c-tag wild-type and mutant (aal-317) proteins in the various eluates
(E) . The mutant and wild-type IkBoc c-tag proteins eluted from the FPLC Mono-Q column
(F) were shown to be free from most of the contaminating proteins-a small amount of 
undigested fusion protein was visible in some of the mutants but this was removed by 
including an additional glutathione-agarose purification step. It should be noted that IkBoc c- 
tag does not stain well with coomassie blue compared to GST, therefore the GST-IkBoc c-tag 
fusion protein appears as a much darker band compared to IkBoc c-tag alone. Also evident 
was a protein band around 30kD which had resulted from the thrombin cleavage step. IkBoc 
c-tag contains a weakly recognised thrombin cleavage site at its N-terminus from amino 
acids 58-63 (EVPRGS) which, although not identical to the true thrombin site, LVPAGS, it 
can be cleaved at a slower rate to give the lower molecular weight product of 30kD. The 
occurence of this product was reduced by performing a “test” thrombin cleavage on a small
92
MWt markers
200
29
18.4
14.3
Wild type .TX+S. 
IxBa c-tag
M U L FT W1 W2 E F
4
IKBa c-tag 
GST
' IKBa c-tag
Figure 15. Glutathione-agarose and FPLC column purifications of 
wild-type and C-terminal mutant IxBa c-tag proteins.
Coomassie blue stained 10% SDS polyacrylamide gels of glutathione- 
agarose and FPLC column purifications are shown above and overleaf for the 
wild-type I kB a c-tag protein (using the TrIton-XlOO and sarkosyl purification 
method-TX+S) and the C-terminal IkB a c-tag mutant proteins - EDE284-286qnq 
(using method TX+S), EDE284-286sss (using method TX+S), EDE300-302qnq 
(using the TritonX-100 purification method-T) and EDE300-302sss (using 
method T) either with GST (GST-lKBa c-tag) or without GST (IKBa c-tag). All 
sample tracks contained a mix of 15|fl of protein solution and 7.5|xl of 3x 
disruption buffer which had been boiled for 2-3 minutes before loading. The 
following abbreviations were used for the sample tracks shown :- M = protein 
molecular weight standards (units=kDa), U = uninduced crude bacterial extract, L 
= IPTG induced crude bacterial load to the glutathione-agarose column, FT = 
flow-through from the glutathione-agarose column, Wl, W2 = first (Wl) and 
second (W2) glutathione-agarose column washes with PBS, 0.5M NaCl, 2mM 
EOTA, lmM PMSF, 2mMbenzamidine, E = lOmM glutathione, 0.5M NaCl, 
50mM Tris/HCl pH8.0 eluate from the glutathione-agarose column, F = FPLC 
Mono-Q column pooled peak fractions In PBS/0.5M NaCl. For lanes L, FT, Wl, 
W2 and E the IkB a c-tag proteins were fused to glutathione-S-transferase (GST) 
to give a combined molecular weight of approximately 63 kDa. For lane F the 
IKBa c-tag proteins had been cleaved by thrombin to yield the final protein at a 
molecular weight of 37 kDa.
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Figure 16. Glutathione-agarose and FPLC column purifications of the 
linker mutant IkB(x c-tag proteins.
Coomassie blue stained 10% SDS polyacrylamide gels of glutathione- 
agarose and FPLC column purifications are shown above and overleaf for the 
linker mutant IKBa c-tag proteins-W258y (using the Triton-XIOO and sarkosyl 
method-TX+S), E275q (using method TX+S) and E275s (using method TX+S) 
either as GST fusions (GST-IxBa c-tag) or without GST (IKBa c-tag).All sample 
tracks contained a mix of 15pl of protein solution and 7.5|iI of 3x disruption 
buffer which had been boiled for 2-3 minutes before loading. The following 
abbreviations were used for the sample tracks shown :- M = protein molecular 
weight standards (units=kDa), U = uninduced crude bacterial extract, L = IPTG 
induced crude bacterial load to the glutathione-agarose column, FT = 
flow-through from the glutathione-agarose column, Wl, W2 or W = first (Wl) 
and second (W2) glutathione-agarose column washes with PBS, 0.5M NaCl, 
2mM EDTA, ImM PMSF, 2mM benzamidine, E = lOmM glutathione, 0.5M 
NaCl, 50mM Tris/HCl pH8.0 eluate from the glutathione-agarose column, F = 
FPLC Mono-Q column pooled peak fractions in PBS/0.5M NaCl. For lanes L, 
FT, W1,W 2,W and E the IKBa c-tag proteins were fused to 
glutathione-S-transferase (GST) to give a combined molecular weight of 
approximately 63 kDa. For lane F the I^!^<a c-tag proteins had been cleaved by 
thrombin to yield the final protein at a molecular weight of 37 kDa.
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sample of the fusion protein using a range of time intervals. This determined the minimum 
incubation time before cleavage at the internal thrombin site became too advanced.
Figures 12 and 18 show the UV absorbance output trace obtained for the FPLC 
column purification of each of the iKBa c-tag proteins. The initial GST flow-through was 
observed to the far left of each trace. In general, the IKBa c-tag proteins eluted between 
0.40M and 0.55M sodium chloride. The peak fractions were analysed using SDS-PAGE. The 
most concentrated fractions were combined and stored at -20OC.
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kFigure 17. FPLC Mono-Q column purification of wild-type and 
C-terminal IKBa c-tag proteins.
The UV absorbance output traces at 280nm are shown (solid lines) 
above and on the following two pages for the elution of the wild-type and 
C-terminal mutant IkB a c-tag proteins (EDE284-286qnq, EDE284-286sss, 
EDE300-302qnq and EDE300-302sss) from the FPLC Mono-Q column using a 
salt gradient ranging from 250mM NaCl to ImM NaCl (dashed lines). The 
position of the fractions collected from the salt gradient are indicated along the 
base of the trace. Glutathione-S-Transferase appeared in the initial column 
flow-through (to left of iKBac-tag peak) before the salt gradient was applied to 
the FPLC Mono-Q column.
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Figure 18. FPLC Mono-Q column purification of the linker mutant 
iKBa c-tag proteins.
The UV absorbance output traces at 280nm are shown above and on 
the following page (solid lines) for the elution of linker mutant iKBac-tag 
proteins (W258y, E275q and E275s) from the FPLC Mono-Q column using a 
salt gradient ranging from 250mM NaCl to ImM NaCl (dashed lines). The 
position of the fractions collected from the salt gradient are indicated along the 
base of the trace. Glutathione-S-Transferase appeared in the initial column 
flow-through (to left of IKBac-tag peak) before the salt gradient was applied to 
the FPLC Mono-Q column.
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CHAPTER 2. IN VITRO CHARACTERISATION OF iKBa C-TAG C-
TERMINAL AND LINKER MUTANTS.
As outlined in chapter 1, the IKBa c-tag mutants were constructed to primarily 
investigate the interaction between specific residues In the linker and C-terminal regions of 
IKBa and the p65 subunit of NF-kB and to also study their effect (if any) on p65 DNA 
binding activity. To examine these functions in vitro, the purified mutant and wild-type 
proteins were analysed by a combination of protein association experiments and DNA 
binding assays (these results are given in sections 2.1 and 2.2). It should be noted at this point 
that a comparison was made between the activities of wild-type IKBa and IKBa c-tag in both 
the protein association experiments and the DNA binding assays by M. Rodriguez, Institut 
Pasteur (unpublished data). The activities of both proteins were found to be the same 
indicating that the C-terminally fused tag epitope did not affect the function of IKBa.
The residues mutated in the C-terminal region (residues 284-286 and 300-302) of 
IkBcx were also of interest because they were located within two separate consensus 
phosphorylation sites for the serine/threonine protein kinase, casein kinase II (casein kinase 
II (CKII) consensus sequence; S/T-X-X-E/D, where S or T is the phosphoacceptor). 
Comparison of the C-terminal amino acid sequence of human I kB a (MAD-3) with the 
equivalent acidic regions in the avian (pp40), porcine (ECI-6) and rat (RL/IF-1) homologues 
of I kB a (figure 9) revealed that the two consensus CKII phosphorylation sites were 
completely conserved (corresponding to MAD-3 residues 283-286; SEDE and residues 299­
302; TEDE) among human, porcine and rat IKBa homologues (MAD-3, ECI-6, RL/IF-1). 
Further examination of the C-terminus of human IKBa revealed an additional CKII site from
residues 291-294 (TESE), the first three residues of which were conserved between the 
human, porcine and rat I kB a homologues. Moreover, a phosphorylation site for the 
functionally related protein kinase, casein kinase I (CKI) (S(P)-X-X-S/T, where S or T is the 
phosphoacceptor) was identified at position 288-291 (SYDT) in human IKBa and was also 
found to be conserved between the rat and porcine IKBa homologues. Figures 9 and 19 
shows another CKI site from residues 293-295 (SEFT) in human IKBa although this does not 
appear to be conserved between any of the other IkB family members. IKBa also contains an
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N-terminal consensus site for tyrosine phosphorylation and a phosphotidylinositol-3-kinase
binding site (residues 39-47: DEEYEQMVK). A protein kinase C phosphorylation site also 
exists in the sixth ankyrin repeat region (residues 260-264: EPSTE).
276 317
Figure 19. Amino acid sequence of the IkB a C-terminus (amino acids 
276-317) and its consensus casein kinase I and casein kinase 11 
phosphorylation sites.
The amino acid sequence for the C-terminus of wild-type IKBa is shown and the 
consensus phosphorylation sites for casein kinase I (S(P)-X-X-S/T, where S or T is the 
phosphoacceptor) and casein kinase II (S/T-X-X-E/D, where S or T is the phosphoacceptor). 
Casein kinase I sites are boxed with a solid line and casein kinase II sites are boxed with a 
dashed line.
Since phosphorylation is important for the in vivo function of iKBa (see section 2.3 
for more details) the consensus phosphorylation sites for the various kinases discussed above 
may play a central role in iKBa activity in vivo. Section 2.3 examines the affect of the C- 
terminal mutations (which alter the CKII consensus sequences), on the ability of iKBa to be 
phosphorylated in vitro by CKII. The relevance of the findings in terms of the in vivo 
function of iKBa is discussed.
2.1. Ability of wild-type and mutant IxBa c-tag purified proteins to 
associate with NF-kB p65 homodimers at A) a range of NaCl 
concentrations and B) a range of pH values.
The type of interaction expected between the negatively charged C-terminal residues 
(including glutamic acid 275 in the linker region) of iKBa and the nuclear localisation signal 
sequence of p65 was primarily ionic. Therefore, any differences in the affinity of mutant and 
wild-type iKBa c-tag for p65 may be detected by altering the ionic stength or pH of the 
solution containing these proteins.
Initial protein association studies were carried out in the presence of a range of 
sodium chloride concentrations by incubating mutant or wild-type iKBa c-tag proteins with 
either GST or GST-p65 proteins bound to glutathione-agarose. Following extensive washing
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to remove any unbound proteins, the remaining associated proteins were separated by SDS- 
PAGE and visualised by Western blotting using either anti-Pk (to detect IKBa c-tag) or 
polyclonal anti-p65 (to detect p65) (Figures 20 and 21). Figure 20 shows that all of the wild- 
type and mutant IKBa c-tag proteins were able to bind to GST-p65 with similar affinities 
even at different salt concentrations. However, it appeared that the salt concentration affected 
the ability of the wild-type and mutant IKBa c-tag proteins to bind to p65: Maximum binding 
was observed at 60-120mM NaCl; at 480mM NaCl binding was reduced and at 960mM NaCl 
binding was almost undetectable. The proteins did not bind GST alone (data not shown) 
which indicated that the GST-p65/lKBa c-tag interaction was achieved through p65 rather 
than GST. Figure 21 illustrates that p65 remained present throughout the range of salt 
concentrations used and therefore the loss of iKBa c-tag binding after 120mM NaCl was not 
due to the dissociation of GST-p65 from the glutathione-agarose beads.
Protein association assays were also performed on purified wild-type or mutant iKBa 
c-tag proteins incubated with either GST or GST-p65 bound to glutathione-agarose using a 
range of pH’s at a constant salt concentration of 60mM. As previously described this was 
followed by extensive washing to remove any unbound proteins and the remaining associated 
proteins were separated by SDS-PAGE and visualised by Western blotting using either anti- 
Pk (to detect iKBa c-tag) or polyclonal anti-p65 (to detect p65) (Figures 22 and 23). It was 
observed that changing the pH from 5.5-9.0 did not affect the ability of either wild-type or 
mutant proteins to interact with p65. In addition, there was no obvious difference in the 
binding affinities for p65 between the mutant and wild-type proteins over the range of pHs 
used. Furthermore, the GST-p65/lKBa c-tag interaction was attainable only through p65 and 
not GST because the proteins were not able to bind GST alone (data not shown). Figure 23 
shows that GST-p65 remained bound to the glutathione agarose beads over the entire range 
of pHs used.
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Figure 20. Protein association assays illustrating the ability of 
wild-type and mutant IkBoc c-tag purified proteins to associate with 
NF-kB p65 homodimers at different NaCl concentrations.
Wild-type IkBoc c-tag proteins purified using either the Triton-XlOO 
(TX) or the Triton-X100/Sarkosyl(TX+S) method and the C-terminal and linker 
mutant IkBcx c-tag proteins were incubated with either GST (data not shown) or 
GST-p65 proteins immobilized on glutathione-agarose in the presence of 
60mM, 120mM, 240mM, 480mM or 960mMNaCl. The proteins were separated 
through a 10% SDS polyacrylamide gel and analysed by Western blotting with 
anti-Pk (shown above and on the next page). The position of the protein 
molecular weight standards are indicated (units=kDa). The position of the IkBoc 
c-tag proteins are also given (around 37kDa). The concentration of salt which 
was used for each assay is shown at the top of each western blot
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Figure 21. Protein association assays illustrating the presence of 
NF-kB p65 homodimers at different NaCl concentrations when 
incubated with wild-type and mutant IkB a c-tag purified proteins.
Wild-type iKBa c-tag proteins purified using either the Triton-XlOO 
(TX) or the Triton-X100/Sarkosyl(TX+S) method and the C-terminal and linker 
mutant IkB (a c-tag proteins were Incubated with either GST (data not shown) or 
GST-p65 proteins Immobilized on glutathione-agarose in the presence of 
60mM, 120mM, 240mM, 480mM or 960mMNaCl. The proteins were separated 
through a 10% SDS polyacrylamide gel and analysed by Western blotting with 
polyclonal anti-p65 (shown above and on the next page). The position of the 
protein molecular weight standards are indicated (units=kDa). The position of 
the p65 protein Is indicated (around 65kDa). The concentration of salt which 
was used for each assay is shown at the top of each Western blot
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Figure 22. Protein association assays Illustrating the ability of 
wild-type and mutant IkBcx c-tag purified proteins to associate with 
NF-kB p65 homodimers at different pH values.
Wild-type I kB a c-tag protein purified using either the Triton-XlOO 
(TX) or the Triton-X 100/S arkosyl(TX+S ) method and the C-terminal and linker 
mutant IkB a c-tag proteins were bound to either GST (data not shown) or 
GST-p65 proteins immobilized on glutathione-agarose in the presence of 60mM 
NaCl and pH5.5, pH6.0, pH6.5 (using the buffer, MES (free acid)), pH6.5, 
pH7.0, pH7.5, pH8.0, pH8.5 or pH9.0 (using the buffer, Bis/Tris/propane 
(TBP)). The proteins were separated through a 10% SDS polyacrylamide gel and 
analysed by Western blotting with anti-Pk and are shown on above and on the 
following 4 pages. The position of the protein molecular weight standards are 
indicated (units=kDa). The position of the IkB a c-tag proteins (around 37kDa) 
are also given. The pH used for each assay is shown at the top of each Western 
blot.
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Figure 23. Protein association assays illustrating the presence of 
NF-kB p65 homodimers at different pH values when incubated with 
wild-type and mutant IKBa c-tag purified proteins .
Wild-type I kB a c-tag protein purified using either the Triton-XlOO 
(TX) or the Triton-X100/Sarkosyl(TX+S) method and the C-terminal and linker 
mutant IkB a c-tag proteins were bound to either GST (data not shown) or 
GST-p65 proteins immobilized on glutathione-agarose in the presence of 60mM 
NaCl and pH5.5, pH6.0, pH6.5 (using the buffer, MES (free acid)), pH6.5, 
pH7.0, pH7.5, pH8.O, pH8.5 or pH9.0 (using the buffer, Bis/Tris/propane 
(BTP)). The proteins were separated through a 10% SDS polyacrylamide gel and 
analysed by Western blotting with polyclonal anti-p65 and are shown on the 
following 4 pages. The position of the protein molecular weight standards are 
indicated (units=kDa). The position of the p65 protein is also given (around 
65kDa). The pH used for each assay is shown at the top of each Western blot.
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2.2. Abiilty of wiid-type and mutant IkBoc c-tag purifed pirro^t^i^ns to inhibit 
the DNA binding activity of NF-kB p65 homodimers.
In order for iKBa to inhibit the DNA binding activity of p65 homodimers, iKBa must 
make physical contact with p65. It is unclear whether the ability of I KBa to Inhibit p65 DNA 
binding activity and bind p65 are separable activities. It is possible that different regions of 
IkBa are responsible for each function. For example, I KBa can associate with p50, retaining 
it in the cytoplasm but fails to inhibit p50 DNA binding (Beg et al.,1992\ Ganchi et al., 
1992).
The purified wild-type and mutant I KBa c-tag proteins were analysed for their ability 
to inhibit the DNA binding activity of the p65 subunit of NF-kB by performing a gel 
electrophoresis DNA binding assay on equal amounts of recombinant p65 (aal2-317) 
incubated with a range of I KBa c-tag protein concentrations in the presence of a 32p labelled 
double-stranded oligonucleotide which contained a recognition site for NF-kB (Figure 24 
A)). In the absence of wild-type or mutant I KBa c-tag, p65 formed a stable complex with its 
DNA binding site (p65 only lane in figure 24 A)).Wild-type I KBa c-tag proteins purified by 
either the tritonX-100 method (TX) or the tritonX-100 and sarkosyl method (TX+S) were 
shown to vary in their ability to inhibit the DNA binding activity of p65 homodimers: Wild- 
type I kBa c-tag purified by the tritonX-100 and sarkosyl method was a more efficient 
inhibitor of p65 DNA binding than the tritonX-100 purified protein. The C-terminal mutants, 
EDE284-286qnq and EDE284-286sss, exhibited a reduction in their ability to inhibit the 
DNA binding of p65 homodimers compared to the wild-type protein whereas the remainder 
of the C-terminal and linker mutants exhibited wild-type inhibitory characteristics.
The information from the DNA binding assays was represented graphically by 
quantitating the amounts of ^2p radioactivity in each of the DNA-proteIn 
(oligonucleotide+p65) complexes using liquid scintillation counting of dried gel slices and 
expressing the values as a fraction of the total radioactivity within the p65 only control 
(given an arbitrary value of 1.00) for each set of gel shifts. This data was compared to the 
amount (fmoles) of wild-type or mutant IkBa c-tag protein used in each binding reaction and 
the information was plotted on a graph (figure 24 B)). Wild-type IkBa c-tag protein purified
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Figure 24.
A) Gel electrophoresis DNA binding assays illustrating the ability of 
wild-type and mutant IxBa c-tag purified, proteins to inhibit the DNA 
binding activity of NF-KB p65 homodimers.
For each binding reaction 20 fmoles of recombinant p65 (amino acids 
12-317) were incubated for 15 minutes (at RT) with 0-200 fmoles of the following 
IkB a c-tag proteins in the presence of binding buffer which contained32 5nM P 
labelled double-stranded oligonucleotide (5'-CTGGGGACTTTCCAGG-3'):- 
wild-type IKBa c-tag proteins purified using either the Triton-XlOO (TX) or the 
Triton-X 100/Sarkosy1(TX+S) method (shown opposite) and the C-terminal and 
linker mutant IKBa c-tag proteins (shown on the following two pages). The 
DNA-protein complexes were resolved on native 6% polyacrylamide gels and 
visualised by autoradiography of the dried gels. The protein-bound and free 
radiolabelled oligonucleotide bands are indicated by B and F respectively.
B) Graphical representation of the ability of wild-type and mutant 
IkB a c-tag purified proteins to inhibit the DNA binding activity of 
NF-KB p65 homodimers.
Liquid scintillation counting of dried gel slices was used to determine 
the amount of 32P radioactivity in each of the DNA-protein complexes 
(oligonucleotide+p65) shown in figure 24 A). The values were expressed as a 
fraction of the total radioactivity present in the p65 only control (which was given 
an arbitrary value of 1.00) and plotted on a graph against the number of fmoles of 
wild-type or mutant IKBa c-tag protein used in each binding reaction (opposite 
and on the next two pages).
A)
p65 (20 fmoles) + 
IKBa proteins (fmoles)
Wild-type.TX. c-tag Wild-type.TX+S. c-tag
B
ar
>
Z
*
u, k» r* m p5
6.25
B)
Wild-type.TX.
Wild-type.TX+S
A)
p65 (20 fmoles) + 
IkBq c-tag proteins (fmoles)
Wild-type.TX+S. EDE284-286qnq
gsSKg ggSKg
uUUU uwMttu
p65 (20 fmoles) + 
IxBa c-tag proteins (fmoles)
Wild-typeTX. EDE300-302mb EDE300-302qnq
& I I 8 U 8 «E
R
B)
c.
p.
m
. a
s f
ra
ct
io
n o
f t
ot
al
 c.
p.
m
. fo
r p
65 Wi
Wild-type.TX+S.
EDE284-286qnq
Wild-type.TX.
EDE300-302qnq
EDE284-286sss EDE300-302sss
A)
p65 (20 fmoles) + 
iKBa c-tag proteins (fmoles)
Wlld-type.TX+S.
z
z
W258y
b
o\ ©
B
p65 (20 fmoles) + 
IkBcx c-tag proteins (fmoles)
Wild-type.TX+S. E275q E275s
BLA
N
K
M r*. P' ®© © m p° (A Ul g $ K b° Km « g S ’
-w
B)
c.
p.
m
. a
s f
ra
ct
io
n o
f t
ot
al
 c.
p.
m
. fo
r p
65
fmoles IkBcx c-tag
—<----- Wild-type.TX+S.
—B-----  E275q
>r»
&
Wild-type.TX+S.
W258y
E275S
using the tritonX-100 and sarkosyl method was able to almost completely inhibit the DNA 
binding activity of p65 homodimers at 50 fmoles, only 1.5 times the number of moles of p65 
(20 fmoles) used for the binding reaction. However, approximately twice the number of 
moles, 100 fmoles,' of the wild-type iKBa c-tag protein purified using the tritonX-100 
method were required to achieve similar inhibition of p65 homodimers (figure 24 B)). For 
the C-terminal mutants, EDE284-286qnq and EDE284-286sss, complete inhibition of p65 
DNA binding activity was only being approached at 200 fmoles of protein - the wild-type 
protein had achieved a similar level of inhibition at only 12.5 fmoles i.e. the mutants 
exhibited an approximate 16-fold reduction in their ability to inhibit p65 DNA binding 
activity compared to the wild-type protein. The remainder of the C-terminal and linker 
mutants were shown to have similar p65 DNA inhibition curves to the wild-type protein.
2.3. The capacity of wild-type and mutant IxBa c-tag purified proteins to 
be phosphorylated by recombinant casein kinase I and II.
The phosphorylation of IkB a is extremely important for its in vivo activity. In resting 
cells phosphorylated iKBa is associated with NF-kB in the cytoplasm. Upon activation of 
cells with cytokines or mitogens, IxBa is further phosphorylated prior to proteasome- 
mediated iKBa degradation and NF-kB translocation (iKBa degradation will be discussed 
further in chapter 3)(Britta-Mareen Traeckhner et al., 1994; Didinato et al., 1995; Roff et al.,
. The in vitro phosphorylation of iKBa by kinases including protein kinase C (PKC), 
protein kinase A (PKA) (Ghosh et al., 1990; Shirakawa at al., 1989), heme regulated eIF2a 
kinase (Ghosh et al., 1990), p38 (Han et al., 1994), Raf-1 (Li et al., 1993) and a PKC-£- 
associated kinase (Diaz-Meco et al., 1994) has already been shown. As discussed at the 
beginining of chapter 2, the residues which were mutated in the C-terminal region of iKBa 
were located within consensus phosphorylation sites for the serine/threonine protein kinase, 
CKII. Therefore, if it was possible to show a failure or reduction in the ability of the C- 
terminal IkB a mutants to be phosphorylated in vitro by CKII compared to the wild-type 
protein, then this may indicate the importance of CKII and the mutated residues in the in vivo
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phosphorylation of IkBa. In addition, assaying for the phosphorylation of the wild-type 
IkBcx by CKI may signify a role for this enzyme in the in vivo phosphorylation of iKBa.
In vitro casein kinase assays were performed on mutant and wild-type iKBa c-tag 
purified proteins and the control proteins, bovine serum albumin (BSA) and purified casein 
kinase using purified recombinant casein kinase I and II. The extent of phosphorylation was 
followed by including radioactively labelled ATP (y(32p)ATP) in the reaction mixture. The 
radioactive phosphate group of ATP would be incorporated into the protein if 
phosphorylation was successful. Full details of the reaction mixtures and reaction conditions 
are given in the Materials and Methods section.
Figure 25 shows an autoradiograph of the CKI reaction mixtures separated through a 
10% polyacrylamide gel. All of the mutant and wild-type iKBa c-tag proteins were 
phosphorylated by CKI. The extent of phosphorylation observed between the wild-type and 
mutant proteins appeared to be approximately equal. This was expected since none of the 
mutant proteins contained amino acid changes within any of the consensus CKI motifs. The 
activity of CKI was confirmed by the successful phosphorylation of casein kinase, a known 
substrate for CKI. Casein kinase is composed of four subunits, al, a2, p and k, ranging from 
19-25kDa. The major subunit, a2 at 25kDa can be clearly seen in figure 25 and the minor 
subunits can be faintly observed below a2. The specificity of CKI activity and the absence of 
contaminating kinase activities were verified by the failure of BSA to be phosphorylated, a 
protein not normally targeted by CKI.
The corresponding autoradiograph obtained from the separation of the CKII reaction 
mixtures through a 10% polyacrylamide gel is given in Figure 26. The linker mutants 
appeared to be phosphorylated by CKII to the same extent as the wild-type iKBa c-tag 
protein. This was predicted since the altered residues in the linker mutants were not located 
within CKII phosphorylation sites. However, in contrast the phosphorylation of the C- 
terminal mutants was reduced to approximately 10-15% of the phosphorylation observed for 
the wild-type iKBa c-tag protein. Interestingly EDE284-286sss was phosphorylated to a 
greater extent (approximately 50% less phosphorylation than the wild-type IKBa c-tag 
protein) than the other C-terminal mutants. It is possible that the conformation of the mutant
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Figure 25. Phosphorylation of wild-type and mutant IkBcx c-tag 
proteins by casein kinase I using y(32p) ATP.
0.22pmoles of either BSA, casein kinase, wild-type IKBa c-tag or 
mutant IidBa c-tag were Incubated at 30 0C for 1 hour in the presence of casein 
kinase I and y(32 P) ATP. The reactions were quenched with 5ill of disruption 
buffer, boiled for 2-3 minutes and then separated through a 10% polyacrylamide 
gel. The gel was dried and exposed to X-ray film overnight at -70 °C. The 
position of the molecular weight markers are indicated to the left of the figure. 
Phosphorylated casein kinase and Ii^lBca c-tag proteins are indicated by arrows. 
The IKBa c-tag mutant proteins are named at the top of the figure together with 
BSA, casein kinase and the wild-type IxBa c-tag protein (incubated with casein 
kinase I (4-) and without casein kinase I (-)). The lane marked X should be 
ignored.
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Figure 26. Phosphorylation of wild-type and mutant IkB(x c-tag 
proteins by casein kinase II using y(32 P) ATP.
0.22pmoles of either BSA, casein kinase, wild-type IkBa c-tag or 
mutant IKBa c-tag were incubated at 30°C for 1 hour in the presence of casein 
kinase II and y(32 P) ATP. The reactions were quenched with 5|il of disruption 
buffer, boiled for 2-3 minutes and then separated through a 10% polyacrylamide 
gel. The gel was dried and exposed to X-ray film overnight at -70 °C. The 
position of the molecular weight markers are indicated to the left of the figure. 
Phosphorylated casein kinase and I kB a c-tag proteins are indicated by arrows. 
The IKBa c-tag mutant proteins are named at the top of the figure together with 
BSA, casein kinase and the wild-type I kB a c-tag protein (incubated with casein 
kinase II (+) and without casein kinase II (-)). The lane marked X should be 
ignored.
protein exposed other casein kinase II phosphorylation sites in the C-terminal region, 
allowing more efficient phosphorylation by CKII. Presumably the C-terminal mutants which 
possessed amino acid changes in CKII consensus sites were now able to prevent the enzyme 
recognising these sequences as targets for phosphorylation. However, phosphorylation was 
not completely blocked and this was probably due to phosphorylation at CKII sites other than 
those changed in the C-terminal mutants. Control proteins identical to those used for CKI 
were included in the CKII assays. Both the activity and specificity of CKII were confirmed 
by the phosphorylation of casein Kinase and lack of such modification for BSA.
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CHAPTER 3. IN VIVO CHARACTERISATION OF IicB<x C-TAG C-
TERMINAL AND LINKER MUTANTS.
Following the in vitro characterisation of the mutant iKBa c-tag proteins it was
decided to study some of their functional properties in vivo. The C-terminal mutants were of 
particular interest because they possessed amino acid changes within a region rich in proline, 
glutamic acid, serine and threonine (PEST) residues, which have been associated with rapid 
protein turnover (Rogers etal, 1986). More detail concerning the C-terminal region and its 
role in iKBa degradation will be given under the sub-headings which follow. The studies 
were performed by transient transfection of either 293 or Cos7 cells with the mammalian 
expression vector pcDNA3Pk (containing the appropriate wild-type or mutant DNA) which 
was engineered to generate C-terminally tagged proteins. The C-terminal Pk-tag linker 
(obtained by annealing together two oligonucleotides corresponding to the positive and 
negative strands of Pk-tag) was cloned into pcDNA3 via EcoRI and Notl restriction sites and 
sequenced (figure 27).
Also included in this chapter is a section of work which was performed in 
collaboration with colleagues from the Pasteur Institute, France. These studies involved the 
identification of lysine residues in the N-terminus of iKBa required for signal-induced 
ubiquitination and degradation of the protein in vivo. More details will be given under the 
appropriate sub-heading (3.6).
3.1. Assessment of signal-induced degradation of wild-type and mutant 
IkB<x c-tag proteins.
When cells are exposed to tumour necrosis factor (TNF), iKBa is rapidly degraded. 
However, deletion of the C-terminal region of IkB a has been shown to stabilise the protein 
(Rodriguez et al, 1995) under conditions of activation. Since the C-terminal and linker IKBa 
c-tag mutants possessed amino acid changes within this region it was decided that these 
mutants would be tested for their ability to be degraded following activation with TNF a.
Before proceeding with the degradation assays the amounts of expression vectors 
were standardised such that equivalent quantities of wild-type and mutant IKBa c-tag protein
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Figure 27. Sequence confirmation of the Pk-tag region cloned into the 
pcDNA3 plasmid.
The dideoxy chain-termination procedure was used to yield the coding 
DNA strands shown above for the Pk-tag region and part of the pcDNA3 plasmid 
(the area of DNA immediately below Pk-tag). The coding DNA sequences are 
read from bottom to top (5' to 3' on the coding DNA) and the lane location of 
each DNA base is shown at the top of the gel (A= adenine, C= cytosine, G= 
guanine and T= thymine). The position and sequence of the first codon of Pk tag 
is boxed (which is translated into glycine) and the final stop codon.
were generated. Therefore, any differences in the signal induced degradation patterns of the 
various IxBa c-tag proteins would not be related to variations in the amounts of protein 
generated from each vector. 293 cells were transfected with wild-type or mutant Ik Ba 
pcDNA3cPk and 36 hours later cytoplasmic extracts were prepared from the cells. The 
extracts were analysed by Western blotting using anti-Pk. The protein bands corresponding 
to wild-type and mutant IkB a c-tag were compared, and the amount of expression vector 
which produced comparable protein amounts was chosen (data not shown) and used for the 
degradation assays.
The degradation assays were performed on 293 cells 36 hours after transfection with 
wild-type or mutant Ik Ba pcDNA3cPk. The cells were pretreated for 5 minutes with the 
protein synthesis inhibitor, cycloheximide (to prevent continued IKBa c-tag protein synthesis 
from the strong cytomegalovirus promoter which would have prevented visualisation of 
IxBa c-tag degradation) followed by activation for 15 or 45 minutes with TNF a. The extent 
of signal-induced degradation was determined by Western blot analysis of cytoplasmic 
proteins using A) anti-Pk or B) a monoclonal anti-lKBa antibody, lOB MAD3.
Figure 28 A) shows the proteolytic degradation patterns observed with the anti-Pk 
antibody which revealed that the linker mutants behaved like the wild-type transfected IKBa 
c-tag, reaching almost complete degradation after 45 minutes. Interestingly however, the C- 
terminal mutants appeared to be only partially degraded after 45 minutes treatment with 
TNFa. However, since the basal turnover of these proteins was not examined (by incubating 
each set of mutant or wild-type transfected 293 cells for 0-45 minutes with cycloheximide 
alone) it cannot be concluded that this partial degradation is due solely to a reduction in 
inducible degradation, it may indicate that the C-terminal mutants have a lower level of basal 
turnover compared to the wild-type protein (see discussion for further details). The anti-Pk 
antibody did not show the presence of protein in the untransfected extracts which indicated 
that the antibody did not cross-react with any of the cellular proteins.
Analysis of the same set of cytoplasmic extracts using the lOB MAD3 monoclonal 
antibody exposed both the ectopic, tagged and the endogenous TiclBca proteins (figure 28 B)) 
in the transfected extracts and endogenous (cellular) IKBa protein only in the untransfected
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Figure 28. TNFa-induced degradation assays performed on 293 cells 
transfected with DNA encoding wild-type and mutant IidBa c-tag 
proteins.
293 cells were transfected with DNA (pcDNA3Pk) encoding either 
wild-type or C-terminal and linker mutant iKBa c-tag. At 36 hours 
post-transfection the cells were pretreated for 5 minutes with 100|ig/ml 
cycloheximide and either left unactivated or activated with 50ng/ml TNFa for 
15 minutes or 45 minutes. Cytoplasmic extracts were prepared and 20ftg of 
each (in disruption buffer) were separated through a 10% SDS polyacrylamide 
gel and the proteins were detected by Western blot analysis using either A) 
anti-Pk (shown above) or B) a monoclonal anti-KBa antibody, MAD 1OB 
(shown on the next page) followed by E.C.L. The position of the protein 
molecular weight standards are shown to the left of each figure (units=kDa) and 
arrows indicate the position of ectopic IxBa c-tag protein and phosphorylated 
and unphosphorylated endogenous IxBa protein. Untransfected 293 
cytoplasmic cell extracts were included as a control. The time in minutes after 
treatment of cells with TNFa is given at the top of each Western blot in 
addition to the name of each mutant
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extracts. The ectopic protein appeared as a slower migrating band on the Western blot as a 
result of the C-terminally fused epitope, tag of 14 amino acids. As observed with the anti-Pk 
antibody, lOB MAD3 showed that the degradation of wild-type and linker mutant I KBa c-tag 
proteins was reached after 45 minutes treatment with TNFa, whereas the C-terminal mutants 
were only partially degraded after this period of time. It was also evident that the endogenous 
IKBa protein was degraded more rapidly than the wild-type and linker mutant ectopic, tagged 
IxBa proteins; After only 15 minutes the endogenous protein was almost completely 
degraded compared to 45 minutes for the wild-type and linker mutant ectopic, tagged I KBa 
protein (see discussion for further details).
3.2. Assessment of signal-induced phosphorylation of wild-type and mutant 
IkBoc c-tag proteins.
Since hyperphosphorylation of IKBa is a pre-requisite to its signal-induced 
degradation (Traenckner et aL, 1994; Roff et al., 1995) it was possible that the increased 
resistance to proteolysis observed for the C-terminal mutant IKBa proteins was a result of 
incomplete hyperphosphorylation. The ability of the C-terminal mutants along with the linker 
mutants to be inducibly phosphorylated was therefore examined.
293 cells were transfected with wild-type or mutant I KBa pcDNA3cPk (C-terminal 
and linker mutants and an I KBa c-tag mutant known to be resistant to proteolysis and 
possessing serine to alanine changes at positions 32 and 36) and 36 hours later the cells were 
pretreated for 15 minutes with a proteasome inhibitor, the peptide aldehyde z-LLL-H, to 
prevent IKBa degradation and stabilise phosphorylated forms of the protein. This was 
followed by 45 minutes or with OKA for 45 minutes followed by TNFa for 15 minutes or no 
indu. The proteins were visualised by Western blotting using the anti-Pk antibody (figure 
29). Only the results for the co-stimulation by OKA and TNFa of transfected cells are 
shown. When unstimulated extracts were compared to stimulated extracts it was clear that the 
stimulated extracts of the wild-type I KBa c-tag protein exhibited an additional slower 
migrating band which corresponded to the hyperphosphorylated form of the protein. This 
slower migrating hyperphoiphorylaied I KBa c-tag species was also observed (somewhat less
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Figure 29. TNFa-induced phosphorylation assays performed on 293 
cells transfected with DNA encoding wild-type and mutant IkBcc 
c-tag proteins.
293 cells were transfected with DNA (pcDNA3Pk) encoding wild-type, 
C-terminal or linker mutant IkBcc c-tag. At 36 hours post-transfection the cells 
were pretreated with 25pM of the proteasome inhibitor z-LLL-H for 15 
minutes (this was maintained until the end of the culture). The cells were then 
either induced with 250nM okadaic acid for 45 minutes followed by TNFa 
for 15 minutes (indicated by + at the top of the Western blot) or not induced at 
all (indicated by - at the top of the Western blot). Cytoplasmic cell extracts 
were prepared in the presence of phosphatase inhibitors. For each sample 
30pg of total protein was separated through a 16.5% polyacrylamide/ 9.4% 
glycerol gel in a buffer gradient and detected by Western blot analysis using 
anti-Pk followed by E.C.L. (shown above). Arrows indicate the position of the 
IkB a c-tag protein and the inducibly phosphorylated form of IkB a c-tag 
(iKBa-P c-tag). The position of the protein molecular weight standards 
(units=kDa) are given to the left of the figure. Untransfected 293 cytoplasmic 
extracts are included as a control. Mutants are named at the top of the figure.
clearly) for the stimulated extracts of the linker mutants (E275q, E275s and W258y) and the 
C-terminal mutants EDE284-286qnq and EDE284-286sss. However, a hyperphosphorylated 
form of IKBa c-tag was not observed in the stimulated extracts of mutants EDE300-302qnq 
and EDE300-302sss. These results indicated that the increased resistance to proteolysis 
exhibited by the C-terminal mutant I KBa c-tag proteins, EDE284-286qnq and EDE284- 
286sss did not result from a loss of the proteins ability to be hyperphosphorylated in response 
to cell signalling. However, mutants EDE300-302qnq and EDE300-302sss appeared not to 
be inducibly phosphorylated and it was therefore possible that the increased resistance to 
proteolysis exhibited by these mutants was due to an inability to be inducibly 
phosphorylated. It should be noted that the apparent lack of hyperphosphorylation observed 
for these C-terminal mutants and the poor shift in mobility exhibited by the other mutants 
may be due to the nature of the amino acids which were changed in each of the mutants i.e 
the substitution of charged residues for their uncharged equivalents. In theory, this should not 
affect the mobility of the mutant proteins because they are analysed by SDS-PAGE and 
therefore the SDS should render the proteins native charge insignificant. However, it is 
possible that the substitutions have, in some way, altered the mobility of the mutants so that 
inducible phosphorylation cannot be detected on the gradient gel.
3.3. Analysis of the ubiquiiiimtion patterns of wiid-type and mutant IkBcx 
c-tag proteins.
Proteolytic degradation of I kB a in stimulated cells has been shown to involve 
ubiquitination of two key residues, lysines 21 and 22, located in the N-terminal region of the 
protein (Rodriguez et al., 1996-see section 3.6). It has been proposed that following signal- 
induced phosphorylation of IKBa on serine residues 32 and 36 (Brown et al., 1995; 
Brockman etal, 1995; Traenckner etal, 1995), lysines 21 and 22 are ubiquitinated marking 
the protein for degradation by the proteasome. Since the C-terminal I kB a c-tag mutants 
exhibited a partial resistance to signal-induced degradation which was not a result of
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incomplete inducible phosphorylation for EDE284-286qnq and EDE284-286sss, it was 
possible that their ability to be ubiquitinated was compromised.
This was tested by transfecting 293 cells with either wild-type or mutant/pcDNA3Pk 
and 36 hours later TNF activating the cells in the presence of z-LLL-H. Cytoplasmic extracts 
from the cells were analysed by Western blotting using the anti-Pk antibody and the proteins 
were visualised after treatment with E.C.L. reagents using a long exposure time. Figure 30 
illustrated the presence of ubiquitin-conjugated forms of all of the mutant IKBa c-tag 
proteins. The amount of ubiquitination was comparable to that observed for the wild-type 
protein. Thus, the incomplete signal-induced degradation of the C-terminal iKBa c-tag 
mutants could not be attributed to any reduction in the ability of these mutants to be 
ubiquitinated. The C-terminal mutants EDE300-302qnq and EDE300-302sss were also 
ubiquitinated despite their apparent failure to be inducibly phosphorylated. This appears to 
agree with the suggestion in section 3.2 that the analysis of the mutant proteins by SDS- 
PAGE was not sufficient to detect the hypeiphosphorylated forms of the proteins.
3.4. The affect of wild-type and mutant IKBa c-tag proteins on NF-KB- 
dependent transcription In response to TNFa.
It would be predicted from the results of the degradation assays that the C-terminal 
IicBca mutants (EDE284-286qnq, EDE284-286sss, EDE300-302qnq and EDE300-302sss) 
which were only partially degraded in response to TNFa should retain NF-kB in the 
cytoplasm of cells. This would prevent the nuclear translocation of NF-kB and subsequent 
activation of NF-KB-dependent genes.
To test this prediction a fixed amount of an NF-KB-dependent (3EnhConALuc) 
luciferase reporter vector was employed to be initially co-transfected with a range of wild- 
type lKBa/pcDNA3Pk concentrations into 293 or Cos 7 cells. Fourty hours later the cells 
were activated with TNFa for 8 hours and the relative luciferase units (RLU) per pg of 
protein was determined.
The results are illustrated in figures 31 and 32 and permit the amount of wild-type 
lKBa/pcDNA3Pk required to give a reasonable level of NF-KB-dependent transcription to be
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Figure 30. Analysis of the ubiquitination patterns obtained from 293 
cells transfected with DNA encoding wild-type and mutant IidBa 
c-tag proteins.
293 cells were transfected with DNA (pcDNA3Pk) encoding either 
wild-type or C-terminal and linker mutant IKBa c-tag . At 36 hours 
post-transfection the cells were pretreated with 25|iM of the proteasome 
inhibitor, zLLLH for 45 minutes and lOOpg/ml cycloheximide for 5 minutes, 
before activation with 50ng/ml TNFa for a further 45 minutes (indicated by 4 
at the top of each Western blot). Unactivated cells (indicated by - at the top of 
each Western blot) were treated with lOOpg/ml cycloheximide only. 
Cytoplasmic extracts were prepared in the presence of iodoacetamide and 20|ig 
of each (in disruption buffer) were separated through a 10% sDs 
polyacrylamide gel and the proteins were detected by Western blot analysis 
with anti-Pk followed by E.C.L. using a long exposure. The position of the 
protein molecular weight standards are shown to the left of each figure 
(units=kDa) and arrows indicate the position of ectopic IKBa c-tag protein and 
its ubiquitin aducts. The mutants are named at the top of each Western blot.
identified. It can be observed that TNFa induced Cos7 cells (figure 31) transfected with only 
the NF-KB-dependent luciferase reporter showed a 17-fold transactivation of the reporter 
vector. However, co-transfection with the highest quantity of wild-type lKBa/pcDNA3Pk 
(1 |ig) resulted in a complete inhibition of transcription from the luciferase reporter. 
Presumably transfecting cells with higher amounts of wild-type lKBa/pcDNA3Pk resulted in 
the expression of more ectopic wild-type IKBa c-tag. Consequently, under conditions of 
activation the cells degradation machinery would not be able to proteolyse all of the ectopic, 
tagged wild-type I KBa protein. This would lead to elevated levels of wild-type IKBa c-tag 
available to bind NF-kB and prevent NF-KB-dependent transcription from the reporter
vector.
However, as the amount of wild-type lKBa/pcDNA3Pk co-transfected into cells was 
reduced to around O.125jig the inhibitory effect on luciferase expression was diminished to 
give a 9-fold transactivation of the luciferase reporter. Further reductions in the amount of 
wild-type lKBa/pcDNA3Pk co-transfected into cells to 0.016|ig resulted in a 15-fold 
transactivation of the reporter, a transactivation similar to that obtained from cells transfected 
with 3EnhConALuc alone (a positive control included to check for expression from the 
luciferase reporter) i.e. following activation of cells with TNFa, the lower levels of ectopic, 
tagged wild-type IkB a protein were not sufficient to replace the degraded IkB a protein 
which allowed free NF-kB to activate luciferase expression. A luciferase reporter, ConAluc, 
lacking the critical enhancer region was also transfected into cells to act as a control for 
enhancer-dependent activation of luciferase expression through NF-kB recognition sites. As 
expected, expression from the ConAluc plasmid failed indicating the requirement for the 
enhancer region to achieve luciferase expression.
In contrast to Cos7 cells, TNFa stimulated 293 cells co-transfected with 
3EnhConAluc and high quantities of wild-type lKBa/pcDNA3Pk did not exhibit an 
inhibitory effect on NF-KB-dependent transactivation of the luciferase reporter (figure 32). 
Instead, a 16-fold transactivation of the reporter was observed (comparable to TNFa 
activated cells transfected with 3EnhConAluc alone), a level of transactivation which 
remained unchanged when cells were transfected with smaller quantities of the wild-type
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Figure 31. Luciferase assays performed on Cos 7 cells co-transfected 
with the NF-KB-dependent reporter vector 3EnhConALuc and DNA 
encoding wild-type IxBa c-tag.
Cos 7 cells were co-transfected with the reporter plasmid 3EnhConALuc 
and DNA encoding the wild-type pcDNA3Pk expression vector (indicated by 
WT along the x-axis with the corresponding quantity of DNA used in /ig). 
Two controls were included: the reporter plasmid, 3EnhConALuc transfected 
alone and the reporter plasmid, ConAluc (which lacked the NF-KB-dependent 
enhancer) also transfected alone. 40 hours post-transfection the cells were 
activated with lOng/ml TNFa for 8 hours (indicated by +) or left unactivated 
(indicated by -) and the luciferase activity was measured in the cell lysates. 
Luciferase activity is expressed as RLU/p,g of cell lysate protein. The level of 
luciferase expression in the TNFa activated cell extracts is expressed as a 
multiple of the corresponding unactivated cell extract (indicated above the + 
lane for each of the transfected plasmids).
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Figure 32. Luciferase assays performed on 293 cells co-transfected 
with the NF-KB-dependent reporter vector 3EnhConALuc and DNA 
encoding wild-type iKB<a c-tag.
293 cells were co-transfected with the reporter plasmid 3EnhConALuc 
and DNA encoding the wild-type pcDNA3Pk expression vector (indicated by 
WT along the x-axis with the corresponding quantity of DNA used in t)g). 
Two controls were included: the reporter plasmid, 3EnhConALuc transfected 
alone and the reporter plasmid, ConAluc (which lacked the NF-kB -dependent 
enhancer) also transfected alone. 40 hours post-transfection the cells were 
activated with lOng/ml TNFa for 8 hours (indicated by 4-) or left unactivated 
(indicated by -) and the luciferase activity was measured in the cell lysates. 
Luciferase activity is expressed as RLU/pg of cell lysate protein. The level of 
luciferase expression in the TNFa activated cell extracts is expressed as a 
multiple of the corresponding unactivated cell extract (indicated above the 4- 
lane for each of the transfected plasmids).
iKBa c-tag expression vector. This was a consequence of the lower expression levels of 
transfected IxBa in 293 cells compared to Cos7 cells. Indeed, 293 cells transfected with 
wild-type or mutant (C-terminal and linker) pcDNA3Pk were found to express lower levels 
of transfected iKBa c-tag than endogenous (cellular) iKBca protein (see figure 33 ).
The level of transactivation from the luciferase reporter in cells expressing elevated 
levels of transfected I KBa should be lower compared to cells transfected with 3EnhConAluc 
alone (since there will be more IkBcx present to retain NF-KB in the cytoplasm, preventing its 
passage to the nucleus and activation of luciferase expression). For example, the 9-fold 
transactivation of the luciferase reporter observed in Cos7 cells transfected with 0.125p.g 
wild-type IKBa/pcDNA3Pk (figure 31) would reflect this situation. Therefore, it was decided 
that these conditions would be used for the luciferase assays which followed.
Before proceeding to test the mutant proteins in this system, the amount of protein 
generated from their respective expression vectors was standardised. The levels of mutant 
iKBa expression were standardised to that obtained for the wild-type protein which had 
produced a 9-fold transactivation of the luciferase reporter (0.125 jig). Thus, any differences 
in the mutants ability to affect signal-induced NF-KB-dependent transcription would not be 
related to variations in the amount of protein generated from each expression vector. Western 
blot analyses from cells transfected with different amounts of the expression vectors 
encoding the mutant proteins were carried out (data not shown) to determine the amount of 
construct required to yield comparable protein levels. Expression vectors encoding mutant or 
wild-type proteins were then co-transfected with the NF-KB-dependent (3EnhConALuc) 
luciferase reporter vector into Cos 7 cells. Fourty hours later the cells were activated with 
TNFa for 8 hours and the RLU per jig of protein was determined.
Shown in figure 34 are the results of this experiment. TNFa activated cells 
transfected with the NF-KB-dependent luciferase reporter alone showed an 45 fold 
transactivation of the luciferase reporter. Co-transfection of cells with wild-type 
lKBa/pcDNA3Pk promoted a 24 fold transactivation. An iKBa mutant known to be resistant 
to proteolysis and possessing serine to alanine changes at positions 32 and 36, was co­
transfected with the luciferase reporter. As anticipated, the mutant caused a massive decrease
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Figure 33. Western blot of 293 cell extracts prepared from cells 
transfected with DNA encoding either wild-type or mutant iKBa 
c-tag proteins illustrating the different expression levels of 
transfected and cellular IkB a .
293 cells were transfected with DNA encoding either wild-type or mutant 
pcDNA3Pk expression vectors (shown at the top of the figure). Untransfected 
293 cells were also included as a control. At 36 hours post-transfection 
cytoplasmic extracts were prepared and 20pg of each (in disruption buffer) 
were separated through a 10% SDS polyacrylamide gel. The proteins were 
detected by Western blot analysis with either A) anti-Pk or B) a monoclonal 
anti-IkB a antibody, MAD 1 OB, followed by E.C.L. Arrows indicate the 
position of transfected IKBa c-tag and cellular iKBa. The position of the 
protein molecular weight standards are also shown (units=kDa). Mutants are 
named at the top of the figure.
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Figure 34. Luciferase assays performed on Cos 7 cells co-transfected 
with the NF-kB-dependent reporter vector 3EnhConALuc and DNA 
encoding either wild-type or mutant IKBa c-tag.
Cos 7 cells were co-transfected with the reporter plasmid 3EnhConALuc 
and DNA encoding either wild-type, C-terminal or linker mutant pcDNA3Pk 
expression vectors (indicated along the x-axis with the corresponding quantity 
of DNA used in t)g). Two controls were included: the reporter plasmid, 
3EnhConALuc transfected alone and the reporter plasmid, ConAluc (which 
lacked the NF-KB-dependent enhancer) also transfected alone. 40 hours 
post-transfection the cells were activated with lOng/ml TNFa for 8 hours 
(indicated by +) or left unactivated (indicated by -) and the luciferase activity 
was measured in the cell lysates. Luciferase activity is expressed as RLU/pg 
of cell lysate protein. The level of luciferase expression in the TNFa activated 
cell extracts is expressed as a multiple of the corresponding unactivated cell 
extract (indicated above the + lane for each of the transfected plasmids).
Each co-transfected with 3EnhConAluc
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Figure 35. Percentage of luciferase activity obtained from 
TNF-activated 293 cells co -transfected with the NF-KB-dependent 
reporter vector 3EnhConALuc and DNA encoding wild-type and 
mutant iKBa c-tag.
The luciferase activity obtained from 293 cells co-transfected with 
the reporter plasmid 3EnhConALuc and DNA encoding the mutant 
pcDNA3Pk expression vector (indicated along the x-axis) was expressed as a 
percentage of the luciferase activity of cells transfected with the wild-type 
construct (indicated by WT along the x-axis). The luciferase activity for the 
wild-type transfected cells was given an arbitrary value of 100%.
in luciferase expression to around 65% of the level observed for the wild-type protein (figure 
35). This can be explained by its ability to resist signal-induced degradation thus allowing it 
to retain NF-kB in the cytoplasm and prevent its nuclear translocation and transactivation. 
Surprisingly, the C-terminal and linker mutants did not show any inhibitory effect on 
luciferase expression. Their levels of transactivation were similar to those observed for the 
wild-type protein. The reason for this is unclear although it is possible that the degradation 
characteristics of the mutant proteins were different in Cos7 cells compared to 293 cells. The 
cell types do have different origins (Cos7 cells are transformed African Green-monkey 
kidney cells whereas 293 cells are transformed human embryonic kidney cells) and it 
possible that some post-translational modification of the mutant proteins may occur in Cos7 
cells but not in 293 cells to alter the degradation of the mutants or perhaps there ability to 
interact with NF-kB. ConALuc was transfected into cells to act as a control for enhancer- 
dependent activation of luciferase expression through NF-kB recognition sites. The results 
clearly showed that ConALuc transfected cells were not able to express luciferase under 
conditions of activation indicating the requirement for the enhancer region. Therefore, it 
would appear that ubiquitination of the C-terminal and linker IxBa c-tag proteins releases 
NF-kB for translocation to the nucleus where it can upregulate gene expression.
3.5 Binding efficiency of wild-type and mutant iKBa c-tag proteins to 
cellular NF- kB p65 homodimers.
In order to determine whether the wild-type and mutant I kB a c-tag proteins were 
able to interact in vivo with NF-kB cytoplasmic extracts were prepared from 293 cells 36 
hours after transfection with pcDNA3Pk encoding wild-type or mutant iKBa c-tag proteins. 
This was followed by immunoprecipitation of the cell lysates with the anti-Pk antibody and 
Western blot analysis using A) anti-Pk and B) polyclonal p65 antibody, (figure 36). Both the 
wild-type and mutant proteins were seen to bind p65 with equal efficiency indicating that the 
proteins were indeed capable of binding to NF-kB.
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Figure 36. Immunoprecipitations by the SV5-P-k (anti-Pk) antibody of 
ectopic wild-type and mutant IkBcx c-tag proteins and endogenous 
p65 protein obtained from 293 cells transfected with DNA encoding 
wild-type and mutant IKBa c-tag proteins .
293 cells were transfected with DNA (pcDNABPk) encoding wild-type, 
C-terminal or linker mutant iKBa c-tag. At 36 hours post-transfection the cells 
were harvested and an immunoprecipitation using protein A sepharose beads 
bound to anti-Pk was carried out on 50-100pg of the cytoplasmic cell lysate. The 
immunoprecipitated proteins in xl disruption buffer were then separated through 
a 10% SDS polyacrylamide gel and detected by Western blot analysis using 
either A) anti-Pk (shown at the top of the figure) or B) polyclonal p65 antibody 
(shown at the base of the figure) followed by E.C.L. The position of the protein 
molecular weight standards are indicated to the left of each figure (units=kDa) 
and arrows show the ectopic iKBa c-tag and endogenous p65 proteins. 
Untransfected 293 cytoplasmic cell extracts were immunoprecipitated with 
anti-Pk and included as a control. Mutants are named at the top of each Western 
blot.
3.6. The identification of lysine residues required for signal-induced 
ubiquitination of I KBa.
When the activity of the 26S proteasome is inhibited, signal-induced degradation of
iKBa is blocked together with NF-kB activation. Furthermore, inhibition of proteosomal 
activity and subsequent stimulation of cells with TNF results in the detection of a hyper- 
phosphorylated form of IkBa and ubiquitinated forms of the protein (Pallombella et al, 
1994; Traenckner et al, 1995; Roff et al, 1996). The ubiquitinated forms of IkBa are not 
detected when inducible phosphorylation and degradation of ikBta is blocked by the 
mutation of serine 32 and serine 36 in the N-terminus of IkBa (Chen et al, 1995; Roff et al, 
1996). This indicates that signal-induced phosphorylation is required for both in vitro and in 
vivo ubiquitination of IkBa.
Ubiquitin chains are added to the e-amino group of lysine residues in the target 
protein marking the protein for degradation by the proteasome. The following studies set out 
to identify which residues were responsible for the signal-induced ubiquitination and 
degradation of iKBa. A panel of seven iKBa mutants containing single and multiple lysine to 
arginine substitutions and a mutant possessing serine to arginine changes at residues 32 and 
36 were generated by M. Rodriguez (Pasteur Institute, France) (figure 37) using a 
polymerase chain reaction strategy reported in Rodriguez et al, 1995. The mutants were 
engineered to contain a C-terminal tag and cloned into the mammalian expression vector, 
pcDNA3 for transient transfection into 293 or Cos7 cells.
The experiments carried out by colleagues at the Pasteur Institute on the lysine IkBa 
mutants were similar to those performed on the C-terminal and linker IkBa mutants, detailed 
in sections 3.1, 3.2, 3.4 and 3.5 of this chapter and section 2.2 of chapter 2. A summary of the 
results obtained from these experiments will be given below together with any experimental 
conditions not detailed in the previously mentioned sections. In addition , the findings of the 
ubiquitination experiment (for details see section 3.3) performed in St. Andrews will be 
given.
An initial investigation of the ability of the lysine to arginine iKBa mutants to 
interfere with TNF induced transactivation of an NF-KB-dependent reporter gene
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Figure 37. Schematic representation of IkBoc C-terminally linked to 
the epitope Pk-tag and derivative mutant proteins with amino acid 
changes in the N-terminus region.
Wild-type IkB a c-tag is shown with the N-terminal amino acid 
sequence encompassing residues 15-60. Also illustrated are the amino acid 
changes introduced into the wild-type sequence to generate the lysine to arginine 
IkBoc mutants and the ankvrin repeats (w*K ), low homology repeat )
and acidic domain ( )(-this forms most of the C-terminal domain), the
Pk-tag epitope and the anti-Pk antibody (X )•
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(3EnhConAluc) was performed in Cos7 cells (see section 3.4). This revealed that co­
transfection of the I kB a mutants containing the double substitutions, K21R and K22R with 
the luciferase reporter (mutant K21R/K22R and mutant K21R/K22R/K38R /K47R) severely 
impaired NF-KB-dependent transcription. However, co-transfection of either mutant K21, 
mutant K22, mutant K38R or mutant K47R with the luciferase reporter resulted in a far 
greater level of luciferase expression (similar to that observed for the wild-type iKBa protein 
but lower than the level observed in cells transfected with 3EnhConAluc alone). The 
inhibitory effect shown for mutants K21R/K22R and K21R/K22R/K38R /K47R was also 
detected using two other NF-kB inducers, ILl and OKA and in 293 cells. In addition, the 
specificity of the NF-kB inhibitory effect was proven through the failure of both mutant and 
wild-type proteins I kB a proteins to prevent transcription from an inducible, but NF-kB- 
independent promoter, LTRAkBLuc. It appeared that the level of inhibition of NF-kB 
activation observed for mutant K21R/K22R was less dramatic than that detected for the 
proteolysis resistant 332A/336A mutant. However, the mutant containing two additional 
changes at K38 and K47 exhibited an inhibitory capacity comparable to the IkBcc mutant,
332A/336A.
In order to check for possible disruptions to the structure of the iKBa lysine mutants 
as a result of their amino acid substitutions, mutants were examined for their ability to 
interact with the p65 subunit of NF-kB. This was achieved by analysing the capacity of the 
mutants in vitro to prevent p65-DNA interactions in a gel electrophoresis DNA binding assay 
and their ability to bind in vivo (in Cos7 cells) overexpressed p65 (co-transfected with the 
pcDNA3 expression vectors containing the various lysine mutants, followed by 
immunoprecipitation of the IkBcx mutants as in section 3.5). For the DNA binding assays the 
IkBoc lysine mutants and p65 protein were generated in vitro individually using a coupled 
transcription/translation system (for more details see Rodriguez et al., 1996). The mutants 
shown in figure 38 were able to inhibit the DNA binding of p65 to the same extent as the 
wild-type iKBa protein and to bind p65 with a similar affinity to the wild-type iKBa protein. 
Therefore, the inhibitory effect of the lysine mutants, K21R/K22R and
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K21R/K22R/K38R/K47R on NF-KB-dependent transcription was not a result of any 
variation in the capacity of the mutants to interact with NF-kB.
Studies to determine whether the transfected lysine iKBa mutants were degraded in 
response to treatment of Cos7 cells with TNF (see section 3.1), revealed that mutant 
K21R/K22R was stable to proteolysis, reflecting its ability to inhibit NF-KB-dependent 
transcription. However, mutant K21R, mutant K22R and mutant K38R/K47R were inducibly 
degraded to the same extent as the wild-type IkB a protein which appeared to be in 
agreement with the higher level of NF-KB-dependent transcription observed for these IkBcx 
proteins. Mutants K21R/K22R and K21R/K22R/K38R/K47R were also shown to be 
inducibly phosphorylated in Cos7 cells (see section 3.2) indicating that the increased 
resistance of K21R/K22R to proteolysis was not due to an impaired capacity of the mutant to 
be phosphorylated.
Since mutant K21R/K22R lacked two potential ubiquitin targets (lysine 21 and 22) it 
was possible that its inability to be inducibly degraded was due to a reduction in the ability of 
the mutant to be ubiquitinated. Mutant K21R/K22R was therefore transfected into 293 cells 
and analysed for its ability to be ubiquitinated under conditions of TNF activation and in the 
presence of the proteasome inhibitor, Z-LLL-H (see section 3.3 for details). As predicted the 
ubiquitination of mutant K21R/K22R was almost eliminated (figure 38). The proteolysis 
resistant S32A/S36A IKBa mutant and an IKBa mutant in which all the lysine residues(all 
K,R) had been substituted with arginine failed to be ubiquitinated. Mutant 
K21R/K22R/K38R/K47R was also not targeted for ubiquitination whereas mutant 
K38R/K47R was ubiquitinated but, to a lesser extent than the wild-type IKBa protein. Since 
the ubiquitination of mutant K21R/K22R was greatly reduced but not completely eliminated 
until lysines 38 and 47 were substituted for arginine residues in mutant 
K21R/K22R/K38R/K47R, lysines 21 and 22 must be critical targets for ubiquitination but 
lysines 38 and 47 must also play an auxiliary role. This view is supported by the slightly 
poorer ubiquitination of mutant K38R/K47R compared to wild-type IKBa.
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Figure 38. In vivo ubiquitination of iKBa and lysine to arginine 
mutants.
Human 293 cells were transfected the indicated IKBa constructs and 
maintained in culture for 24 Hours. For the last 60 min in culture, cells were 
either incubated with control medium (-) or with 10|jlM z-LLL-h followed by 
lOng/ml TNF. Cell extracts were prepared in the presence of iodoacetamide to 
inhibit the action of ubiquitin C-terminal hydrolases and analysed by Western 
blot with the SV5 PK tag Mab. The positions of the molecular mass markers, 
ectopic IKBa and its ubiquitin aducts are indicated (Rodriguez et al., 1996).
CHAPTER 4. STRUCTURAL ANALYSIS OF THE C- TERMINAL
REGION OF IKBa USING CIRCULAR DICHROISM (CD) SPECTRO­
SCOPY.
Proteolysis studies had allowed IxBa to be arranged into three distinct domains, an 
unstructured N-terminal region and a highly organised central core consisting of 5 ankyrin 
repeats connected to the acidic C-terminal region by a protease sensitive linker (Jaffray et al, 
1995). It appeared that both the ankyrin repeats and the C-terminal region were generally 
resistant to proteolysis compared to the N-terminal and linker domains. This suggested that 
the central core and C-terminus possessed tightly organised structures. Indeed, circular 
dichroism spectroscopy had previously revealed that the ankyrin repeats of the IxB-like 
protein, cactus adopted an alpha- helical secondary structure (Gay et al, 1993). It was 
possible that the ankyrin repeats existed as a single folded unit of alpha helices.
The functional integrity of I KBa was apparently reflected in the domain organisation 
of the protein, in that loss of either part of the ankyrin repeats or the C-terminus left the 
protein unable to inhibit p65 DNA binding and/or interact with p65 (Inoue et al., 1992; 
Hatada et al., 1993; Jaffray etal, 1995; Rodriguez et al., 1995). It was conceivable that the 
C-terminal region of IkBoc, like the ankyrin repeat domain could form an independently 
folded unit and that any disruption of this structure (such as the deletion of residues within 
the C-terminus) would be deleterious to the activity of IkBoc.
In order to determine whether the C-terminal region of IxBa could form a self- 
contained structure a series of four molecules corresponding to the C-terminal domain were 
generated; a chemically synthesised peptide corresponding to residues 275-317 of iKBa 
(supplied by Francoise Baleux, France) and three bacterially expressed, glutathione/FPLC 
purified C-terminal proteins-amino acids 265-317 c-tag (provided by E. Jaffray, St. Andrews 
University), amino acids 265-317 and amino acids 275-317 (construction and purification 
details are given in the following sections). These were analysed under different pH 
conditions and in the presence of trifluoroethanol (TFE), an agent known to promote a-helix, 
using the technique of circular dichroism (CD) spectroscopy. This method examines the 
interaction between polarised light and optically active molecules. Specifically, the technique
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measures the wavelength dependence of the differential absorption of right and left circularly
polarised light from an optically active molecule in order to elucidate the conformation of a 
macromolecule or macromolecular complex in solution. The technique can be used to
identify elements of secondary structure in proteins, nucleic acids and nucleoproteins.
4.1. Construction of GST fusion proteins, 265-317 and 275-317 containing 
the C-terminal region of I KBa.
The coding sequence of the C-terminal region (265-317 and 275-317) of IkB(X was 
generated by the PCR technique (Landt et al., 1990) represented schematically in Figure xx, 
chapter 1, section 1.1 (for further details on this technique refer to chapter 1, section 1.1). 
The PCR products were analysed by separation through a 0.8% agarose gel and showed that 
the 265-317 construct had the expected size of approximately 159 base pairs and the 275-317 
construct had the expected size of approximately 129 base pairs (data not shown).
PCR amplified DNA was digested with the restriction endonucleases, BamHI and 
EcoRI, purified and ligated into the pGEX2T vector (also digested with BamHI and EcoRI) 
and transformed into competent E.coli (XL-blue). Tetracycline and ampicillin resistant E.coli 
transformants were isolated and small scale preparations of their DNA (mini-preps.), were 
prepared and used as double stranded DNA templates to sequence the cDNA of the 265-317 
and 275-317 constructs using the dideoxy-chain termination procedure. Figure 39 shows the 
sequencing data obtained for the cDNA of constructs 265-317 and 275-317 and indicates that 
the cloning procedure had generated the expected products with no inadvertent mutations 
being produced.
4.2 Expression and purification of the proteins, 265-317 and 275-317 
containing the C-terminal region of IxBa in E.coli.
For the expression and purification of the proteins, 265-317 and 275-317 (containing 
the C-terminus of IkB a) in E.coli (XL-blues ) the glutathione-S-transferase (GST)-fusion 
expression system was used (Smith and Johnson., 1988) (Refer to Chapter 1, section 1,2 for 
further details). The vector employed in this study was the pGEX-2T expression vector
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Figure 39. Sequence confirmation of the constructs, 265-317 and
275-317, corresponding to the C-terminal region of iKBa.
The dideoxy chain-termination procedure was used to yield the coding 
DNA strands shown opposite for each of the two constructs, 265-317 and 
275-317. THe coding dNa sequences are read from bottom to top (5' to 3' on the 
coding DNA) and the Jane location of each DNA base is shown at the top of the 
geJ (A= adenine, C= cytosine, G= guanine and T= thymine). THe position and 
sequence of the first codon in each construct is boxed (ATA for 265-317 which 
codes for isoJeucine and GAA for 275-317 which codes for glutamic acid). The 
stop codon, TGA is also indicated.
(Promega) which allows the production of high levels of protein with a cleavable N- 
terminally fused 26 kD enzyme, glutathione-S-transferase (GST).
Screening for the over-expression of glutathione-S-transferase fusion proteins, 265­
317 and 275-317, from the pGEX-2T vector was carried out as follows: 1ml overnight 
cultures of the positively identified 265-317/pGEX-2T and 275-317/pGEX-2T E.coli (XL-1 
blue) clones (i.e. the clones which when sequenced exhibited the expected changes) were 
diluted the following day, 1:100, into 1ml of LB-broth and grown until an OD6OOnm was
reached. The cultures were then induced with IPTG for 3-4 hours and the cells were 
harvested by centrifugation, resuspended in PBS/0.5M NaCl and disruption buffer, boiled 
and then separated through a 10% polyacrylamide gel. An uninduced culture was included as 
a control. The construct, 265-317 was estimated have a molecular weight of 6171Da and the 
construct, 275-317 was estimated to have a molecular weight of 5049Da (as calculated 
through a DNA strider computer programme). The combined molecular weight of the GST 
fusions proteins would therefore be estimated at 32.2kDa for 265-317 and 31kDa for 275­
317. The coomassie blue stained gels were used to identify clones possessing appropriately 
sized protein bands. 1ml overnight cultures of clones positive for the fusion proteins were 
diluted 1:100 into 1litre of LB-broth and grown at 37°C to the appropriate density before 
induction with IPTG to yield the fusion protein.
The individual fusion proteins were then purified by glutathione-agarose column 
chromatography using the tritonX-100 and sarkosyl method (see materials and methods), 
cleaved with thrombin and recovered using FPLC chromatography. Proteins were eluted 
from the column using a concentration gradient of sodium chloride (250mM to 1M). An 
additional glutathione-agarose purification step was included if the FPLC purified protein 
sample contained any undigested fusion protein (which can bind to the FPLC mono-Q 
column). The fusion protein was absorbed onto the column whereas the thrombin cleaved 
protein was passed through the column to yield the final mutant IkB<x c-tag proteins.
Figures 40 and 41(A) show the results of the purification steps. The thrombin cleaved 
fusion protein (i.e. the FPLC column load), the FPLC column flow-through (i.e. GST), FPLC 
column washes and the optional glutathione-agarose purification step are not shown. The
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Figure 40. Glutathione-agarose column purifications of the proteins, 
265-317 and 275-317 corresponding to the C-terminal region of IkBcc.
Coomassie blue stained 10% SDS polyacrylamide gels of glutathione- 
agarose column purifications (using the tritonXIOO and sarkosyl method) are 
shown for the proteins, 265-317 and 275-317 fused to GST . All sample tracks 
contained a mix of 15|il of protein solution and 7.5|il of 3x disruption buffer 
which had been boiled for 2-3 minutes before loading. The following 
abbreviations were used for the sample tracks shown :- M = protein molecular 
weight standards (units = kDa), U = uninduced crude bacterial extract, C = 
induced crude bacterial extract, L = IPTG induced crude bacterial load to the 
glutathione-agarose column, FT = flow-through from the glutathione-agarose 
column, W = glutathione-agarose column washes with PBS, 0.5M NaCl, 2mM 
EDTA, lmM PMSF, 2mMbenzamidine, E = lOmM glutathione, 0.5M NaCl, 
50mM Tris/HCl pH8.0 eluate from the glutathione-agarose column. For lanes L, 
FT, W and E the proteins were fused to glutathione-S-transferase (GST) to give 
a combined molecular weight of approximately 30-32kD.
Figure 41A. FPLC purified proteins, 265-317 and 275-317 
corresponding to the C-terminal region of IKBa.
Coomassie blue stained 10% SDS polyacrylamide gels of the FPLC 
purified proteins, 265-317 and 275-317 are shown (4-6kDa). All sample tracks 
contained a mix of 15pil of protein solution and 7.5pd of 3x disruption buffer 
which had been boiled for 2-3 minutes before loading. The following 
abbreviations were used for the sample tracks shown :- M = protein molecular 
weight standards (units=kDa), F = FPLC Mono-Q column pooled peak fractions 
in PBS/0.5M NaCl.
polyacrylamide gels illustrate that the glutathione-agarose affinity chromatography yielded 
virtually pure GST-fusion proteins in the various eluates (E). The proteins, 265-317 and 275­
317 containing the C-terminal region of iKBa eluted from the FPLC Mono-Q column (F) 
were shown to be free from contaminating proteins. It should be noted that the iKBa C- 
terminal proteins do not stain well with coomassie blue compared to GST, therefore the 
GST-IKBa C-terminal fusion proteins appear as much darker bands compared to the iKBa C- 
terminal proteins alone.
Figure 42(B) shows the UV absorbance output trace obtained for the FPLC column 
purification of the iKBa C-terminal proteins (265-317 and 275-317). The initial GST flow­
through was observed to the far left of each trace. 265-317 was eluted at the end of the salt 
gradient (IM) whereas 275-317 was eluted between 0.40M and 0.55M sodium chloride. The 
peak fractions were analysed using SDS-PAGE. The most concentrated fractions were 
combined and stored at -70 °C.
4.3. Circular Dichroism spectroscopy of C-terminal iKBa proteins using 
different pH conditions and in the presence of trifluoroethanol (TFE).
CD spectroscopy was performed in the far ultraviolet (UV) region (190-260nm) on a 
chemically synthesised peptide corresponding to residues 275-317 of iKBa (supplied by 
Francoise Baleux, France) and three bacterially expressed, glutathione/FPLC purified C- 
terminal proteins-265-317 c-tag (corresponding to the C-terminal region, part of the low 
homology sixth ankyrin repeat (265-317) and the c-tag region of wild-type IKBa c-tag and 
provided by E. Jaffray, St. Andrews University), 265-317 (corresponding to the C-terminal 
region and part of the low homology sixth ankyrin repeat (265-317) of wild-type IkBoc) and 
275-317 (corresponding to the C-terminal region (275-317) of wild-type IkBoc) (sections 4.1 
and 4.2) using different pH conditions and in the presence of an a-helix stabilising agent, 
triflouroethanol (TFE) (figures A-L). All proteins were analysed in a buffer of relatively low 
UV absorbance: The dried C-terminal peptide was resuspended to a concentration of 
0.5mg/ml in a solution of 50mM sodium fluoride and lOmM sodium phosphate ranging in 
pH from 6.0-8.0. The three C-terminal fragments of IKBa, 265-317 c-tag (0.51 mg/ml), 265-
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Figure 42A. FPLC Mono-Q column purification of the C-terminal 
IkB(x proteins, 265-317 and 275-317.
The UV absorbance output traces at 280nm are shown (solid lines) 
opposite for the C-terminal IkB a proteins, 265-317 and 275-317 from the FPLC 
Mono-Q column using a salt gradient ranging from 250mM NaCl to ImM NaCl 
(dashed lines). The position of the fractions collected from the salt gradient are 
indicated along the base of the trace. Glutathione-S-Transferase appeared in the 
initial column flow-through (to left of IkB apeak) before the salt gradient was 
applied to the FPLC Mono-Q column.
265-317 IkBoc C-term
A
28
0
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l] 
(M
)
317 (0.2mg/ml) and 275-317 (0.2mg/ml) were dialysed overnight against 50mM sodium 
fluoride, lOmMsodium phosphate pH7.0, O.5mM DTT. Additionally, 1ml aliquots of 265­
317 and 275-317 were dialysed overnight against 50mMsodium fluoride, lOmMsodium 
phosphate pH5.6, pH6.4 (275-317 only), pH7.0 and pH8.0 and 0.5mM DTT.
The various forms of regular secondary structure in proteins and peptides display 
distinct CD patterns in the far ultraviolet region as shown in figure 41(B). In order to assess 
the contributions of the various secondary structure constituents from the CD spectrum this 
study employed the CONTIN procedure of Provencher and Glockner (1981). This method 
directly analyses the CD spectrum of a protein or peptide by comparing it to the CD spectra 
of 16 proteins whose structures have been determined by X-ray crystallography to high 
resolution (Price, 1995). The use of CD data over the range of 190-240nm (as used in this 
study) only accurately determines the amount of a-helix and p-sheet in the protein or peptide 
whereas the contributions of p-turns, 3io helix and random structure are much less well 
estimated.
The CD spectrum of the C-terminally tagged (this is the 14 amino acid tag region 
which was also fused to the full-length mutant IkBo proteins-see chapter 1) protein referred 
to as 265-317 c-tag in either the absence or presence of 50% TFE is shown in figure 42(B). 
The CD spectrum of 265-317 c-tag in buffered aqueous solution (pH7.0) exhibited a single 
negative absorption at 197-200nm, indicative of a conformationally mobile species (possibly 
random coil) (dithiothreitol was included in the solution to prevent a cysteine residue at 
position 308 in the full length protein from cross-linking molecules of 265-317 c-tag). 
However, in the presence of 50% TFE the spectrum of 265-317 c-tag altered to display a 
maximum at 190nm and a minimum at 208nm signifying an increase in a-helical content, a- 
helical structures usually exhibit a minimum at 222nm. There is a small plateau of absorption 
around 222nm for 265-317 c-tag but no obvious trough. Application of the CONTIN 
procedure (Provencher and Glockner, 1981) to the spectrum recorded in the absence of 50% 
TFE (table 1-note, remaining secondary structure may include random coil) indicated that the 
predominant secondary structure was P-sheet (62%). However, after the addition of 50% 
TFE to 265-317 c-tag the level of a-helix was raised (11%), although the major secondary
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Figure 41. CD spectra associated with various secondary structures.
a-helix (------- ) , (------- ), p-uim type I (........ ),
left-handed extended 3io helix (-/-/-/), irregular structure (—— ) (from Price,
1995). ~
Figure 42: Circular dichroism spectroscopy of 265-317 c-tag in the presence or
absence of 50% trifluoroethanol (TFE) at pH7.O.
The CD spectrum of 265-317 c-tag (0.51 mg/ml in pH7.O 50mM sodium 
fluoride/lOmM sodium phosphate buffer, 0.5mM dithiothreitol (DTT)) was recorded in the 
presence (purple line) or absence (red line) of 50% TFE, a helix stabilising agent. WL 
along the x-axis represents the wavelength (nm) at which the spectra were recorded. The 
units for the molar ellipticity, theta (0) along the y-axis are degrees x cm2 x dmoT'1 and are 
given in terms of the mean residue weight of the protein.
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structure component was still p-sheet (60%). Therefore, it appeared that 265-317 c-tag was 
predominantly P-sheet.
Table 1. Predicted secondary structure content of 265-317 c-tag in the 
presence and absence of 50% TFE (pH7.0).
Secondary Structure Content
a-helix p-sheet
Remaining 
secondary 
structure e.g. 
p-turn, 3io helix
No TFE 0% 62% 38%
+50% TFE 11% 60% 29%
Since 265-317 c-tag contained a C-terminal tag region, this could dramatically affect 
the structure of the protein (although the functional characteristics of the full-length IkBoc 
proteins possessing a C-terminal tag were identical to that of non-tagged I KBa). Furthermore, 
265-317 c-tag included part of the low homology sixth ankyrin repeat which may also have 
affected the secondary structure of the protein. Therefore, it was decided that a chemically 
synthesised peptide corresponding to residues 275-317 of IKBa would be analysed by CD 
spectroscopy. The peptide, referred to as either C-terminus or C-terminal peptide, contained 
a chemical blocking group at a cysteine residue (position 308, full length IKBa) to prevent 
any cross-linking between peptide molecules.
Since the association between IKBa and NF-kB could involve a partial quenching of 
a selection of negatively charged carboxyl groups in the C-terminal region of IkB a it was 
decided to examine the conformation of the C-terminal peptide over a range of pH values. 
The CD spectrum of the C-terminal peptide in buffered solutions of pH6.0, pH7.0 and pH8.0 
(in the absence of TFE) is shown in figure 43. No change in the conformation of the C-
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4Figure 43: Circular dichroism spectroscopy of the C-terminal peptide (amino 
acids 275-317) at pH6.0, pH7.0 and pH8.O.
The CD spectrum of the C-terminal peptide (amino acids 275-317)(0.5mg/ml) 
was recorded in either 50mM sodium fluoride/1 OmM sodium phosphate buffer pH6.0 (red 
line), pH7.0 (blue line) or pH8.0 (green line). WL along the x-axis represents the 
wavelength (nm) at which the spectra were recorded. The units for the molar ellipticity, 
theta (0) along the y-axis are degrees x cm? x dmol'1 and are given in terms of the mean 
residue weight of the protein.
. 000E+03
terminal peptide was observed over the range of pH’s used and the peptide appeared to adopt 
a random conformation as indicated by the characteristic trough at 197nm. At pH7.0 in the 
presence of 50% TFE there was a slight shift in the negative absorption to around 204nm but 
the spectrum indicated that 275-317 was predominantly a random coil (figure 44). Similar 
results were obtained at pH6.0 and pH8.O (data not shown). Secondary structure predictions 
(through the application of the CONTIN procedure to the spectra) suggested that the C- 
terminal peptide comprised mainly p-sheet or remaining secondary structure constituents 
such as {--turns, 3 io helix or random coil (data not shown).
Evidently, the bacterially expressed protein, 265-317 c-tag was able to assume a more 
ordered structure than the C-terminal peptide. There were several explanations for the less 
ordered conformation of the C-terminal peptide: The loss of part of the low homology sixth 
ankyrin repeat (10 amino acids); the loss of the C-terminal tag region or the presence of the 
large blocking group (CH2NHCOCH3) on a cysteine residue to prevent cross-linking. 
Therefore, it was decided that the bacterially expressed proteins referred to as 265-317 and 
275-317 (containing neither a tag region nor a chemical blocking group) would be examined 
using circular dichroism spectroscopy in an attempt to clarify these points.
Both of the proteins, 265-317 and 275-317 were analysed in the presence and absence 
of 50% TFE in a buffered solution at pH5.6, pH7.0 and pH8.0 and 275-317 was also 
examined at pH6.4 using CD spectroscopy. The results are illustrated in figures 45-48. 
Figures 45-47 show that at pH5.6, pH7.0 and pH8.O 265-317 assumed a random 
conformation (this may include p-turns and 310 helix) in the absence of TFE as indicated by 
the absorption minimum at 190nm. However, in the presence of 50% TFE the a-helical 
content of 265-317 increased. This was also the case when the pH was lowered in the 
presence of 50% TFE as shown by the appearance of minima at 204-208nm and 222nm and a 
slight positive absorption at 190nm (Figure 48 shows this more clearly). A comparison of the 
secondary structure predictions for 265-317 c-tag at pH7.0 in the presence of TFE (table 1 
and figure 42B)with the predictions for 265-317 at pH7.0 in the presence of TFE (table 2 and 
figure 46, note remaining secondary structure may also include random coil) revealed that the 
C-terminally tagged protein contained more p-sheet and a-helix but less of the remaining
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Figure 44: Circular dichroism spectroscopy of the C-terminal peptide (amino 
acids 275-317) in the presence or absence of 50% triflouroethanol (TFE) at
pH7.0.
The CD spectrum of the C-terminal peptide (amino acids 275-317)(0.5mg/ml) 
was recorded in 50mM sodium fluoride/1 OmM sodium phosphate buffer, pH7.0 in either 
the presence (blue line) or absence (red line) of 50% TFE. WL along the x-axis represents 
the wavelength (nm) at which the spectra were recorded. The units for the molar 
ellipticity, theta (0) along the y-axis are degrees x cm2 x dmol'1 and are given in terms of 
the mean residue weight of the protein.
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Figure 45: Circular dichroism spectroscopy of 265-317 in the presence or 
absence of 50% triflouroethanol (TFE) at pH5.6.
The CD spectrum of 265-317 (0.2mg/ml) was recorded in the presence (blue 
line) or absence (red line) of 50% tFe in 0.5mM dithiothreitol, 5OmM sodium 
fluoride/1 OmM sodium phosphate buffer, pH5.6. WL along the x-axis represents the 
wavelength (nm) at which the spectra were recorded. The units for the molar ellipticity, 
theta (0) along the y-axis are degrees x cm2 x dmol"1 and are given in terms of the mean 
residue weight of the protein.
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Figure 46: Circular dichroism spectroscopy of 265-317 in the presence or 
absence of 50% triflouroethanol (TFE) at pH7.O.
The CD spectrum of 265-317 (0.2mg/ml) was recorded in the presence (blue 
line) or absence (red line) of 50% TFe in 0.5mM dithiothreitol, 5OmM sodium 
fluoride/1 OmM sodium phosphate buffer, pHT.O. WL along the x-axis represents the 
wavelength (nm) at which the spectra were recorded. The units for the molar ellipticity, 
theta (6) along the y-axis are degrees x cm2 x dmol4 and are given in terms of the mean 
residue weight of the protein.
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Figure 47: Circular dichroism spectroscopy of 265-317 in the presence or 
absence of 50% triflouroethanol (TFE) at pH8.O.
The CD spectrum of 265-317 (0.2mg/ml) was recorded in the presence (blue 
line) or absence (red line) of 50% TFE in 0.5mM dithiothreitol, 5OmM sodium 
fluoride/1 OmM sodium phosphate buffer, pH8.0. WL along the x-axis represents the 
wavelength (nm) at which the spectra were recorded. The units for the molar ellipticity, 
theta (0) along the y-axis are degrees x cm2 x dmol"1 and are given in terms of the mean 
residue weight of the protein.
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Figure 48: Circular dichroism spectroscopy of 265-317 in the presence of 50% 
triflouroethanol (TFE) at pH5.6, pH7.0 and pH8.O.
The CD spectrum of 265-317 (0.2mg/ml) was recorded in the presence of 50% 
TFE in either 0.5mM dithiothreitol, 50mM sodium fluoride/1 OmM sodium phosphate 
buffer, pH5.6 (purple line), pH7.0 (blue line) or pH8.0 (red line). WL along the x-axis 
represents the wavelength (nm) at which the spectra were recorded. The units for the molar 
ellipticity, theta (0) along the y-axis are degrees x cm2 x dmofi and are given in terms of 
the mean residue weight of the protein.
w a) h %
l
Uloo
m
+o
&
ro IU m OS-
0) 01 01 O i-
Ul Ul Ul o rI I 1 p
w 01 OlI V
!-»■ 4& L
Nl nJ nJ
•O T3 ■O r
I I I t-
nJ CD **•• • •
m O O h
m Ul Ul ■
o o o p
X X X
H
T1
H
*1
H
T1
**
m m m t
o o o
p-
• • r-
o o o U
Ul Ul Ul -
n n n
3 3 3 p
z - r r
r-i - 
□ r 3 _
1....t- 4--r- r-
l » 
4—
1 t^
O
+3
00
0
W
0)O
- il
- {f -
J- G
p If -
r 11 1
*- ( -»
r*
r J 11 1
r VB ! -
r t 4
r v J _
u '■ •4
p * i
i 4
t—4. _ 4—-4—.4- _I—4—4—4—4-...4—4-4 - _4..—4_
-1-- 4—4—4—4—4 —4--4- -4—4__4
secondary structure constituents than the non-tagged protein. The results suggest that the C- 
terminal tag serves to stabilise the protein in a more ordered conformation comprising 
predominantly of P-sheet. Application of the CONTIN procedure to the spectra (table 2) 
illustrated that the a-helical content of 265-317 at each pH (pH5.6, 7%; pH7.0, 5% and 
pH8.0, 6%) was raised in the presence of 50% TFE. However, in both the presence and 
absence of TFE the overall structure was predominantly P-sheet or remaining secondary 
structure constituents such as p-turns, 3 io helix or random coil.
Figures 49-53 show that at pH5.6, pH6.4, pH7.0 and pH8.0 275-317 adopted a 
random conformation (which may include p-turns and 3io helix) in the absence of TFE as 
indicated by the absorption minimum at 190nm. However, in the presence of 50% TFE 275­
317 shifted its conformation slightly to that of an a-helix. It appeared that as the pH was 
lowered in the presence of 50% TFE, 275-317 adopted a more a-helical conformation as 
shown by the appearance of an almost positive absorption at 190nm (Figure 53 shows this 
more clearly). A comparison of the spectrum of the C-terminal peptide at pH7.0 in the 
presence and absence of TFE (figure 44) with 275-317 at pH7.0 in the presence and absence 
of TFE (figure 51) reveals a striking similarity suggesting that the blocking group in the C- 
terminal peptide did not affect the structure of the protein. Application of the CONTIN 
procedure to the spectra (table 3) showed that the a-helical content of 275-317 at each pH 
(pH5.6, 5%; pH6.4, 6%; pH7.0, 2% and pH8.0, 6%) was raised in the presence of 50% TFE. 
However, in both the presence and absence of TFE the overall structure was predominantly 
P-sheet or remaining secondary structure constituents such as P-turns, 3 io helix or random 
coil. Surprisingly, a comparison of the secondary structure predictions for 275-317 in the 
absence of TFE at pH5.6 with those for 265-317 under the same conditions (table 2) revealed 
that 275-317 contained more P-sheet (63%) and less of the remaining secondary structure 
constituents (37%) than 265-317 (P-sheet, 49% and random coil, 50%). This suggests that the 
extra ten amino acids contained in the protein, 265-317 do not stabilise the structure at lower 
pH’s but instead appear to induce a less ordered conformation in the protein.
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Figure 49: Circular dichroism spectroscopy of 275-317 in the presence or
absence of 50% triflouroethanol (TFE) at pH5.6.
The CD spectrum of 275-317 (0.2mg/ml) was recorded in the presence (blue 
line) or absence (red line) of 50% TFE in 0.5mM dithiothreitol, 5Om.M. sodium 
fluoride/1 OmM sodium phosphate buffer, pH5.6. WL along the x-axis represents the 
wavelength (nm) at which the spectra were recorded. The units for the molar ellipticity, 
theta (0) along the y-axis are degrees x cm 2 x dmol _1 and are given in terms of the mean 
residue weight of the protein.
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Figure 50: Circular dichroism spectroscopy of 275-317 in the presence or
absence of 50% triflouroethanol (TFE) at pH6.4.
The CD spectrum of 275-317 (0.2mg/ml) was recorded in the presence (blue 
line) or absence (red line) of 50% TFE in 0.5mM dithiothreitol, 5OmM sodium 
fluoride/1 OmM sodium phosphate buffer, pH6.4. WL along the x-axis represents the 
wavelength (nm) at which the spectra were recorded. The units for the molar ellipticity, 
theta (0) along the y-axis are degrees x cm2 x dmoT1 and are given in terms of the mean 
residue weight of the protein.
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Figure 51: Circular dichroism spectroscopy of 275-317 in the presence or
absence of 50% triflouroethanol (TFE) at pH7.0.
The CD spectrum of 275-317 (0.2mg/ml) was recorded in the presence (blue 
line) or absence (red line) of 50% tFe in 0.5mM dithiothreitol, 5OmM sodium 
fluoride/1 OmM sodium phosphate buffer, pH7.0. WL along the x-axis represents the 
wavelength (nm) at which the spectra were recorded. The units for the molar ellipticity, 
theta (0) along the y-axis are degrees x cm2 x dmol4 and are given in terms of the mean 
residue weight of the protein.
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Figure 52: Circular dichroism spectroscopy of 275-317 in the presence or 
absence of 50% triflouroethanol (TFE) at pH8.0.
The CD spectrum of 275-317 (0.2mg/ml) was recorded in the presence (blue 
line) or absence (red line) of 50% TFe in 0.5mM dithiothreitol, 5Om.M sodium 
fluoride/1 OmM sodium phosphate buffer, pH8.0. WL along the x-axis represents the 
wavelength (nm) at which the spectra were recorded. The units for the molar ellipticity, 
theta (0) along the y-axis are degrees x cm2 x dmol-l and are given in terms of the mean 
residue weight of the protein.
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Figure 53: Circular dichroism spectroscopy of 275-317 in the presence of 50% 
triflouroethanol (TFE) at pH5.6, pH7.0 and pH8.O.
The CD spectrum of 275-317 (0.2mg/ml) was recorded in the presence of 50% 
TFE in either 0.5mM dithiothreitol, 5OmM sodium fluoride/1 OmM sodium phosphate 
buffer, pH5.6 (orange line), pH6.4 (purple line), pH7.0 (blue line) or pH8.0 (red line). WL 
along the x-axis represents the wavelength (nm) at which the spectra were recorded. The 
units for the molar ellipticity, theta (0) along the y-axis are degrees x cm2 x dmol-1 and are 
given in terms of the mean residue weight of the protein.
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Table 2. Predicted secondary structure content of 265-317 in the presence 
and absence of 50% TFE (pH5.6, pH7.0 and pH8.0).
Secondary Structure Content
a-helix P-sheet
Remaining 
secondary 
structure e.g. 
P-turn, 3io helixpH
5.6 (No TFE) 1% 49% 50%
5.6 (+50% TFE) 7% 50% 43%
7.0 (No TFE) 0% 53% 47%
7.0 (+50% TFE) 5% 51% 44%
8.0 (No TFE) 1% 50% 49%
8.0 (+50% TFE) 6% 36% 58%
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Table 3. Predicted secondary structure content of 275-317 in the presence 
and absence of 50% TFE (pH5.6, pH7.0 and pH8.0).
Secondary Structure Content
a-helix p-sheet
Remaining 
secondary 
structure e.g. 
P-turn, 3io helixpH
5.6 (No TFE) 0% 63% 37%
5.6 (+50% TFE) 5% 50% 45%
6.4 (No TFE) 1% 57% 42%
6.4 (+50% TFE) 6% 45% 49%
7.0 (No TFE) 1% 52% 47%
7.0 (+50% TFE) 2% 51% 47%
8.0 (No TFE) 0% 48% 52%
8.0 (+50% TFE) 6% 44% 50%
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DISCUSSION
1. IkBcc: Inhibition of p65 homodiincr DNA binding and association with
p65 in vitro.
Experimental findings have indicated ihai iKBa inhibits ihe DNA binding activity of 
the p65 subunit rather than the p50 subunit of NF-kB (reviewed in Grimm and Baeuerle, 
1993). Therefore, studies have mainly focused on the interaction between the p65 subunit of 
NF-kB and iKBa. Deletion analysis of the avian homologue of human iKBa, pp40 had 
suggested that the C-terminal region and ankyrin repeats were essential for association with 
c-Rel homodimers and for inhibition of c-Rel and NF-kB DNA binding activity in vitro 
(Inoue et al, 1992). In addition, a later investigation using deletion mutants of human iKBa 
also demonstrated that the C-terminal domain and the ankyrin repeats were critical for 
association with p65 and for preventing p65 DNA binding in vitro (Hatada et al, 1993). 
Furthermore, both studies showed that the N-terminal region of iKBa was dispensable for 
interaction with c-Rel or p65 and for inhibition of c-Rel, p65 or NF-kB DNA binding 
activity.
It was possible that the apparent functional requirement for the C-terminal region of 
iKBa was a consequence of conformational changes induced in the protein through the 
deletion of the C-terminal domain. Therefore, the purpose of this study was to examine the 
contribution of smaller areas of protein sequence to the function of I kB a (in particular, its 
relationship with p65) through the substitution, rather than deletion of a lower number of 
residues. As indicated in the results section the potential areas of contact within the p65 
protein for iKBa were considered. Studies had indicated that the nuclear localisation signal of 
p65 was required for association with iKBa (Beg et al, 1992). In addition, it had been 
reported that that a C-terminal domain in p65 assisted in the iKBa-mediated inhibition of 
DNA binding (Ganchi et al, 1992). Since the NLS was positively charged it was reasoned 
that the interaction between iKBa and p65 may be ionic. Therefore, conserved areas of 
negatively charged residues were chosen for substitution in the C-terminal region of human 
iKBa, namely residues 284-286 and residues 300-302. A second set of iKBa mutants were
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also generated with amino acid substitutions in the low homology sixth ankyrin repeat as this 
area had been shown to contact p65 through protease sensitivity studies (Jaffray etal, 1995). 
Single residue substitutions were produced at positions 258 and 275.
Protein association assays carried out in vitro on bacterially expressed and purified C- 
terminal and linker I kB a c-tag mutant and p65 proteins revealed that the amino acid 
substitutions at positions 258, 275, 284-286 and 300-302 did not affect the ability of IKBa c- 
tag to interact with p65. However, it appeared that the substitution at position 284-286 in the 
C-terminus of IKBa c-tag reduced the inhibitory capacity of the protein in vitro: Both 
EDE284-286qnq and EDE284-286sss displayed a 16-fold decrease in their ability to inhibit 
the DNA binding of p65 homodimers. The results suggest that the ability of I KBa to inhibit 
the DNA binding activity of p65 homodimers can be mediated by a region (around residues 
284-286) of the protein which is distinct from the area which controls its association with 
p65.
These results have since been confirmed by other groups. This includes a study on the 
C-terminal domain of I kB a which identified the region between residues 283 and 286 as 
being critical for inhibiting the DNA binding of p65 or c-Rel but dispensable for association 
with either p65 or c-Rel (Ernst et al, 1995). Further analysis of the acidic stretch of amino 
acids from 284-286 revealed that the residues were located in a consensus casein kinase II 
phosphorylation site. The mutation of a serine residue at position 283 to an uncharged amino 
acid (alanine) resulted in a slight loss of inhibitory activity, whereas substituting serine with 
aspartic acid did not affect the inhibitory capacity of the protein. The study suggested that a 
negative charge at position 283, supplied by phosphorylation of serine in vivo, may contribute 
to the proteins inhibitory capacity.
Similar results were obtained from another study using avian pp40 where substitution 
of four C-terminal serine residues to alanine abolished pp40 mediated inhibition of DNA 
binding by c-Rel but serine to aspartic acid substitutions did not affect the inhibitory function 
of pp40 (Sachdev etal, 1995).
Therefore, it appears that the inhibitory function of iKBa resides in the C-terminal 
region, whereas the area responsible for association with p65 is located outwith this domain.
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Although the single amino acid substitutions introduced at positions 258 and 275 in the low 
homology ankyrin repeat did not affect the ability of iKBa c-tag to interact with p65 several 
recent studies have shown that the deletion of part of the low homology ankyrin repeat with 
the C-terminal region (residues 261-317, 263-317 or 269-317) prevents p654KBa interaction 
in vivo (Sun et al, 1996; Beauparlant et al, 1996). It is possible that these results were due to 
a conformational change in iKBa, induced following the removal of a large number of 
residues but proteolysis sensitivity studies have also demonstrated that residues within the 
low homology sixth ankyrin repeat of iKBa are protected from proteolysis in the presence of 
p65 in vitro (Jaffray et al, 1995).
Although it is clear that the acidic C-terminus of I KBa is critical for inhibiting the 
DNA binding activity of NF-kB, the actual mechanism of this inhibition has not been 
elucidated. However, a recent protein footprinting study has demonstrated that Ik By and 
DNA appear to protect the same set of lysine residues in p50 homodimers from chemical 
modification (Bell et al, 1996) but that iKBa failed to protect these residues in p50 
homodimers. These findings indicate that IkBy can inhibit the DNA binding of p50 
homodimers by directly interacting with residues critical for p50 DNA binding. In contrast, 
IkBa does not contact these critical DNA binding residues and therefore cannot inhibit p50 
DNA binding, although it can physically interact with p50, presumably at a site distinct from 
the DNA binding region of p50. It is possible that the mode of IkBy inhibition on p50 DNA 
binding is similar to the mechanism of IkBa inhibition on p65. The acidic C-terminus of 
IkBa may form an intramolecular interaction with regions in or around the DNA binding 
domain of NF-kB. This could induce a conformational change in the DNA binding region so 
that NF-kB is no longer able to recognise its specific DNA binding site as suggested by Ernst 
et al (1995). Indeed early studies demonstrated that the N-terminal DNA binding domain of 
c-Rel was both necessary and sufficient for association with iKBa (Kerr etal, 1991).
A mutational analysis of Drosophila Dorsal in yeast has suggested that sites outwith 
the DNA binding region are required for Cactus-mediated (an IkB protein) inhibition of 
Dorsal. This study isolated two Dorsal mutants from yeast cells possessing amino acid 
changes at either residues 233 or 234 corresponding to an area close to the nuclear
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localisation signal in p50. Both mutations were found to prevent Cactus-mediated inhibition 
of Dorsal in vivo. However, the nature of the genetic screen used in this study meant that the 
Dorsal mutants had to translocate to the nucleus, bind DNA and activate transcription before 
they could be inhibited by Cactus (Lehming et al, 1995). Therefore, Dorsal mutants 
containing alterations in, for example their nuclear localisation signal were not detected and 
this conclude that only residues 233 and 234 are required for cactus inhibition. It is likely 
that other regions of dorsal are also important for Cactus-mediated inhibition.
The effect of sodium chloride and pH on the association between iKBa c-tag and p65 
was also examined in this study. It was reasoned that in the event of their being an ionic 
interaction between p65 and IkB a c-tag, changing the ionic strength or pH of the solution 
containing these proteins should disrupt this interaction. Furthermore, if the negatively 
charged residues at positions 275, 284-286 and 300-302 in iKBa were required for binding to 
p65 then their substitution with uncharged residues may partially remove any dependence on 
the ionic strength or pH of their environment.
Raising the concentration of sodium chloride (from 60mM to 960mM) dramatically 
reduced the ability of IkB a c-tag to interact with p65, whereas varying the pH conditions 
(between pH5.5 and pH9.0) had no effect on I KBa c-tag-p65 association. Both the mutant 
and wild-type iKBa c-tag proteins behaved similarly over the range of salt concentrations and 
pH’s used. This indicated that the amino acid substitutions at positions 275, 284-286 and 300­
302 in iKBa c-tag were not required for specific interactions with p65. In addition, it would 
appear that other interactions besides those of an ionic nature facilitate lKBa-p65 association 
since varying the pH alone (from pH5.5 to 9.0) did not affect this interaction. Indeed, the 
observation that high salt concentrations almost abolished lKBa-p65 binding supports this 
proposal since ionic strength affects both ionic interactions and hydrogen bonding. This is 
achieved through the association of sodium or chloride ions with charged groups or with 
dipoles (peptide bonds) within the proteins which can compete out protein-protein 
interactions (and intermolecular interactions).
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2. IPho*^|pthor^llO^ioi^, ulMiq^^ii^iin^t^iioii and cd^e^irad^t^iioi of IkBoc.
2.1. The tole of the C-terminal oflKBa.
Several early studies had shown that the induction of cells with agents such as tumour 
necrosis factor resulted in the stimulation of NF-kB DNA binding activity. In addition, NF- 
kB activation was accompanied by the rapid, transient hyperphosphorylation and degradation 
of iKBa (Beg et at., 1993; Brown et al, 1993; Cordle et al, 1993; Henkel et al, 1993; 
Mellits et al, 1993; Rice and Ernst, 1993; Sun et al, 1993). More recently, experimental 
evidence has indicated that the inducible phosphorylation of iKBa marks the protein for 
ubiquitin-mediated proteolytic degradation which then leads to its dissociation from NF-kB 
(Finco etal., 1994; Miyamota etal, 1994; Palombella etal, 1994; Traenckner etal, 1994; 
Alkalay etal, 1995a; Didonato et al, 1995; Lin et al, 1995; Chen et al, 1995; Lin et al, 
1995; Roff etal, 1996; Alkalay etal, 1995b).
Although it was demonstrated that the N-terminal serine residues at positions 32 and 
36 in IkB(X were targeted for inducible phosphorylation and that this event was essential for 
inducer-mediated degradation (Brown et al, 1995; Traenckner et al, 1995), other studies had 
demonstrated that residues in and around the C-terminal region (residues 257-317) were also 
important for inducible degradation of iKBa (Rodriguez etal, 1995). Indeed, the C-terminal 
region of IkB a contains a PEST sequence (proline, glutamic acid/aspartic acid, serine and 
threonine) which is associated with rapid protein turnover. Since the C-terminal and linker 
iKBa c-tag mutants generated in this study contained amino acid substitutions within this 
domain it was proposed that they may play a role in the inducer-mediated degradation of 
IkB a.
Interestingly, the amino acid substitutions at positions 258 or 275 in the linker region 
(or low homology sixth ankyrin repeat) of I KBa c-tag did not affect the ability of the protein 
to be degraded in response to tumour necrosis factor a (TNFa) (in 293 cells) but the C- 
termlnal substitutions at positions 284-286 or 300-302 appeared to partially block TNFa- 
inducible degradation. However, since the basal turnover of these mutants was not 
investigated their apparent failure to be degraded in response to TNFa may have been a 
result of a slower rate of basal degradation. Indeed, this was strongly suggested by the
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observation that in order to achieve similar levels of protein expression for the various mutant 
and wild-type IkBa c-tag proteins in 293 cells, far lower quantities of the vectors expressing 
the C-terminal I KBa c-tag mutants were required.
The degradation assays also revealed that transiently transfected wild-type or linker 
mutant IKBa c-tag was not degraded in response to TNFa as rapidly as endogenous (cellul^^r) 
IKBa. However, other groups have observed (M. Rodriguez, Pasteur Institute) that the stable 
transfection of cells with a vector expressing IkB a c-tag shows a similar rate of inducible 
degradation to the endogenous protein. Perhaps the stable transfection of cells with I KBa c- 
tag gives the protein time to establish itself in the cells ubiquitin-dependent degradation 
pathway (which will be initially turning over mainly endogenous I KBa). The cells 
degradation machinery will presumably take time to either readjust its rate or increase the 
level of its component proteins to cope with the influx of exogenous I KBa. Increasing the 
level of the proteins comprising the degradation pathway may be achieved through the 
induction of their coding genes.
Studies have shown that the degradation of ikBa is enhanced in mature B-cell lines 
and that this may account for the presence of constitutively active NF-kB (i.e. nuclear) 
(Miyamoto et al, 1994). Indeed, it is tempting to speculate that the expression of various 
components of the constitutive degradation pathway for IkB a are increased by NF-kB in 
order achieve a more efficient turnover of IKBa..
Inducibly phosphorylated forms of all the mutants except EDE300-302qnq and 
EDE300-302sss were detected on a gradient gel but all of the mutants appeared to be targeted 
for inducible ubiquitination. Studies have shown that blocking the inducible phosphorylation 
of iKBa through the mutation of the N-terminal residues, serine 32 and 36 prevents 
ubiquitination (Roff et al, 1996; Rodriguez et al, 1996). Therefore, it would be predicted 
that mutants EDE300-302qnq and EDE300-302sss should not be ubiquitinated. However, it is 
possible that both of these mutants are being inducibly phosphorylated but that the gradient 
gel is not detecting the phosphorylated proteins. An explanation for this possibility lies within 
the nature of the amino acids which were altered In these mutants i.e. charged residues were 
replaced with uncharged amino acids. This may have affected the mobility of these mutants
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on the gradient gel so as to occlude inducibly phosphorylated forms of the proteins 
(presumably there are instances where the native charge of a protein, if it is high enough, will 
affect its mobility on a gel even in the presence of SDS). Indeed, it was noted in the results 
section that the shift in mobility observed for the inducibly phosphorylated forms of the other 
mutants, which also contained charged to uncharged amino acid substitutions was poor 
compared to the wild-type protein. Attempts were made to separate the inducibly 
phosphorylated forms of the various mutants by isoelectric focusing without success. If time 
had permitted it would have been useful to try and radioactively label the inducibly 
phosphorylated forms of the wild-type and mutant iKBa c-tag proteins in 293 cells. However, 
since iKBa is heavily constitutively phosphorylated this may have masked any inducible 
phosphorylation.
Since the C-terminal mutants appeared to be phosphorylated (observed at least for 
mutants EDE284-286qnq and EDE284-286sss) and ubiquitinated in response to TNFa (in 
293 cells) this indicated that the proteins should undergo inducible degradation. Therefore, as 
explained earlier this may suggest that the C-terminal mutants are being inducibly degraded 
to the same extent as the wild-type protein and that it is the basal turnover of the C-terminal 
mutants which is slower. Alternatively, some other ubiquitin-independent degradation 
pathway could exist which may or may not require iKBa to be inducibly phosphorylated but 
that the amino acid changes introduced into the C-terminal mutants are sufficient to block 
their degradation via this pathway. Perhaps these amino acids are required for a post­
translational modification which is recognised by the components of this pathway.
Indeed a very recent study on pervanadate (a protein tyrosine inhibitor and T cell 
activator) induced Jurkat T cells has shown that NF-kB is activated via tyrosine 
phosphorylation but not degradation of iKBa. This proteolysis-independent pathway for NF- 
kB activation appears to require the expression of a tyrosine kinase, p56Ick. in addition, it was 
suggested that reactive oxygen intermediates may induce I KBa tyrosine phosphorylation 
since the reoxygenation of hypoxic cells stimulated tyrosine phosphorylation of iKBa (Imbert 
et al, 1996). Furthermore, a study on the p50 precursor protein, pl05 has revealed that 
alternative signalling pathways exist for pi 05 phosphorylation and processing and for I KBa
128
phosphorylation and degradation following PMA/ionomycin treatment (in Jurkat T cells) 
(MacKichan et al, 1996). Therefore, it is possible that different signalling pathways exist for 
TNFa induction of iKBa itself, and that these direct the protein to different degradation 
pathways.
However, recent data support the idea that the C-terminal region of IKBa is not 
required for inducible degradation. Instead it appears to be essential for the basal turnover of 
the protein. This includes a report which generated a C-terminal deletion mutant 
corresponding to residues 1-277 that was degraded in response to TNFa (Sun et al, 1996). In 
contrast, the removal of residues 264-317 rendered iKBa resistant to TNFaiinduced 
degradation. The group proposed that a glutamine and leucine rich region in the low 
homology sixth ankyrin repeat of I KBa participates in signal-induced degradation.
Further studies on the C-terminal region of I KBa have revealed that the substitution of 
serine to alanine at position 283 and a threonine to alanine substitution at positions 291 and 
299 did not affect signal-induced degradation of the protein but increased the intrinsic 
stability of the protein (Lin et al., 1996). Another investigation utilising a transient 
transfection system in 293 cells which allowed the stability of free I KBa to be studied (i.e. 
IKBa not bound to NF-kB) reported that the mutation of serine 283, 288, 293 and threonine 
291 to alanine doubled the half-life of free I KBa (Schwarz et al., 1996). Interestingly, Lin et 
al (1996) also reported that following TNFa induction of cells phosphorylation of the IKBa 
mutant containing the three C-terminal amino acid substitutions (S283A, T291A and T299A) 
was reduced by about 10-fold. Therefore, it is possible that the C-terminus does contribute to 
the hyperphosphorylation of I KBa.
The reports on I KBa degradation have also demonstrated that casein kinase II may be 
responsible for the constitutive phosphorylation of I KBa in its C-terminal region (Barroga et 
al, 1995; McElhlnny et al., 1996; Lin et al., 1996; Schwarz et al, 1996). Casein Kinase II is a 
found in the nucleus and cytoplasm of all eukaryotic cells studied to date. Although the 
enzyme can phosphorylate several cellular proteins including Fos, Jun, serum response factor, 
p53 and Myc, its physiological role is unclear. However, many of the proteins targeted for 
phosphorylation by casein kinase II are involved in DNA replication and transcription.
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Furthermore, several of the casein kinase II protein substrates are also substrates for kinases 
participating In cell cycle regulation. Moreover, the activity of casein kinase II has been 
shown to be regulated in several cell-types by growth-stimulatory factors suggesting that the 
enzyme may be important for mitogenesis (reviewed in Allende et al, 1995). The 
consequences of casein kinase II phosphorylation on the activity of different proteins varies 
extensively. For example, mutations In the casein kinase II phosphorylation sites or 
dephosphorylation of the nuclear phosphoprotein, serum response factor reduces the rates of 
association and dissociation from the serum response element DNA binding sites. 
Conversely, c-Jun DNA binding activity is reduced through casein kinase II phosphorylation 
(reviewed in Allende et al, 1995).
The role of casein kinase II in the constitutive phosphorylation of IKBa ( in Its C- 
terminal region) (Barroga et al, 1995; McElhInny et al, 1996; Lin et al, 1996; Schwarz et 
al, 1996) support the observation In this study that the in vitro casein kinase II 
phosphorylation of the C-terminal mutants containing changes In their consensus casein 
kinase II phosphorylation sites was drastically reduced:
Barroga et al (1995) showed that casein kinase II physically associates with and 
phosphorylates IkB a in vivo and in vitro. Furthermore, the mutation of potential casein 
kinase II phosphorylation sites in the C-terminal region of I KBa, namely serine 283, 288 and 
293 and threonine 291 and 296 was shown to abolish casein kinase II dependent 
phosphorylation of IKBa. McElhinney et al (1996) performed a sequence analysis of I KBa 
phosphoisoforms obtained following Incubation of purified I KBa with either purified casein 
kinase II or cellular extracts from U937 cells (known to contain a casein kinase Il-like 
activity). The C-terminus of IKBa was found to be phosphorylated on serine 283, 288 and 
293 and threonine 291. Furthermore, the study linked the basal turnover of IkB a to its basal 
(or constitutive) phosphorylation through casein Kinase II in U937 cells.
The investigation performed by Lin et al (1996) revealed that in NIH 3T3 cells stably 
transfected with a vector expressing an IkB a mutant containing a serine to alanine 
substitution at position 283 and a threonine to alanine substitution at positions 291 and 299, 
the constitutive phosphorylation of the mutant was blocked. Importantly these residues were
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the constitutive phosphorylation of the mutant was blocked. Importantly these residues were 
all located within consensus casein kinase II phosphorylation sites (S/T-X-X-E/D). Indeed, 
phosphoamino acid analysis of the purified mutant protein following incubation with either 
purified casein kinase II or a partially purified kinase activity from Jurkat cells (suspected to 
be casein kinase II) revealed that its phosphorylation was reduced by 10- to 20-fold. Under 
the same conditions, a single amino acid substitution at position 291 (threonine to alanine) 
also reduced phosphorylation by two- to four-fold whereas a substitution at position 283 
(serine to alanine) did not affect phosphorylation. It has been proposed that threonine 291 
may serve as a “docking site” for casein kinase II where it can sequentially phosphorylate 
other serine and threonine residues in the C-terminal region of I KBa.
In contrast, Schwartz et al (1996) have shown that serine 293 of I KBa is the preferred 
site for casein kinase II phosphorylation whereas adjacent serine and threonine residues act as 
secondary phosphorylation targets. However, Lin et al (1996) used a different cell type to the 
one employed in this study and therefore it is possible that distinct patterns of casein kinase II 
phosphorylation exist between different cell types.
Interestingly, unpublished data in the report by Lin et al (1996) and results from our 
laboratory (Jaffrey, 1995) failed to demonstrate a role for casein kinase II phosphorylation in 
the N-terminal region of iKBa. This is surprising since the two N-terminal serine residues 
(S32 and S36) which have been previously shown to be targets for inducible phosphorylation 
are located within consensus casein kinase II phosphorylation sites. Since Lin et al (1996) 
also showed that the triple mutant (S283A, T291A and T299A) completely blocked 
constitutive phosphorylation in vivo it is likely that the N-terminal serine residues at positions 
32 and 36 do not undergo casein kinase Il-dependent phosphorylation in vivo.
The C-terminal of the Drosophila IkB protein, Cactus has also been shown to be the 
target for basal phosphorylation and degradation in the Drosophila embryo (Belvin et al, 
1995). In parallel to the study carried out by Schwarz et al (1996) on iKBa, the degradation 
characteristics of free Cactus were examined. The removal of the PEST region of Cactus 
increased the half-life of the free protein. It has been proposed that the C-terminal region of 
Cactus mediates signal-independent degradation of free Cactus, perhaps via basal
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IkB (a system. Indeed, it has been demonstrated that free wild-type I KBa is basally 
phosphorylated and turned over rapidly (but much less rapidly (half-life ~32 minutes) than 
TNFa induced degradation of NF-kB bound I KBa (half-life ~5 minutes)) (Sun et al., 1993; 
Schwarz et al., 1996), whereas unpublished data indicates that an I KBa mutant (free) 
containing mutations in all of the potential C-terminal casein Kinase II phosphorylation sites 
(of which there are five, S283, S288, T291, S293 and T296) is not phosphorylated and has a 
longer half-life (see Verma et al., 1995). Furthermore, this mutant was not phosphorylated in 
vivo when transiently transfected into 293 cells but was still able to bind p65, indicating that 
basal phoshorylation is not a requirement for NF-kB-IkB a association. The results also 
revealed that the mutant was inducibly phosphorylated and degraded in response to TNFa. 
This suggests that basal phosphorylation is not essential for induced phosphorylation and 
degradation of I KBa.
The in vivo characterisation of the C-terminal and linker mutants generated in this 
study also demonstrated that all of the I KBa c-tag mutants were able to interact with p65 in 
293 cells. In addition, both the linker and C-terminal mutants allowed NF-KB-dependent 
transcription from a luciferase reporter following the activation of Cos7 cells with TNFa. 
This result was surprising since the C-terminal mutants were more stable than either the wild- 
type or linker mutant proteins and consequently they would have been predicted to bind NF- 
kB, thereby reducing NF-KB-dependent transcription in the nucleus. However, this result may 
be due to differences in the degradation characteristics of the mutant proteins in Cos7 cells 
compared to 293 cells. Alternatively the mutants could undergo a post-translational 
modification in Cos7 cells which prevents them from interacting with NF-kB.
It is worth noting that the level of transactivation from the transfected luciferase 
reporter in activated Cos7 cells was greater in the absence of both transfected wild-type and 
mutant iKBa c-tag. Presumably overexpressing wild-type or mutant I KBa c-tag will, under 
conditions of activation overload the cells degradation machinery leading to a build-up of 
exogenous iKBa c-tag. This will be available to bind NF-kB and therefore lower the level of 
NF-KB-dependent transcription.
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2.2. The role of the N-terminal region of I kB a
It had been shown that inhibition of proteasomal activity followed by TNFa Induction 
of cells resulted in the detection of a hyperphosphorylated form and ubiquitinated forms of 
.IkB a (Pallombella et at., 1994; Traenckner et al, 1995; Roff et al., 1996). Furthermore, a 
mutant containing N-terminal serine to alanine substitutions at positions 32 and 36 was not 
only resistant to signal induced degradation but was unable to undergo either inducible 
phosphorylation or ubiquitination (Chen et al, 1995; Roff et al, 1996). This indicates that 
inducible phosphorylation of residues 32 and 36 is a prerequisite for signal induced 
ubiquitination and degradation of IKBa. Indeed, the experiments performed with colleagues 
at the Pasteur Institute have provided additional evidence for the involvement of the N- 
terminal region in the inducible degradation of IKBa.
The study set out to Identify residues within the N-terminal region of IKBa which 
may represent targets for ubiquitination. Since ubiquitin chains are added to the e-amino 
group of lysine residues the study focused on the nine lysine residues within the N-terminal 
region of IKBa. Although not mentioned in the results section, transiently overexpressed 
IKBa mutants containing only single lysine to arginine substitutions were ubiquitinated to the 
same extent as wild-type IKBa in response to TNFa induction of cells. However, the 
generation of mutants containing multiple lysine to arginine substitutions in the N-terminal 
region at positions 21, 22, 38 and 47 completely blocked TNFa Induced ubiquitination 
together with NF- kB -dependent transcription but did not affect inducible phosphorylation. 
The generation of two double mutants containing either lysine to arginine substitutions at 
positions 21 and 22 or 38 and 47 revealed that lysines 21 and 22 were probably the primary 
targets for ubiquitination whereas lysines 38 and 47 represented the secondary targets.
The discovery that more than one lysine residue was required for efficient 
ubiquitination of IKBa is comparable to the situation observed for the c-Jun transcription 
factor (Treier et al, 1994). In this study ubiquitination of c-Jun but not its viral counterpart, 
v-Jun was observed in vitro. Attempts to identify a single lysine residue responsible for the 
ubiquitination of c-Jun failed. Indeed double and triple mutations also had no affect on 
ubiquitination. It was proposed that either ubiquitination was occurring at multiple sites or
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that the ubiquitin-attachment machinery was able to move from a lysine residue which had 
been mutated and begin adding ubiquitin chains to an alternative lysine. However, in the case 
of I KBa ubiquitination it appears that lysines 21 and 22 are specific targets for ubiquitination 
and that their removal is only partially compensated for by the secondary ubiquitination sites 
at positions 38 and 47.
Therefore, it would appear that the N-terminal region of I KBa is essential for both 
inducible degradation and ubiquitination. It has been proposed that after the signal-induced 
phosphorylation of I KBa on serine 32 and 36, the protein is recognised by the ubiquitin- 
attachment machinery. Having covalently attached multiple ubiquitin molecules to lysines 21 
and 22 (and possibly to lysines 38 and 47) the protein is then degraded by the 26S 
proteasome. The importance of lysine 21 and 22 for signal induced ubiquitination and 
degradation of I KBa has been confirmed by other groups (Baldi et al., 1996; Didonato et al., 
1996).
Interestingly, the N-terminal domain of IKBa has been shown to be highly susceptible 
to proteolytic degradation in vitro as determined via protease sensitivity studies (Jaffray etal, 
1996). This suggests that the region is probably highly unstructured and therefore ideal for a 
signal response domain so that it can allow easy access of kinases (and possible 
phosphatases) and the ubiquitin-proteasome machinery. However, one would think that the 
apparently unstructured nature of the region would increase the probability of degradation by 
non-specific proteases in vivo. Perhaps the C-terminal region of I KBa can mask this region in 
unstimulated cells to prevent such degradation. Indeed, the protease sensitivity studies 
indicated that the low homology sixth ankyrin repeat was also highly susceptible to 
proteolysis in vitro and it was suggested that the region may act as a flexible linker between 
the fifth ankyrin repeat and the C-terminus (Jaffray et al., 1995). This hinge-like domain 
would therefore permit the free movement of the C-terminal “arm” allowing it to lie over the 
N-terminal region.
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2.3. Modelfor basal and cignat- induced J i& a degradation.
Represented schematically in figure 54 is one possible model for the basal (i.e. 
constitutive) and inducible degradation of I KBa. It appears that I KBa protein stability is 
regulated at two levels. The first involves the signal-dependent turnover of iKBa. Following 
activation of cells, Kinase(s) phosphorylate I KBa on the N-terminal residues, serine 32 and 36 
(step 1). It is likely that this event marks I KBa for covalent modification by a specific 
ubiquitin ligase (step 2). After the ligase catalysed addition of multiple molecules of ubiquitin 
to lysine 21 and 22 (and possibly the secondary ubiquitination sites at residues 38 and 47) of 
IkB a, the protein dissociates from NF-kB, allowing the translocation of NF-kB to the 
nucleus where it can activate transcription of target genes (step 3). Ubiquitinated iKBa is 
rapidly degraded by the proteasome (step 4). It should be noted that steps 1 and 2 are 
reversible by phosphatase(s) and C-terminal hydrolase(s) respectively. Presumably following 
activation the equilibrium of each reaction is pushed forward. As reported by Verma et al 
(1995) recent unpublished work indicates that constitutive phosphorylation of iKBa is not 
necessarily required for interaction with NF-kB and this is indicated with a question mark.
The second level of regulation exerted on IkB a is signal-independent degradation. 
This pathway involves constitutive phosphorylation of the C-terminal region of I KBa via 
casein kinase II. As in the inducible degradation pathway, phosphorylation may target the 
protein for constitutive degradation via a ubiquitin-dependent or -independent proteolytic 
pathway. I KBa may or may not be bound to NF-kB prior to the phosphorylation and 
degradation events. If this pathway represents the degradation of free iKBa it could represent 
a mechanism for the removal of excess I KBa in cells. This would be particularly important 
during the activation of NF-kB, where excess I KBa could prevent the passage of NF-kB to 
the nucleus and the subsequent induction of target genes.
In conclusion, both pathways are probably crucial for regulating the activity of NF- 
kB. It will be important to elucidate the mechanism of the basal degradation pathway and to 
identify other pathways involved in I KBa turnover in cells in order to gain a better incite into 
the global regulation of NF-kB.
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3. Structure of the C-terminal region of IkBcc.
Proteolysis sensitivity studies on IkB(X had revealed that the C-terminal region, in 
contrast to the N-terminus was highly resistant to proteolysis, indicative of a tightly organised 
structure (Jaffray et al., 1995). This study set out to determine whether or not the C-terminus 
of IKBa was able to exist as an independently folded domain. The technique of Circular 
Dichroism (CD) Spectroscopy was used to predict the secondary structure content of the C- 
terminal domain. However, as indicated in the results section CD spectroscopy can only 
accurately determine the amount of p-sheet and a-helix and the remaining secondary 
structure constituents are averaged (e.g. P-turns and 3io helix).
The secondary structure predictions (calculated by applying the CONTIN procedure 
to the CD spectra) indicated that the C-terminal region of IKBa (amino acids 275-317) was 
comprised mainly of p-sheet and remaining secondary structure constituents such as P-turns 
and 3io helix. The a-helical content of the region was very low in comparison (around 6% 
compared to 40-50% p-sheet). The presence of a ten amino acid section from the low 
homology sixth ankyrin repeat of IKBa (residues 265-317) did not appear to alter the level of 
secondary structure content. However, at lower pH’s and in the absence of TFE, the increase 
in p-sheet content observed for the region corresponding to residues 275-317 of IKBa was not 
accompanied by a similar increase in the P-sheet content of the region corresponding to 
residues 265-317.
It is possible that the increase in p-sheet content observed at lower pH’s for the C- 
terminal region (275-317) reflects the conditions produced by the proposed interaction of the 
C-terminus of IKBa with the DNA binding domain of p65 i.e. at lower pH’s carboxyl groups 
will be protonated and therefore available for hydrogen bonding to p65. The results indicate 
that the sixth low homology region may slightly destabilise this interaction. A CD study on 
the acidic activation domains of the yeast GCN4 and GAL4 proteins also revealed that lower 
pH’s increased their p-sheet content (Van Hoy etal., 1993).
The fusion of a C-terminally fused 14 amino acid tag region to amino acids 265-317 
appeared to increase the p-sheet content of the protein. This suggests that the tag region can 
structurally stabilise the C-terminal region and part of the low homology sixth ankyrin repeat.
136
It is possible that tag acts as a stabilising influence in the proposed interaction between the C- 
terminal region of I KBa with the DNA binding domain of p65. However, it is likely that this 
influence is probably minimal as the tag region when fused to full-length Ik Ba does not 
improve IKBa’s ability to inhibit the DNA binding of p65. This raises an important point 
concerning the purification of IKBa c-tag, whereby the inclusion of an additional step in the 
purification procedure (the triton X100 and sarkosyl procedure) resulted in IKBa c-tag acting 
as a more efficient inhibitor of p65 DNA binding. This could indicate that the purification 
technique stabilises the structure of the C-terminal region (possibly by raising the level of P- 
sheet) so that it can interact more strongly with the DNA binding region of p65. It is also 
worth noting that the CD studies were performed on independent C-terminal fragments of 
IKBa and that their conformation in the full-length protein is probably affected (possibly 
stabilised) by the N-terminal domain and anKyrin repeats.
To summarise, a schematic for the proposed secondary structure of IkB a is given in 
figure 55. The structure is based on the data obtained from this CD study, proteolysis 
sensitivity work (Jaffray et aL, 1995) and secondary structure prediction programmes (Gay 
and Ntwasa, 1993). The functional role of the various domains within I KOz are also
indicated.
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Figure 55: The proposed secondary structure of IxBa.
IkB a can be divided into three main domains: an unstructured N-terminal signal response 
domain shown to be critical for inducible phosphorylation and degradation of IkB a: a 
central ac-helical region of five ankyrin repeats, responsible for protein-protein interations; 
a C-terminal region of high P-sheet content required for constitutive phosphorylation and 
degradation of IkB a as well as for the inhibition of p65 DNA binding activity. In 
addition, a fourth domain may exist- the so-called flexible linker region proposed to 
represent the sixth ankyrin repeat and implicated in protein-protein interactions and 
signal-induced degradation of iKBa.The positions of the amino acids implicated in 
constitutive and inducer-mediated phosphorylation and degradation are indicated. Key: 
ROI-reactive oxygen intermediates.
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